SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,PROSTATIC NEOPLASMS,_LEUPROLIDE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5728396.0,A61K38/09,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CC(=O)[O-],PROSTATIC NEOPLASMS,_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,PROSTATIC NEOPLASMS,_LEUPROLIDE_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",4851211,A61K9/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATIC NEOPLASMS,_PREDNISONE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,PROSTATIC NEOPLASMS,_ABIRATERONE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5604213,C07J41/0005,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,PROSTATIC NEOPLASMS,_ABIRATERONE_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5604213,C07J41/0005,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,OVARIAN CANCER,_EXEMESTANE,NCT04460807,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy|Ospedale Oncologico IRCCS Bari, Bari, BA, Italy|Ospedale degli Infermi, Biella, BI, Italy|AULSS 1 Dolomiti - Ospedale ""Santa Maria del Prato"", Feltre, BL, Italy|Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi, Bologna, BO, Italy|ASST degli Spedali Civili di Brescia, Brescia, BS, Italy|Fondazione Poliambulanza, Brescia, BS, Italy|Ospedale di Manerbio, Manerbio, BS, Italy|AOU Cagliari, Policlinico Universitario, Cagliari, CA, Italy|Ospedale Policlinico ""SS. Annunziata"", Chieti, CH, Italy|Azienda Sanitaria Locale CN2, Alba, CN, Italy|Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy|Ospedale di Mondovì CN1, Mondovì, CN, Italy|Ospedale Sant Anna di Como, Como, CO, Italy|ARNAS Garibaldi, Catania, CT, Italy|Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy|ASL 3 Ospedale Villa Scassi, Genova, GE, Italy|IRCCS AOU San Martino - IST, Genova, GE, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, LC, Italy|Ospedale ""Vito Fazzi"", Lecce, LE, Italy|UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy|Presidio Ospedaliero Unico Av3, Macerata, MC, Italy|Istituto Europeo di Oncologia (IEO), Milano, MI, Italy|AOU Policlinico di Modena, Modena, MO, Italy|A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Palermo, PA, Italy|Ospedale ""Guglielmo da Saliceto"", Piacenza, PC, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy|CRO Centro di Riferimento Oncologico, Aviano, PN, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy|Azienda Ospedaliera Regionale San Carlo, Potenza, PZ, Italy|Ospedale ""degli Infermi"", Faenza, RA, Italy|Ospedale ""Umberto I"", Lugo, RA, Italy|Ospedale Santa Maria delle Croci, Ravenna, RA, Italy|Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy|Policlinico Umberto I, Università di Roma ""La Sapienza"", Roma, RM, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, RM, Italy|ASST Valtellina e Alto Lario, Sondrio, SO, Italy|Azienda Ospedaliero Universitaria di Sassari, Sassari, SS, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, TO, Italy|AO Ordine Mauriziano, Torino, TO, Italy|Azienda Ospedaliero-Universitaria Città della Salute e della Scienza - Ospedale Ostetrico Ginecologico Sant'Anna, Torino, TO, Italy|Presidio Ospedaliero S. Andrea, Vercelli, VC, Italy|Medical Oncology Division, Ente Ospedaliero Ospedali Galliera, Genova, Italy|Istituto Nazionale Tumori - IRCCS ""Fondazione G.Pascale"", Napoli, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy",4808616,C07J1/0011,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,BREAST NEOPLASM,_GOSERELIN,NCT01723774,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Baylor College of Medicine, Houston, Texas, United States",7118552.0,A61M5/326,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,NEOPLASMS,_FULVESTRANT,NCT02530411,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom|Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom|Royal United Hospital Bath, Bath, United Kingdom",6774122,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,NEOPLASMS,_VANDETANIB,NCT02530411,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom|Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom|Royal United Hospital Bath, Bath, United Kingdom",RE42353,C07D401/12,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,OVARIAN CANCER,_LETROZOLE,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",4978672,C07D213/57,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,OVARIAN CANCER,_METFORMIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6288095.0,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,OVARIAN CANCER,_ASPIRIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6015577,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,OVARIAN CANCER,_OLAPARIB,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",7151102,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,PCOS,_FLUTAMIDE,NCT00930228,Phase 1,Recruiting,Female,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","University of Virginia, Charlottesville, Virginia, United States",3995060,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,26.6453109920121,2145.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,276.2118,74.92,3.0,1.0,1.0,23.2,63.42,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NEOPLASMS,_DOCETAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NEOPLASMS,_PACLITAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,SOFT TISSUE SARCOMA,_DOCETAXEL,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SOFT TISSUE SARCOMA,_GEMCITABINE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N=C(N)NCCC[C@H](N)C(=O)O,SOFT TISSUE SARCOMA,_ARGININE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,GASTRIC CANCER,_DOCETAXEL,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,GASTRIC CANCER,_CAPECITABINE,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,GASTRIC CANCER,_EPIRUBICIN,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4950738.0,A61K41/0042,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,GASTRIC CANCER,_LEUCOVORIN,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,GASTRIC CANCER,_NIRAPARIB,NCT04178460,Phase 1,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-Sen University Cancer Center, Guangzhou, China|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China|The University of Hong Kong, Queen Mary Hospital, Hong Kong, China|Sir Run Shaw Hospital, School Of Medicine ,Zhejiang University, Zhejiang, China",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PROSTATE CANCER,_NIRAPARIB,NCT04194554,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States",8859562,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,BREAST CANCER,_NIRAPARIB,NCT02826512,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antoni van Leeuwenhoek, Amsterdam, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PANCREATIC CANCER,_NIRAPARIB,NCT03601923,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,PROSTATIC NEOPLASMS,_ENZALUTAMIDE,NCT03834519,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California, United States|UCLA Hematology & Oncology ( Site 0081), Santa Monica, California, United States|Sibley Memorial Hospital ( Site 0096), Washington, District of Columbia, United States|Georgia Cancer Center at Augusta University ( Site 0026), Augusta, Georgia, United States|Quincy Medical Group ( Site 0021), Quincy, Illinois, United States|Tulane Cancer Center ( Site 0066), New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005), Baltimore, Maryland, United States|Chesapeake Urology Research Associates ( Site 0076), Towson, Maryland, United States|Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States|Dana Farber Cancer Institute ( Site 0033), Boston, Massachusetts, United States|UMass Memorial Medical Center ( Site 0053), Worcester, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute ( Site 0077), Detroit, Michigan, United States|Henry Ford Health System ( Site 0039), Detroit, Michigan, United States|St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada, United States|University of New Mexico Cancer Center ( Site 0048), Albuquerque, New Mexico, United States|Memorial Medical Center ( Site 0095), Las Cruces, New Mexico, United States|Associated Medical Professionals of NY ( Site 0060), Syracuse, New York, United States|Duke Cancer Center Cary ( Site 0010), Cary, North Carolina, United States|The Urology Group- Cincinnati ( Site 0094), Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center ( Site 0036), Cleveland, Ohio, United States|Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina, United States|Huntsman Cancer Institute ( Site 0002), Salt Lake City, Utah, United States|Virginia Cancer Institute ( Site 0052), Richmond, Virginia, United States|Blue Ridge Cancer Care ( Site 0086), Roanoke, Virginia, United States|Seattle Cancer Care Alliance ( Site 0079), Seattle, Washington, United States|Froedtert and Medical College of Wisconsin ( Site 0045), Milwaukee, Wisconsin, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), Berazategui, Buenos Aires, Argentina|Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Hospital Britanico de Buenos Aires ( Site 1006), Caba, Ciudad Autonoma De Buenos Aires, Argentina|Instituto Medico Alexander Fleming ( Site 1010), Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Sanatorio Parque ( Site 1002), Rosario, Santa Fe, Argentina|Hospital Aleman ( Site 1004), Buenos Aires, Argentina|CEMAIC ( Site 1014), Cordoba, Argentina|St. Vincent's Hospital ( Site 0158), Darlinghurst, New South Wales, Australia|Macquarie University ( Site 0151), Macquarie University, New South Wales, Australia|Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales, Australia|Southern Medical Day Care Centre ( Site 0160), Wollongong, New South Wales, Australia|Royal Brisbane and Women s Hospital ( Site 0155), Herston, Queensland, Australia|John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland, Australia|Box Hill Hospital ( Site 0146), Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 0152), Melbourne, Victoria, Australia|Fiona Stanley Hospital ( Site 0162), Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Oberosterreich, Austria|Medizinische Universitat Graz ( Site 0374), Graz, Steiermark, Austria|SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0375), Wien, Austria|Hospital de Caridade de Ijui ( Site 1038), Ijui, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021), Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035), Itajai, Santa Catarina, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 1022), Sao Jose do Rio Preto, Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 1026), Sao Paulo, Brazil|Cross Cancer Institute ( Site 0110), Edmonton, Alberta, Canada|BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113), Kelowna, British Columbia, Canada|BC Cancer-Vancouver Center ( Site 0112), Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII-HSC ( Site 0114), Halifax, Nova Scotia, Canada|Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada|CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Canada|Private practice ( Site 1048), Temuco, Araucania, Chile|Sociedad de Investigaciones Medicas Limitadas ( Site 1041), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Region Metropolitana De Santiago, Chile|Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Región Metropolitana De Santiago, Chile|C.H. de Saint Quentin ( Site 0481), Saint Quentin, Aisne, France|Centre Leon Berard ( Site 0422), Lyon, Auvergne, France|Clinique Sainte Anne ( Site 0431), Strasbourg, Bas-Rhin, France|Institut Paoli Calmettes ( Site 0419), Marseille, Bouches-du-Rhone, France|CHU Jean Minjoz ( Site 0423), Besancon, Doubs, France|CHU de Brest -Site Hopital Morvan ( Site 0441), Brest, Finistere, France|Institut Bergonie ( Site 0421), Bordeaux, Gironde, France|Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, Haute-Garonne, France|Hopital Foch ( Site 0428), Suresnes, Hauts-de-Seine, France|Institut Regional du Cancer de Montpellier - ICM ( Site 0443), Montpellier, Herault, France|Institut De Cancerologie De L Ouest ( Site 0448), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, Loiret, France|Centre D Oncologie de Gentilly ( Site 0432), Nancy, Meurthe-et-Moselle, France|Institut Sainte Catherine ( Site 0447), Avignon, Provence-Alpes-Cote-d'Azur, France|Centre Jean Perrin ( Site 0434), Clermont-Ferrand, Puy-de-Dome, France|C.H.U. Lyon Sud ( Site 0436), Pierre Benite, Rhone, France|CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, Somme, France|Institut Gustave Roussy ( Site 0416), Villejuif, Val-de-Marne, France|Institut Mutualiste Montsouris ( Site 0446), Paris, France|Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304), Freiburg, Baden-Wurttemberg, Germany|Universitaetsklinikum in Mannheim ( Site 0314), Mannheim, Baden-Wurttemberg, Germany|Studienpraxis Urologie ( Site 0309), Nuertingen, Baden-Wurttemberg, Germany|Universitaetsklinik fuer Urologie ( Site 0307), Tuebingen, Baden-Wurttemberg, Germany|Universitaetsklinikum Erlangen ( Site 0303), Erlangen, Bayern, Germany|Klinikum Rechts der Isar ( Site 0300), Muenchen, Bayern, Germany|Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318), Nuernberg, Bayern, Germany|Universitaetsklinikum Duesseldorf ( Site 0306), Duesseldorf, Nordrhein-Westfalen, Germany|Krankenhaus der Barmherzigen Brueder Trier ( Site 0310), Trier, Rheinland-Pfalz, Germany|Universitaetsklinikum Jena ( Site 0305), Jena, Thuringen, Germany|Charite Universitaetsmedizin Berlin ( Site 0301), Berlin, Germany|Tallaght University Hospital ( Site 0730), Dublin, Ireland|Mid Western Cancer Centre ( Site 0728), Limerick, Ireland|Meir Medical Center ( Site 0544), Kfar Saba, Central, Israel|Assaf Harofe ( Site 0547), Be'er- Ya'akov, HaMerkaz, Israel|Rabin Medical Center ( Site 0545), Petach-Tikwa, HaMerkaz, Israel|Ha Emek Medical Center ( Site 0548), Afula, HaTsafon, Israel|Soroka Medical Center ( Site 0549), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0542), Tel-Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0543), Haifa, Israel|Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0462), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano, Italy|Medical Oncology Ospedale San Donato ( Site 0461), Arezzo, Italy|Policlinico S.Orsola-Malpighi ( Site 0453), Bologna, Italy|Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0463), Roma, Italy|Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Italy|Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Italy|Fujita Health University Hospital ( Site 0724), Toyoake, Aichi, Japan|National Cancer Center Hospital East ( Site 0702), Kashiwa, Chiba, Japan|Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba, Japan|National Hospital Organization Shikoku Cancer Center ( Site 0716), Matsuyama, Ehime, Japan|Kobe City Medical Center General Hospital ( Site 0726), Kobe, Hyogo, Japan|Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa, Japan|Kitasato University Hospital ( Site 0705), Sagamihara, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0706), Yokohama, Kanagawa, Japan|Nara Medical University Hospital ( Site 0715), Kashihara, Nara, Japan|Kindai University Hospital ( Site 0714), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 0713), Suita, Osaka, Japan|Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama, Japan|Dokkyo Medical University Saitama Medical Center ( Site 0707), Koshigaya, Saitama, Japan|Fuji City General Hospital ( Site 0725), Fuji, Shizuoka, Japan|Hamamatsu University Hospital ( Site 0720), Hamamatsu, Shizuoka, Japan|Yamaguchi University Hospital ( Site 0717), Ube, Yamaguchi, Japan|Chiba Cancer Center ( Site 0704), Chiba, Japan|Kyushu University Hospital ( Site 0718), Fukuoka, Japan|University of Miyazaki Hospital ( Site 0721), Miyazaki, Japan|Nagano Municipal Hospital ( Site 0723), Nagano, Japan|Nagasaki University Hospital ( Site 0719), Nagasaki, Japan|Osaka International Cancer Institute ( Site 0722), Osaka, Japan|Toranomon Hospital ( Site 0711), Tokyo, Japan|Nippon Medical School Hospital ( Site 0709), Tokyo, Japan|Keio University Hospital ( Site 0710), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 0174), Hwasun Gun, Jeonranamdo, Korea, Republic of|National Cancer Center ( Site 0176), Goyang-si, Kyonggi-do, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0173), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0171), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 0172), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Medisch Centrum Leeuwarden ( Site 0477), Leeuwarden, Fryslan, Netherlands|Radboud University Medical Center ( Site 0470), Nijmegen, Gelderland, Netherlands|Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Noord-Holland, Netherlands|Vrije Universiteit Medisch Centrum ( Site 0479), Amsterdam, Noord-Holland, Netherlands|Spaarne Ziekenhuis ( Site 0473), Hoofddorp, Noord-Holland, Netherlands|Ziekenhuisgroep Twente ( Site 0469), Almelo, Overijssel, Netherlands|Medisch Centrum Haaglanden ( Site 0471), Leidschendam, Zuid-Holland, Netherlands|Erasmus MC ( Site 0475), Rotterdam, Zuid-Holland, Netherlands|Franciscus Gasthuis en Vlietland ( Site 0489), Schiedam, Zuid-Holland, Netherlands|Auckland City Hospital ( Site 0193), Auckland, New Zealand|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Chelyabinskaya Oblast', Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 0559), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Omskaya Oblast', Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Samarskaya Oblast', Russian Federation|SBHI Leningrad Regional Oncology Dispensary ( Site 0588), Saint Petersburg, Sankt-Peterburg, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Sankt-Peterburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Sankt-Peterburg, Russian Federation|Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579), Tomsk, Tomskaya Oblast', Russian Federation|Hospital del Mar ( Site 0333), Barcelona, Barcelona [Barcelona], Spain|Hospital General Universitari Vall d Hebron ( Site 0334), Barcelona, Barcelona [Barcelona], Spain|Hospital Clinic ( Site 0323), Barcelona, Barcelona [Barcelona], Spain|Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona [Barcelona], Spain|Hospital Parc Tauli ( Site 0335), Sabadell, Barcelona [Barcelona], Spain|Hospital Josep Trueta ( Site 0321), Girona, Girona [Gerona], Spain|Hospital Quiron Madrid ( Site 0325), Pozuelo de Alarcon, Madrid, Spain|Hospital San Pedro de Alcantara ( Site 0326), Caceres, Spain|Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Spain|National Cheng Kung University Hospital ( Site 0134), Tainen, Tainan, Taiwan|China Medical University Hospital ( Site 0132), Taichung, Taiwan|Taichung Veterans General Hospital ( Site 0133), Taichung, Taiwan|National Taiwan University Hospital ( Site 0131), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0135), Taipei, Taiwan|University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, Bristol, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 0540), Cambridge, Cambridgeshire, United Kingdom|Musgrove Park Hospital ( Site 0537), Taunton, Somerset, United Kingdom|University of North Midlands NHS Foundation Trust ( Site 0527), Stoke-on-Trent, Staffordshire, United Kingdom|Mount Vernon Cancer Centre ( Site 0536), Northwood, United Kingdom|Royal Marsden Hospital ( Site 0526), Sutton, United Kingdom",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATIC NEOPLASMS,_OLAPARIB,NCT03834519,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California, United States|UCLA Hematology & Oncology ( Site 0081), Santa Monica, California, United States|Sibley Memorial Hospital ( Site 0096), Washington, District of Columbia, United States|Georgia Cancer Center at Augusta University ( Site 0026), Augusta, Georgia, United States|Quincy Medical Group ( Site 0021), Quincy, Illinois, United States|Tulane Cancer Center ( Site 0066), New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005), Baltimore, Maryland, United States|Chesapeake Urology Research Associates ( Site 0076), Towson, Maryland, United States|Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States|Dana Farber Cancer Institute ( Site 0033), Boston, Massachusetts, United States|UMass Memorial Medical Center ( Site 0053), Worcester, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute ( Site 0077), Detroit, Michigan, United States|Henry Ford Health System ( Site 0039), Detroit, Michigan, United States|St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada, United States|University of New Mexico Cancer Center ( Site 0048), Albuquerque, New Mexico, United States|Memorial Medical Center ( Site 0095), Las Cruces, New Mexico, United States|Associated Medical Professionals of NY ( Site 0060), Syracuse, New York, United States|Duke Cancer Center Cary ( Site 0010), Cary, North Carolina, United States|The Urology Group- Cincinnati ( Site 0094), Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center ( Site 0036), Cleveland, Ohio, United States|Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina, United States|Huntsman Cancer Institute ( Site 0002), Salt Lake City, Utah, United States|Virginia Cancer Institute ( Site 0052), Richmond, Virginia, United States|Blue Ridge Cancer Care ( Site 0086), Roanoke, Virginia, United States|Seattle Cancer Care Alliance ( Site 0079), Seattle, Washington, United States|Froedtert and Medical College of Wisconsin ( Site 0045), Milwaukee, Wisconsin, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), Berazategui, Buenos Aires, Argentina|Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Hospital Britanico de Buenos Aires ( Site 1006), Caba, Ciudad Autonoma De Buenos Aires, Argentina|Instituto Medico Alexander Fleming ( Site 1010), Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Sanatorio Parque ( Site 1002), Rosario, Santa Fe, Argentina|Hospital Aleman ( Site 1004), Buenos Aires, Argentina|CEMAIC ( Site 1014), Cordoba, Argentina|St. Vincent's Hospital ( Site 0158), Darlinghurst, New South Wales, Australia|Macquarie University ( Site 0151), Macquarie University, New South Wales, Australia|Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales, Australia|Southern Medical Day Care Centre ( Site 0160), Wollongong, New South Wales, Australia|Royal Brisbane and Women s Hospital ( Site 0155), Herston, Queensland, Australia|John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland, Australia|Box Hill Hospital ( Site 0146), Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 0152), Melbourne, Victoria, Australia|Fiona Stanley Hospital ( Site 0162), Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Oberosterreich, Austria|Medizinische Universitat Graz ( Site 0374), Graz, Steiermark, Austria|SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0375), Wien, Austria|Hospital de Caridade de Ijui ( Site 1038), Ijui, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021), Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035), Itajai, Santa Catarina, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 1022), Sao Jose do Rio Preto, Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 1026), Sao Paulo, Brazil|Cross Cancer Institute ( Site 0110), Edmonton, Alberta, Canada|BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113), Kelowna, British Columbia, Canada|BC Cancer-Vancouver Center ( Site 0112), Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII-HSC ( Site 0114), Halifax, Nova Scotia, Canada|Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada|CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Canada|Private practice ( Site 1048), Temuco, Araucania, Chile|Sociedad de Investigaciones Medicas Limitadas ( Site 1041), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Region Metropolitana De Santiago, Chile|Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Región Metropolitana De Santiago, Chile|C.H. de Saint Quentin ( Site 0481), Saint Quentin, Aisne, France|Centre Leon Berard ( Site 0422), Lyon, Auvergne, France|Clinique Sainte Anne ( Site 0431), Strasbourg, Bas-Rhin, France|Institut Paoli Calmettes ( Site 0419), Marseille, Bouches-du-Rhone, France|CHU Jean Minjoz ( Site 0423), Besancon, Doubs, France|CHU de Brest -Site Hopital Morvan ( Site 0441), Brest, Finistere, France|Institut Bergonie ( Site 0421), Bordeaux, Gironde, France|Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, Haute-Garonne, France|Hopital Foch ( Site 0428), Suresnes, Hauts-de-Seine, France|Institut Regional du Cancer de Montpellier - ICM ( Site 0443), Montpellier, Herault, France|Institut De Cancerologie De L Ouest ( Site 0448), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, Loiret, France|Centre D Oncologie de Gentilly ( Site 0432), Nancy, Meurthe-et-Moselle, France|Institut Sainte Catherine ( Site 0447), Avignon, Provence-Alpes-Cote-d'Azur, France|Centre Jean Perrin ( Site 0434), Clermont-Ferrand, Puy-de-Dome, France|C.H.U. Lyon Sud ( Site 0436), Pierre Benite, Rhone, France|CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, Somme, France|Institut Gustave Roussy ( Site 0416), Villejuif, Val-de-Marne, France|Institut Mutualiste Montsouris ( Site 0446), Paris, France|Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304), Freiburg, Baden-Wurttemberg, Germany|Universitaetsklinikum in Mannheim ( Site 0314), Mannheim, Baden-Wurttemberg, Germany|Studienpraxis Urologie ( Site 0309), Nuertingen, Baden-Wurttemberg, Germany|Universitaetsklinik fuer Urologie ( Site 0307), Tuebingen, Baden-Wurttemberg, Germany|Universitaetsklinikum Erlangen ( Site 0303), Erlangen, Bayern, Germany|Klinikum Rechts der Isar ( Site 0300), Muenchen, Bayern, Germany|Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318), Nuernberg, Bayern, Germany|Universitaetsklinikum Duesseldorf ( Site 0306), Duesseldorf, Nordrhein-Westfalen, Germany|Krankenhaus der Barmherzigen Brueder Trier ( Site 0310), Trier, Rheinland-Pfalz, Germany|Universitaetsklinikum Jena ( Site 0305), Jena, Thuringen, Germany|Charite Universitaetsmedizin Berlin ( Site 0301), Berlin, Germany|Tallaght University Hospital ( Site 0730), Dublin, Ireland|Mid Western Cancer Centre ( Site 0728), Limerick, Ireland|Meir Medical Center ( Site 0544), Kfar Saba, Central, Israel|Assaf Harofe ( Site 0547), Be'er- Ya'akov, HaMerkaz, Israel|Rabin Medical Center ( Site 0545), Petach-Tikwa, HaMerkaz, Israel|Ha Emek Medical Center ( Site 0548), Afula, HaTsafon, Israel|Soroka Medical Center ( Site 0549), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0542), Tel-Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0543), Haifa, Israel|Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0462), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano, Italy|Medical Oncology Ospedale San Donato ( Site 0461), Arezzo, Italy|Policlinico S.Orsola-Malpighi ( Site 0453), Bologna, Italy|Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0463), Roma, Italy|Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Italy|Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Italy|Fujita Health University Hospital ( Site 0724), Toyoake, Aichi, Japan|National Cancer Center Hospital East ( Site 0702), Kashiwa, Chiba, Japan|Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba, Japan|National Hospital Organization Shikoku Cancer Center ( Site 0716), Matsuyama, Ehime, Japan|Kobe City Medical Center General Hospital ( Site 0726), Kobe, Hyogo, Japan|Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa, Japan|Kitasato University Hospital ( Site 0705), Sagamihara, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0706), Yokohama, Kanagawa, Japan|Nara Medical University Hospital ( Site 0715), Kashihara, Nara, Japan|Kindai University Hospital ( Site 0714), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 0713), Suita, Osaka, Japan|Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama, Japan|Dokkyo Medical University Saitama Medical Center ( Site 0707), Koshigaya, Saitama, Japan|Fuji City General Hospital ( Site 0725), Fuji, Shizuoka, Japan|Hamamatsu University Hospital ( Site 0720), Hamamatsu, Shizuoka, Japan|Yamaguchi University Hospital ( Site 0717), Ube, Yamaguchi, Japan|Chiba Cancer Center ( Site 0704), Chiba, Japan|Kyushu University Hospital ( Site 0718), Fukuoka, Japan|University of Miyazaki Hospital ( Site 0721), Miyazaki, Japan|Nagano Municipal Hospital ( Site 0723), Nagano, Japan|Nagasaki University Hospital ( Site 0719), Nagasaki, Japan|Osaka International Cancer Institute ( Site 0722), Osaka, Japan|Toranomon Hospital ( Site 0711), Tokyo, Japan|Nippon Medical School Hospital ( Site 0709), Tokyo, Japan|Keio University Hospital ( Site 0710), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 0174), Hwasun Gun, Jeonranamdo, Korea, Republic of|National Cancer Center ( Site 0176), Goyang-si, Kyonggi-do, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0173), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0171), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 0172), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Medisch Centrum Leeuwarden ( Site 0477), Leeuwarden, Fryslan, Netherlands|Radboud University Medical Center ( Site 0470), Nijmegen, Gelderland, Netherlands|Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Noord-Holland, Netherlands|Vrije Universiteit Medisch Centrum ( Site 0479), Amsterdam, Noord-Holland, Netherlands|Spaarne Ziekenhuis ( Site 0473), Hoofddorp, Noord-Holland, Netherlands|Ziekenhuisgroep Twente ( Site 0469), Almelo, Overijssel, Netherlands|Medisch Centrum Haaglanden ( Site 0471), Leidschendam, Zuid-Holland, Netherlands|Erasmus MC ( Site 0475), Rotterdam, Zuid-Holland, Netherlands|Franciscus Gasthuis en Vlietland ( Site 0489), Schiedam, Zuid-Holland, Netherlands|Auckland City Hospital ( Site 0193), Auckland, New Zealand|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Chelyabinskaya Oblast', Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 0559), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Omskaya Oblast', Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Samarskaya Oblast', Russian Federation|SBHI Leningrad Regional Oncology Dispensary ( Site 0588), Saint Petersburg, Sankt-Peterburg, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Sankt-Peterburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Sankt-Peterburg, Russian Federation|Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579), Tomsk, Tomskaya Oblast', Russian Federation|Hospital del Mar ( Site 0333), Barcelona, Barcelona [Barcelona], Spain|Hospital General Universitari Vall d Hebron ( Site 0334), Barcelona, Barcelona [Barcelona], Spain|Hospital Clinic ( Site 0323), Barcelona, Barcelona [Barcelona], Spain|Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona [Barcelona], Spain|Hospital Parc Tauli ( Site 0335), Sabadell, Barcelona [Barcelona], Spain|Hospital Josep Trueta ( Site 0321), Girona, Girona [Gerona], Spain|Hospital Quiron Madrid ( Site 0325), Pozuelo de Alarcon, Madrid, Spain|Hospital San Pedro de Alcantara ( Site 0326), Caceres, Spain|Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Spain|National Cheng Kung University Hospital ( Site 0134), Tainen, Tainan, Taiwan|China Medical University Hospital ( Site 0132), Taichung, Taiwan|Taichung Veterans General Hospital ( Site 0133), Taichung, Taiwan|National Taiwan University Hospital ( Site 0131), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0135), Taipei, Taiwan|University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, Bristol, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 0540), Cambridge, Cambridgeshire, United Kingdom|Musgrove Park Hospital ( Site 0537), Taunton, Somerset, United Kingdom|University of North Midlands NHS Foundation Trust ( Site 0527), Stoke-on-Trent, Staffordshire, United Kingdom|Mount Vernon Cancer Centre ( Site 0536), Northwood, United Kingdom|Royal Marsden Hospital ( Site 0526), Sutton, United Kingdom",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,OVARIAN CANCER,_ENZALUTAMIDE,NCT03464201,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Mar, Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|Hospital Madrid Sanchinarro (CIOCC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital de Navarra, Pamplona, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital La Fe, Valencia, Spain",7709517,C07D233/70,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,BREAST CANCER,_ENZALUTAMIDE,NCT02955394,Phase 2,Recruiting,Female,"18 Years to 101 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|West Cancer Center, Germantown, Tennessee, United States",7709517,C07D233/70,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,OVARIAN CANCER,_CYCLOPHOSPHAMIDE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",3987166,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,OVARIAN CANCER,_FLUDARABINE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",7547776,C07H19/16,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,NEOPLASMS,_CYCLOPHOSPHAMIDE,NCT03967223,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,NEOPLASMS,_FLUDARABINE,NCT03967223,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,PROSTATE CANCER,_CYCLOPHOSPHAMIDE,NCT03089203,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",3987166,7,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,PANCREATIC CANCER,_CYCLOPHOSPHAMIDE,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,PANCREATIC CANCER,_LEUCOVORIN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,PANCREATIC CANCER,_IRINOTECAN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,PANCREATIC CANCER,_ALDOXORUBICIN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.26,750.758,267.84,15.0,7.0,6.0,75.89,189.86,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,HEPATOCELLULAR CARCINOMA,_CYCLOPHOSPHAMIDE,NCT04011033,Phase 2|Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,BREAST CANCER,_METHOTREXATE,NCT02897700,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ganzhou City People's Hospital, Ganzhou, Jiangxi, China|China-Japan Union Hospital, Jilin University, Changchun, Jilin, China|Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China",6746429,A61M5/2425,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
O=c1[nH]cc(F)c(=O)[nH]1,BREAST CANCER,_FLUOROURACIL,NCT02897700,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ganzhou City People's Hospital, Ganzhou, Jiangxi, China|China-Japan Union Hospital, Jilin University, Changchun, Jilin, China|Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China",6670335,A61K8/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,LYMPHEDEMA,_TACROLIMUS,NCT04390685,Phase 1|Phase 2,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydvestjysk Sygehus, Esbjerg, Denmark|Department of Plastic and Reconstructive Surgery, Odense, Denmark|Sygehus Lillebælt Vejle, Vejle, Denmark",5260301,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,HEPATOCELLULAR CARCINOMA,_FLUDARABINE,NCT02905188,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Houston Methodist Hospital, Houston, Texas, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,METASTATIC COLORECTAL CANCER,_CAPECITABINE,NCT03869892,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Oncología e Investigación de Buenos Aires COIBA, Berazategui, Argentina|Fundación Favaloro Oncology Unit, Buenos Aires, Argentina|Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina|Fundación COIR Centro Oncológico de Interación Regional, Mendoza, Argentina|Instituto de Oncología de Rosario, Santa Fe, Argentina|ISIS Centro especializado, Santa Fe, Argentina|Centro Médico San Roque, Tucumán, Argentina|Blacktown Hospital Cancer and Haematology Centre, Blacktown, Australia|Frankston Private Peninsula and Southeast Oncology Group, Frankston, Australia|Lake Macquarie Private Hospital, Gateshead, Australia|St George Hospital St George Hospital Cancer Care Centre, Kogarah, Australia|Adventist HealthCare Integrated Cancer Centre, Wahroonga, Australia|Southern Medical Day Care Centre, Wollongong, Australia|Med. Universität Graz Klinische Abteilung für Onkologie, Graz, Austria|Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern Interne I, Linz, Austria|Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK), Salzburg, Austria|Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I, St. Poelten, Austria|Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie, Wien, Austria|Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica, Barretos, Brazil|Cenantron - Clinica, Belo Horizonte, Brazil|Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa, Brasília, Brazil|Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica, Ijuí, Brazil|Hospital Mae de Deus Oncologia, Porto Alegre, Brazil|Hospital São Rafael Centro Intergrado de Pesquisa, Salvador, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa, Santo André, Brazil|Hospital de Base Centro Integrado de Pesquisa, São José Do Rio Preto, Brazil|ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa, São Paulo, Brazil|Hospital A C Camargo Unidade de Pesquisa Clinica, São Paulo, Brazil|""Complex oncology center - Burgas"" EOOD Department of medical oncology, Burgas, Bulgaria|""Multiprofile hosp. for active treatmen Dr. Tota Venkova"" AD Department of medical oncology, Gabrovo, Bulgaria|SHAT of oncology diseases Dr. Marko Antonov Markov"" EOOD Department of medical oncology and palliative therapy, Varna, Bulgaria|Masarykuv onkologicky ustav Klinika komplexni onkologicke pece, Brno, Czechia|Vseobecna fakultni nemocnice Onkologicka klinika VFN a 1. LF UK, Praha, Czechia|Thomayerova nemocnice Onkologicka klinika 1. LF UK a TN, Praha, Czechia|Aalborg Universitetshospital, Syd Onkologisk Afdelin, Aalborg, Denmark|Regionshospitalet Herning, Hospitalsenheden Vest Onkologisk Afdeling, Herning, Denmark|Rigshospitalet Onkologisk Klinik, Kobenhavn, Denmark|Odense Universitetshospital Onkologisk Afdeling R, Odense, Denmark|East Tallinn Central Hospital Center of Oncology, Tallinn, Estonia|North Estonia Medical Centre Foundation Oncology and Haematology clinic, Tallinn, Estonia|Tartu University Hospital, Hematology - Oncology clinic, Radiotherapy and oncological therapy, Tartu, Estonia|Institut Sainte Catherine, Avignon, France|CHU Jean Minjoz Service d'oncologie médicale, Besancon, France|CHU Morvan Institut de Cancérologie et d'Hématologie, Brest, France|Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale, Lyon, France|Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale, Montbeliard, France|Centre Antoine Lacassagne Dpt d'Oncologie Médicale, Nice, France|Hôpital Saint-Antoine Service d'Oncologie Médicale, Paris, France|Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive, Paris, France|Hopital Haut-Leveque Hepato-gastroenterologie et oncologie digestive, Pessac, France|CHU Toulouse Rangueil Oncologie médicale digestive, Toulouse, France|Onkologische Schwerpunktpraxis Kurfuerstendamm, Berlin, Germany|Lübecker Onkologische Schwerpunktpraxis im Hochschulstadttei, Luebeck, Germany|Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III, Muenchen, Germany|Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly, Budapest, Hungary|Semmelweis University Radiology and Oncotherapy Clinic, Budapest, Hungary|Del-Pesti Centrumkh-Orsz. Hematologiai es Infektologiai Int. Szent Laszlo Telephely, Budapest, Hungary|Szent Imre Egyetem Oktatokorhaz Klinikai Onkologia, Budapest, Hungary|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O., Budapest, Hungary|Uzsoki Utcai Korhaz Onkoradiologiai Osztaly, Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz Onkoradiologiai Osztaly, Győr, Hungary|Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont, Kecskemét, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak Onkoradiologiai Osztaly, Nyíregyháza, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont Onkoterapias Intezet, Pécs, Hungary|JNSZ Megyei Hetenyi Geza Korhaz es Rendelointezet Megyei Onkologiai Centrum, Szolnok, Hungary|Markusovsky Egyetemi Oktatokorhaz Onkoradiologiai Osztaly, Szombathely, Hungary|Zala Megyei Korhaz Onkologiai osztaly, Zalaegerszeg, Hungary|Bon Secours Hospital, Cork, Ireland|Cork University Hospital Department of Medical Oncology, Cork, Ireland|Azienda Policlinico Universitaria - Presidio Monserrato Oncologia Medica, Cagliari, Italy|Azienda Socio Sanitaria Territoriale di Cremona ONCOLOGIA, Cremona, Italy|Istituto Nazionale Tumori I.R.C.C.S ""Fondazione G. Pascale"" Struttura Complessa di Oncologia Medica Addominale, Napoli, Italy|Istituto Oncologico Veneto IOV - IRCCS Unità Operativa Complessa Oncologia Medica 1, Padova, Italy|A.O.U. Pisana-Ospedale Santa Chiara U.O. di Oncologia Medica 2, Pisa, Italy|Ospedale San Carlo U.O. Oncologia Medica, Potenza, Italy|Arcispedale Santa Maria Nuova Unità di Oncologia, Reggio Emilia, Italy|Policlinico Universitario Campus Biomedico UOC di Oncologia Medica, Roma, Italy|Istituto Clinico Humanitas I.R.C.C.S Dipartimento di Oncologia Medica ed Ematologia, Rozzano (mi), Italy|IRCSS Casa Sollievo della Sofferenza Dipartimento Onco-Ematologia, San Giovanni Rotondo, Italy|Ospedale S. Bortolo -ULSS8 Berica Distretto Est U.O. ONCOLOGIA, Vicenza, Italy|P. Stradins Clinical University Hospital, Riga, Latvia|Riga East Univerity Hospital Oncology Centre of Latvia, Riga, Latvia|Oncology Hospital, Branch of Hospital of Lithuanian Uni. of Health Sciences Kauno klinikos, Kaunas, Lithuania|Hospital of Lithuania Univ of Health Sciences Kauno klinikos Oncology Institute, Kaunas, Lithuania|Klaipeda University hospital, Klaipėda, Lithuania|National Cancer Institute, Vilnius, Lithuania|Rijnstate Oncologie, Arnhem, Netherlands|Albert Schweitzer Ziekenhuis Interne Geneeskunde, Dordrecht, Netherlands|Catharina Ziekenhuis Interne Gesneeskunde/Oncologie, Eindhoven, Netherlands|St. Anna Ziekenhuis Interne Geneeskunde, Geldrop, Netherlands|Ikazia Ziekenhuis Oncologie, Rotterdam, Netherlands|ETZ Elisabeth Interne Geneeskunde, Tilburg, Netherlands|Bernhoven Interne Geneeskunde, Uden, Netherlands|Bialostockie Centrum Onkologii im Marii Curie-Sklodowskiej Oddzial Onkologii Klinicznej im Dr Ewy Pileckiej z pododdzialem Chemioterapii Dziennej, Białystok, Poland|Przychodnia Lekarska ""KOMED"", Konin, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii Oddzial Kliniczny Onkologii i Immunoonkologii, Olsztyn, Poland|Opolskie Centrum Onkologii im. Tadeusza Koszarowskiego Oddzial Onkologii Klinicznej, Opole, Poland|NU-MED Centrum Diagnostyki i Terapii Onkologicznej Tomaszów Mazowiecki II Sp. z o.o., Pododdzial Chemioterapi, Tomaszów Mazowiecki, Poland|Centro Hospitalar do Porto - Hospital de Santo Antonio Institute of Biomedical Sciences Abel Salazar, Porto, Portugal|Instituto Português de Oncologia do Porto FG, EPE -IPO Porto Medical Oncology Dept., Porto, Portugal|Institutul Oncologic ""Prof Alexandru Trestioreanu"" Busuresti Sectia Oncologie Medicala I, Bucuresti, Romania|Spitalul Clinic ""Fundeni"" Departament Oncologie Medicala - Gastroenterologie, Bucuresti, Romania|Spitalul Clinic ""Coltea"" Sectia Oncologie Medicala, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. I. Chiricuta"" Cluj Napoca Oncologie Medicala, Cluj-Napoca, Romania|S.C Oncolab S.R.L Sectia Oncologie Medicala, Craiova, Romania|Institutul Regional de Oncologie Iasi Clinica de Oncologie Medicala, Iaşi, Romania|Spitalul Clinic Judetean de Urgenta Sibiu Sectia Oncologie Medicala, Sibiu, Romania|S.C ONCOMED S.R.L Departament Oncologie Medicala, Timişoara, Romania|Arkhangelsk Clinical Oncology Dispensary chemotherapy department, Arkhangel'sk, Russian Federation|Clinical Oncology Dispensary No.1 Chemotherapy Department, Krasnodar, Russian Federation|Kursk Regional Clinical Oncology Dispensary Oncology Department, Kursk, Russian Federation|Russian Cancer Research Center n.a. NN Blokhin Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation|Moscow City Oncology Hospital # 62 chemotherapy department, Moscow, Russian Federation|Omsk Clinical Oncologic Dispensary Chemotherapy, Omsk, Russian Federation|Pyatigorsk Interdistrict Oncology Dispensary Chemotherapy department, Pyatigorsk, Russian Federation|Rostov Research Institute of Oncology Chemotherapy department, Rostov-on-Don, Russian Federation|Regional Clinical Oncology Dispensary, Ryazan', Russian Federation|Scientific Centre for Specialized Medical Care (oncological) Chemotherapy, Saint Petersburg, Russian Federation|Saint Petersburg City Oncology Clilnic, Saint Petersburg, Russian Federation|Multidisciplinary clinic ""Reaviz"", Samara, Russian Federation|Oncology Dispensary No.2, Sochi, Russian Federation|State Research Institution of Oncology of Tomsk Chemotherapy, Tomsk, Russian Federation|SBIH of YR ""Clinical oncology hospital"" chemotherapy department, Yaroslavl, Russian Federation|Narodny onkologicky ustav Oddelenie klinickej onkologie, Bratislava, Slovakia|Hospital General Universitario Alicante Servicio de Oncología, Alicante, Spain|Hospital Germans Trias i Pujol Unidad de Investigación clínica (UIC) ICO-Oncología medica, Badalona, Spain|H. Valle de Hebrón Servicio de Oncología - (VHIR), Barcelona, Spain|Hospital de la Santa Creu I Sant Pau Oncología Medica, Barcelona, Spain|Hospital Uni. Reina Sofía - Hospital Provincial Departamento de Oncología Médica, Córdoba, Spain|Hospital Virgen de las Nieves Unidad de Oncología Médica, Granada, Spain|INSTITUTO CATALAN DE ONCOLOGÍA - ICO Oncología Médica, Hospitalet de Llobregat, Spain|Hospital Unviersitario Gregorio Marañon Servicio de Oncología Médica, Madrid, Spain|Hospital Universitario Ramón y Cajal, Servicio de Oncologia Médica, Madrid, Spain|H. Clínico San Carlos Servicio de Oncología Médica, Madrid, Spain|HOSPITAL 12 DE OCTUBRE Servicio Oncología Médica, Madrid, Spain|H. Universitario La Paz Oncología Médica, Madrid, Spain|Hospital Universitario Marqués de Valdecilla Oncología médica, Santander, Spain|H.Virgen Del Rocio, Sevilla, Spain|Hospital Quirónsalud Valencia Servicio de Oncología Médica, Valencia, Spain|Hospital Universitario Miguel Servet Servicio de Oncología, Zaragoza, Spain|Falu Lasarett Onkologmottagningen, Falun, Sweden|Lanssjukhuset Ryhov Onkologiska kliniken, Jönköping, Sweden|Karolinska University Hospital, Solna Studiebehandlingsenheten, B8:09, Solna, Sweden|Lanssjukhuset Sundsvall-Harnöoand Onkologkliniken Sundsvall, Sundsvall, Sweden|Norrlands Universitetssjukhus Cancercentrum Umea, Umeå, Sweden|Akademiska sjukhuset Onkologmottagningen, Uppsala, Sweden|Universitetssjukhuset Orebro, Örebro, Sweden|Cherkasy Regional Oncological Dispensary Regional Clinical Oncological Centre, Cherkasy, Ukraine|Dnipro Regional Oncology Dispensary, Dnipro, Ukraine|Institute of Medical Radiology of S.P. Grygoryev of AMS UKR, Kharkiv, Ukraine|Kharkiv Regional Oncology Center, Kharkiv, Ukraine|National Institute of Cancer Abdominal Oncology Department, Kyiv, Ukraine|Kyiv City Clinical Oncology Centre Chemotherapy Department #2, Kyiv, Ukraine|Lviv Regional Oncology Center Chemotherapy department, Lviv, Ukraine|Odesa Regional Oncology Dispensary Day patient Department, Odesa, Ukraine|Podillia Regional Oncology Centre Chemotherapy Department, Vinnytsya, Ukraine|Aberdeen Royal Infirmary Oncology Department, Aberdeen, United Kingdom|University Hospitals Bristol Bristol Haematology & Oncology Centre, Bristol, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary The HOPE Clinical Trials Unit, Leicester, United Kingdom|Royal Marsden Hospital Department of Medicine, London, United Kingdom|Hammersmith Hospital Gary Weston Centre, London, United Kingdom|Sarah Cannon Research Institute UK Clinical Trials, London, United Kingdom|Christie Hospital NHS Foundation Trust GI & Endocrine, Manchester, United Kingdom|Royal Marsden Hospital Department of Medicine, Sutton, United Kingdom",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,RECTAL CANCER,_CAPECITABINE,NCT01716949,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Klinik Bad Trissl, Innere Medizin, Bad Trissl, Germany|University Hospital, Duesseldorf, Germany|Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Germany|LMU München, Campus Großhadern, Medizinische Klinik III, Hyperthermie, München, Germany|Schlossbergklinik, Oberstaufen, Germany|Universitätsklinikum Tübingen, Radioonkologie, Tübingen, Germany",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,HEPATOCELLULAR CARCINOMA,_CAPECITABINE,NCT04411706,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,HEPATOCELLULAR CARCINOMA,_APATINIB,NCT04411706,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,STOMACH NEOPLASMS,_CAPECITABINE,NCT03675737,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128), Orange, California, United States|University of California at Los Angeles (UCLA) ( Site 0124), Santa Monica, California, United States|University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113), Miami, Florida, United States|Greater Baltimore Medical Center ( Site 0102), Baltimore, Maryland, United States|Minnesota Oncology Hematology, PA ( Site 8000), Minneapolis, Minnesota, United States|University of Rochester ( Site 0122), Rochester, New York, United States|Cancer Treatment Centers of America - Philadelphia ( Site 0112), Philadelphia, Pennsylvania, United States|Allegheny General Hospital ( Site 0118), Pittsburgh, Pennsylvania, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8001), Roanoke, Virginia, United States|Wenatchee Valley Clinic [Wenatchee, WA] ( Site 0116), Wenatchee, Washington, United States|Instituto de Investigaciones Metabolicas ( Site 0312), Buenos Aires, Argentina|Fundacion Favaloro - Hospital Universitario ( Site 0302), Buenos Aires, Argentina|Centro Oncologico Riojano Integral ( Site 0313), La Rioja, Argentina|Liverpool Hospital ( Site 2301), Liverpool, New South Wales, Australia|Southern Medical Day Care Centre ( Site 2303), Wollongong, New South Wales, Australia|Box Hill Hospital ( Site 2300), Box Hill, Victoria, Australia|Instituto do Cancer do Ceara ( Site 0407), Fortaleza, Ceara, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0403), Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0401), Rio de Janeiro, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0404), Sao Paulo, Brazil|BC Cancer - Abbotsford ( Site 0206), Abbotsford, British Columbia, Canada|Sunnybrook Research Institute ( Site 0202), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0203), Toronto, Ontario, Canada|McGill University Health Centre ( Site 0208), Montreal, Quebec, Canada|Instituto Clinico Oncologico del Sur ( Site 0500), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0501), Santiago, Region M. De Santiago, Chile|Sociedad Oncovida S.A. ( Site 0508), Santiago, Region M. De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 0502), Santiago, Region M. De Santiago, Chile|Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421), Beijing, Beijing, China|Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China|Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital ( Site 2414), Fuzhou, Fujian, China|900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China|The First Affiliated Hospital of Xiamen University ( Site 2430), Xiamen, Fujian, China|Guangdong General Hospital ( Site 2431), Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital ( Site 2401), Harbin, Heilongjiang, China|Henan Cancer Hospital ( Site 2415), Zhengzhou, Henan, China|Hubei Cancer Hospital ( Site 2434), Wuhan, Hubei, China|Xiangya Hospital Central-South University ( Site 2419), Changsha, Hunan, China|The 81st Hospital of PLA ( Site 2413), Nanjing, Jiangsu, China|Jiangsu Cancer Hospital ( Site 2432), Nanjing, Jiangsu, China|Yancheng First People s Hospital ( Site 2426), Yancheng, Jiangsu, China|The First Hospital of Jilin University ( Site 2416), Chang chun, Jilin, China|The Affiliated Hospital of Qingdao University ( Site 2405), Qingdao, Shandong, China|Shanghai East Hospital ( Site 2403), Shanghai, Shanghai, China|Zhongshan Hospital affiliated to Fudan University ( Site 2407), Shanghai, Shanghai, China|1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428), XiAn, Shanxi, China|Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420), Urumqi, Xinjiang, China|Sir Run Run Show Hospital ( Site 2427), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 2417), Hangzhou, Zhejiang, China|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0608), Valledupar, Cesar, Colombia|Oncomedica S.A. ( Site 0606), Monteria, Cordoba, Colombia|Instituto Nacional de Cancerologia E.S.E ( Site 0605), Bogota, Distrito Capital De Bogota, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0604), Cali, Valle Del Cauca, Colombia|CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica|Policlinico San Bosco ( Site 3002), San Jose, Costa Rica|ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica|FN Ostrava ( Site 3105), Ostrava, Moravskoslezsky Kraj, Czechia|Fakultni Thomayerova Nemocnice [Prague, Czech Republic] ( Site 3101), Praha 4, Czechia|Rigshospitalet ( Site 3202), Copenhagen, Hovedstaden, Denmark|Aalborg University Hospital ( Site 3204), Aalborg, Nordjylland, Denmark|Odense Universitets Hospital ( Site 3201), Odense, Syddanmark, Denmark|CHU-Jean Minjoz ( Site 1002), Besancon, Doubs, France|C.H.R.U. de Brest - Hopital Morvan ( Site 1007), Brest, Finistere, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1004), Saint-Herblain, Loire-Atlantique, France|Centre Oscar Lambret ( Site 1003), Lille, Nord, France|CHU de Rouen ( Site 1006), Rouen, Seine-Maritime, France|Institut Gustave Roussy ( Site 1000), Villejuif, Val-de-Marne, France|CHU Hopital Saint Antoine ( Site 1001), Paris, France|Celan SA ( Site 0705), Guatemala, Guatemala|Oncomedica ( Site 0702), Guatemala, Guatemala|Grupo Angeles SA ( Site 0701), Guatemala, Guatemala|Private Clinic ( Site 0704), Guatemala, Guatemala|Centro Regional de Sub Especialidades Medicas SA ( Site 0703), Quetzaltenango, Guatemala|Prince of Wales Hospital ( Site 2503), Hong Kong, Hong Kong|Princess Margaret Hospital. ( Site 2502), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 2501), Hong Kong, Hong Kong|Bacs-Kiskun Megyei Korhaz ( Site 3306), Kecskemet, Bacs-Kiskun, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 3302), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Beaumont Hospital ( Site 2101), Dublin, Ireland|St. James s Hospital ( Site 1200), Dublin, Ireland|Tallaght University Hospital ( Site 1202), Dublin, Ireland|Meir Medical Center ( Site 1308), Kfar Saba, Central, Israel|Soroka University Medical Center ( Site 1305), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 1304), Ramat Gan, Tel Aviv, Israel|Edith Wolfson Medical Center ( Site 1307), Holon, Tell Abib, Israel|Sourasky Medical Center ( Site 1306), Tel Aviv, Tell Abib, Israel|Hadassah Ein Karem Jerusalem ( Site 1301), Jerusalem, Yerushalayim, Israel|Rambam Medical Center ( Site 1303), Haifa, Israel|Rabin Medical Center ( Site 1302), Petah Tikva, Israel|Istituto Europeo di Oncologia ( Site 1411), Milano, Lombardia, Italy|Istituto Oncologico Veneto ( Site 1412), Padova, Italy|Aichi Cancer Center Hospital ( Site 2619), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 2617), Kashiwa, Chiba, Japan|Hyogo Cancer Center ( Site 2604), Akashi, Hyogo, Japan|Kobe City Medical Center General Hospital ( Site 2603), Kobe, Hyogo, Japan|Ibaraki Prefectural Central Hospital ( Site 2610), Kasama, Ibaraki, Japan|Kagawa University Hospital ( Site 2615), Kita-gun, Kagawa, Japan|Kitasato University Hospital ( Site 2618), Sagamihara, Kanagawa, Japan|Kanagawa Cancer Center ( Site 2614), Yokohama, Kanagawa, Japan|Kansai Medical University Hospital ( Site 2608), Hirakata, Osaka, Japan|Kindai University Hospital ( Site 2616), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 2600), Suita, Osaka, Japan|Saitama Cancer Center ( Site 2601), Kitaadachi-gun, Saitama, Japan|National Hospital Organization Kyushu Cancer Center ( Site 2612), Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2611), Hiroshima, Japan|Kumamoto University Hospital ( Site 2602), Kumamoto, Japan|Niigata Cancer Center Hospital ( Site 2613), Niigata, Japan|Osaka International Cancer Institute ( Site 2607), Osaka, Japan|National Cancer Center Hospital ( Site 2606), Tokyo, Japan|Tokyo Metropolitan Komagome Hospital ( Site 2605), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2609), Tokyo, Japan|Seoul National University Hospital ( Site 2803), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2800), Seoul, Korea, Republic of|Asan Medical Center ( Site 2802), Seoul, Korea, Republic of|Samsung Medical Center ( Site 2801), Seoul, Korea, Republic of|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0808), Guadalajara, Jalisco, Mexico|Christus Muguerza Clinica Vidriera ( Site 0802), Monterrey, Nuevo Leon, Mexico|Medical Care and Research S.A. de C.V. ( Site 0809), Merida, Yucatan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0806), Ciudad de Mexico, Mexico|Instituto Nacional de Cancerologia. ( Site 0804), Mexico City, Mexico|Auckland City Hospital ( Site 2700), Auckland, New Zealand|Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0908), Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas ( Site 0901), Lima, Peru|Hospital Nacional Arzobispo Loayza ( Site 0902), Lima, Peru|Clinica San Gabriel ( Site 0907), Lima, Peru|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1506), Wroclaw, Dolnoslaskie, Poland|Dolnoslaskie Centrum Onkologii we Wroclawiu ( Site 1504), Wroclaw, Dolnoslaskie, Poland|Szpital Uniwersytecki w Krakowie ( Site 1503), Krakow, Malopolskie, Poland|Magodent Szpital Elblaska ( Site 1509), Warszawa, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1500), Warszawa, Mazowieckie, Poland|Przychodnia Lekarska Komed ( Site 1514), Konin, Wielkopolskie, Poland|Regionalny Szpital Specjalistyczny im Wl. Bieganskiego w Grudziadzu ( Site 1505), Grudziadz, Poland|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1608), Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|Blokhin National Medical Oncology ( Site 1604), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1614), Moscow, Moskva, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 1609), Samara, Samarskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 1616), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 1603), Saint Petersburg, Sankt-Peterburg, Russian Federation|Cancer Care Langenhoven Drive Oncology Centre ( Site 1708), Port Elizabeth, Eastern Cape, South Africa|Universitas Annex National Hospital ( Site 1701), Bloemfontein, Free State, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 1700), Johannesburg, Gauteng, South Africa|Wits Clinical Research ( Site 1707), Parktown-Johannesburg, Gauteng, South Africa|Tshwane District Hospital ( Site 1702), Pretoria, Gauteng, South Africa|The Oncology Centre Overport and Umhlanga ( Site 1705), Durban, Kwazulu-Natal, South Africa|Cancercare Rondebosch Oncology ( Site 1709), Cape Town, Western Cape, South Africa|Groote Schuur Hospital ( Site 1706), Cape Town, Western Cape, South Africa|Outeniqua Cancercare Oncology Unit ( Site 1704), George, Western Cape, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 1703), Kraaifontein, Western Cape, South Africa|Hospital Universitario General de Asturias ( Site 1802), Oviedo, Asturias, Spain|Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 1806), Badalona, Barcelona, Spain|Hospital Universitario Marques de Valdecilla ( Site 1804), Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid ( Site 1805), Pozuelo de Alarcon, Madrid, Spain|Hospital General Universitari Vall d Hebron ( Site 1801), Barcelona, Spain|Universitaetsspital Basel ( Site 1900), Basel, Basel-Stadt, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1907), Geneva, Geneve, Switzerland|Kantonsspital Graubuenden ( Site 1903), Chur, Grisons, Switzerland|Kantonsspital St. Gallen ( Site 1901), St. Gallen, Sankt Gallen, Switzerland|Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1905), Bellinzona, Ticino, Switzerland|Universitaetsspital Zuerich ( Site 1902), Zuerich, Zurich, Switzerland|Luzern Kantonsspital ( Site 1904), Luzern, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 2902), Kaohsiung, Taiwan|National Cheng Kung University Hospital ( Site 2901), Tainan, Taiwan|National Taiwan University Hospital ( Site 2900), Taipei, Taiwan|Mackay Memorial Hospital ( Site 2903), Taipei, Taiwan|Adana Sehir Hastanesi ( Site 2002), Adana, Turkey|Hacettepe University Medical Faculty ( Site 2017), Ankara, Turkey|Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006), Ankara, Turkey|Trakya Universitesi Tip Fakultesi ( Site 2015), Edirne, Turkey|Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000), Erzurum, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001), Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011), Izmir, Turkey|Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009), Malatya, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012), Sakarya, Turkey|City Clinical Hosp.4 of DCC ( Site 2201), Dnipro, Dnipropetrovska Oblast, Ukraine|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2200), Kryviy Rih, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2204), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 2208), Kharkiv, Kharkivska Oblast, Ukraine|Clinic of National Cancer Institute ( Site 2203), Kyiv, Kyivska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2213), Kyiv, Kyivska Oblast, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2205), Kyiv, Kyivska Oblast, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2210), Lviv, Lvivska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 2212), Odesa, Odeska Oblast, Ukraine|Medical Centre LLC Oncolife ( Site 2202), Zaporizhzhya, Zaporizka Oblast, Ukraine|South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 1205), Torquay, Devon, United Kingdom|Castle Hill Hospital ( Site 1201), Cottingham, East Riding Of Yorkshire, United Kingdom|University College London Hospital ( Site 1211), London, London, City Of, United Kingdom|St. Georges University Hospital NHS Foundation Trust ( Site 1204), London, London, City Of, United Kingdom",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,COLORECTAL CANCER METASTATIC,_CAPECITABINE,NCT04245865,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Oncology, Vejle Hospital, Vejle, Denmark",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,COLORECTAL CANCER METASTATIC,_FLUOROURACIL,NCT04245865,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Oncology, Vejle Hospital, Vejle, Denmark",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1,COLORECTAL CANCER METASTATIC,_TOCOTRIENOL,NCT04245865,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Oncology, Vejle Hospital, Vejle, Denmark",US-20070293449-A1,A61K9/1272 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.68,382.5787,29.46,2.0,1.0,2.0,48.12,122.8,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,COLON CANCER,_CAPECITABINE,NCT01918527,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Hilleroed Hospital, Hillerød, Denmark|Roskilde Hospital, Roskilde, Denmark|Sygehus Sønderjylland, Sønderborg, Denmark|Vejle Hospital, Vejle, Denmark|Haukeland University Hospital, Bergen, Norway|Sahlgrenska University Hospital, Göteborg, Sweden",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,SOFT TISSUE SARCOMA,_EVEROLIMUS,NCT03114527,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,SOFT TISSUE SARCOMA,_RIBOCICLIB,NCT03114527,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",8324225,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,BREAST NEOPLASM,_RIBOCICLIB,NCT03283384,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Ziekenhuisgroep Twente, Almelo, Netherlands|Ziekenhuis Amstelland, Amstelveen, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre Ziekenhuizen, Apeldoorn, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Stichting Reinier Haga Groep (Reinier de Graaf Gasthuis), Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HAGA Ziekenhuis, Den Haag, Netherlands|Stichting Deventer Ziekenhuisgroep, Deventer, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|Tergooi Ziekenhuizen, Hilversum, Netherlands|Westfriesgasthuis, Hoorn, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Bravis Ziekenhuis, Roosendaal, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Ziekenhuis Rivierenland, Tiel, Netherlands|Elisabeth Tweesteden Ziekenhuis, Tilburg, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands|Streekziekenhuis Koningin Beatrix, Winterswijk, Netherlands|Isala, Zwolle, Netherlands",8324225,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,ADVANCED PANCREATIC CANCER,_GEMCITABINE,NCT04098081,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Medical Center, Baltimore, Maryland, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,ADVANCED PANCREATIC CANCER,_GALETERONE,NCT04098081,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Medical Center, Baltimore, Maryland, United States",WO-2008154382-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,GASTRIC CANCER,_PACLITAXEL,NCT03801668,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,PANCREATIC CANCER,_PACLITAXEL,NCT04054362,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts Health NHS Trust, London, London, Greater, United Kingdom",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,PANCREATIC CANCER,_PARICALCITOL,NCT04054362,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts Health NHS Trust, London, London, Greater, United Kingdom",5246925,C07C401/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,GASTROINTESTINAL STROMAL TUMORS,_PACLITAXEL,NCT03944304,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,BREAST NEOPLASM,_ENTINOSTAT,NCT03280563,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Wellness Oncology and Hematology - Main Office, West Hills, California, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Cancer Center, Portland, Oregon, United States|UPMC Pinnacle Health System, Harrisburg, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Houston Methodist Hospital; Department of Pharmacy, Houston, Texas, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus; Davidof Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Pharmacy, Tel Aviv, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of",WO-2004058234-A2,0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BREAST NEOPLASM,_ABEMACICLIB,NCT03280563,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Wellness Oncology and Hematology - Main Office, West Hills, California, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Cancer Center, Portland, Oregon, United States|UPMC Pinnacle Health System, Harrisburg, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Houston Methodist Hospital; Department of Pharmacy, Houston, Texas, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus; Davidof Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Pharmacy, Tel Aviv, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of",7855211,C07D401/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,MYELODYSPLASTIC SYNDROME,_ENTINOSTAT,NCT02936752,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,NEUROENDOCRINE TUMORS,_ENTINOSTAT,NCT03211988,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N=C(N)NCCC[C@H](N)C(=O)O,GASTRIC CANCER,_ARGININE,NCT01704664,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Medical University of Bialystok, Bialystok, Podlaskie, Poland",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
NC(=O)CC[C@H](N)C(=O)O,GASTRIC CANCER,_GLUTAMINE,NCT01704664,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Medical University of Bialystok, Bialystok, Podlaskie, Poland",5288703.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,PANCREATIC CANCER,_LIDOCAINE,NCT04048278,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Illnois at Chicago, Chicago, Illinois, United States",5234957.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,PANCREATIC CANCER,_LIDOCAINE_HYDROCHLORIDE,NCT04048278,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Illnois at Chicago, Chicago, Illinois, United States",4091090,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
S=P(N1CC1)(N1CC1)N1CC1,BREAST CANCER,_THIOTEPA,NCT01646034,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NKI-AVL, Amsterdam, Netherlands",4766149,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,RECTAL CANCER,_LEUCOVORIN,NCT03000374,Phase 2,Recruiting,All,"18 Years to 74 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital de Sabadell, Sabadell, Barcelona, Spain|Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Hospital Politécnico Universitario La Fe, Valencia, Spain",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,COLORECTAL CANCER METASTATIC,_LEUCOVORIN,NCT03164655,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ico Paul Papin, Angers, France|Centre Eugene Marquis, Rennes, France|Chp Saint Gregoire, Saint-Grégoire, France|Gustave Roussy, Villejuif, France",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,COLORECTAL CANCER METASTATIC,_IRINOTECAN,NCT03164655,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ico Paul Papin, Angers, France|Centre Eugene Marquis, Rennes, France|Chp Saint Gregoire, Saint-Grégoire, France|Gustave Roussy, Villejuif, France",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATE CANCER,_HYDROCORTISONE,NCT00859781,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arizona Cancer Center, Tucson, Arizona, United States|Cedars Sinai, Los Angeles, California, United States|USC/Norris Comprehensive cancer center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Florida, Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",5635497,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,PROSTATE CANCER,_KETOCONAZOLE,NCT00859781,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arizona Cancer Center, Tucson, Arizona, United States|Cedars Sinai, Los Angeles, California, United States|USC/Norris Comprehensive cancer center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Florida, Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",5456851,A61K8/49,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATIC NEOPLASMS,_PREDNISOLONE,NCT04034095,,Recruiting,Male,"20 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Akita University Hospital, Akita, Japan|Juntendo University Hospital, Bunkyo-Ku, Japan|Tokyo Medical and Dental University Hospital, Bunkyo-Ku, Japan|The University of Tokyo Hospital, Bunkyo, Japan|Chiba University Hospital, Chiba, Japan|Chiba Cancer Center, Chiba, Japan|University of Yamanashi Hospital, Chuo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gifu University Hospital, Gifu, Japan|Harasanshin Hospital, Hakata-Ku, Japan|Hamamatsu Medical University Hospital, Hamamatsu, Japan|Saitama Medical University International Medical Center, Hidaka, Japan|Kansai Medical University Hospital, Hirakata, Japan|Hirosaki University Hospital, Hirosaki, Japan|Hiroshima University Hospital, Hiroshima, Japan|University of Occupational and Environmental Health, Hukuoka, Japan|Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan|Tokyo Medical University Ibaraki Medical Center, Inashiki, Japan|Kanazawa Medical University Hospital, Kahoku-District, Japan|Kyoto Prefectural University of Medicine Hospital, Kamigyo, Japan|St.Marianna University School of Medicine, Kanagawa, Japan|Kanazawa University Hospital, Kanazawa, Japan|Nara Medical University Hospital, Kashihara, Japan|Kimitsu Chuo Hospital, Kisarazu, Japan|Kagawa University Hospital, Kita-Gun, Japan|Kobe City Medical Center General Hospital, Kobe-City,, Japan|Kobe University Hospital, Kobe, Japan|Kochi Medical School Hospital, Kochi, Japan|Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan|The Cancer Institute Hospital of JFCR, Koto-Ku, Japan|NHO Shikoku Cancer Center, Matsuyama-Shi, Japan|Kitasato University Hospital, Minami-Ku, Sagamihara-Shi, Japan|Kyorin University Hospital, Mitaka, Japan|University of Miyazaki Hospital, Miyazaki, Japan|Iwate Medical University Hospital, Morioka, Japan|Aichi Medical University Hospital, Nagakute, Japan|Nagano Municipal Hospital, Nagano, Japan|Nagasaki University Hospital, Nagasaki, Japan|Nagoya University Hospital, Nagoya, Japan|Nagoya City University Hospital, Nagoya, Japan|University of the Ryukyus Hospital, Nakagami gun, Japan|Tokyo Metropolitan Police Hospital, Nakano-ku, Japan|Miyagi Cancer Center, Natori-shi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka-City, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Osaka International Cancer Institute, Osaka-Shi, Japan|Osaka University Hospital, Osaka, Japan|Toho University Medical Center Omori Hospital, Ota, Japan|Gunma Prefectural Cancer Center, Ota, Japan|Shiga University of Medical Science Hospital, Otsu, Japan|Saitama Medical Center, Saitama, Japan|Sapporo Medical University Hospital, Sapporo, Japan|Hokkaido University Hospital, Sapporo, Japan|Tohoku University Hospital, Sendai, Japan|Tohoku Medical And Pharmaceutical University Hospital, Sendai, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Showa University Hospital, Shinagawa, Japan|JCHO Tokyo Shinjuku Medical Center, Shinjuku-ku, Japan|Chutoen General Medical Center, Shizuoka, Japan|Osaka Medical College Hospital, Takatsuki, Japan|Tokushima University Hospital, Tokushima, Japan|Toranomon Hospital, Tokyo, Japan|The Jikei University Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Teikyo University Hospital, Tokyo, Japan|Ehime University Hospital, Toon, Japan|Toyama University Hospital, Toyama-shi, Japan|Fujita Health University Hospital, Toyoake, Japan|Mie University Hospital, Tsu, Japan|Yamaguchi University Hospital, Ube, Japan|Wakayama Medical University Hospital, Wakayama, Japan|Yamagata University Hospital, Yamagata, Japan|Yokohama Rosai Hospital, Yokohama, Japan|Yokohama City University Medical Center, Yokohama, Japan|Yokohama City University Hospital, Yokohama, Japan|Yokosuka Kyosai Hospital, Yokosuka, Japan|Tottori University Hospital, Yonago, Japan|University of Fukui Hospital, Yoshida, Japan|Oita University Hospital, Yufu, Japan",5178878,A61K9/0056,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],METASTATIC COLORECTAL CANCER,_LEUCOVORIN_CALCIUM,NCT04097444,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ac Medical Inc., Chuo Ku, Tokyo, Japan",4500711,C07D475/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,METASTATIC COLORECTAL CANCER,_IRINOTECAN_HYDROCHLORIDE,NCT04097444,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ac Medical Inc., Chuo Ku, Tokyo, Japan",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,PROSTATE CANCER,_HYDROXYCHLOROQUINE,NCT03513211,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia",4181725,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,GASTROINTESTINAL CANCER,_HYDROXYCHLOROQUINE,NCT04214418,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Irving Medical Center, New York, New York, United States",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,GASTROINTESTINAL CANCER,_COBIMETINIB,NCT04214418,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Irving Medical Center, New York, New York, United States",7803839,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,_OCTREOTIDE,NCT03972488,Phase 3,Recruiting,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sunnybrook Health Sciences Centre, Toronto, Canada|BC Cancer Agency, Vancouver, Canada|CHU Paris Nord-Val de Seine, Clichy, France|Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot, Lyon, France|Institut du Cancer de Montpellier - Oncology, Montpellier, France|Institut Gustave Roussy, Villejuif, France|A.O.di Bologna Policl.S.Orsola, Bologna, Italy|Istituto Oncologico Romagnolo, Meldola, Italy|IRCCS fondazione Pascale - Oncology, Napoli, Italy|Seoul National University Bundang Hospital, Seongnam-Si, Korea, Republic of|Seoul National University Hospital - Department of Internal, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System - Medical Oncology, Seoul, Korea, Republic of|Erasmus Medisch Centrum, Rotterdam, Netherlands|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Bristol Haematology and Oncology Centre, Bristol, United Kingdom",5538739.0,A61K38/31,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,METASTATIC COLORECTAL CANCER,_DEXAMETHASONE,NCT03626922,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Davis Cancer Pavilion & Shands Medical Plaza, Gainesville, Florida, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central IL-Swansea, Swansea, Illinois, United States|University of Michigan-Oncology, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Michigan-Brighton Center for Specialty Care, Brighton, Michigan, United States|Minnesota Oncology-Minneapolis, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|HealthPartners Riverside Clinic, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium-MMCORC, Saint Louis Park, Minnesota, United States|Thomas Jefferson University Hospital-Sidney Kimmel Cancer Network, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,METASTATIC COLORECTAL CANCER,_FOLIC_ACID,NCT03626922,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Davis Cancer Pavilion & Shands Medical Plaza, Gainesville, Florida, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central IL-Swansea, Swansea, Illinois, United States|University of Michigan-Oncology, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Michigan-Brighton Center for Specialty Care, Brighton, Michigan, United States|Minnesota Oncology-Minneapolis, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|HealthPartners Riverside Clinic, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium-MMCORC, Saint Louis Park, Minnesota, United States|Thomas Jefferson University Hospital-Sidney Kimmel Cancer Network, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,METASTATIC COLORECTAL CANCER,_PEMETREXED,NCT03626922,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Davis Cancer Pavilion & Shands Medical Plaza, Gainesville, Florida, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central IL-Swansea, Swansea, Illinois, United States|University of Michigan-Oncology, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Michigan-Brighton Center for Specialty Care, Brighton, Michigan, United States|Minnesota Oncology-Minneapolis, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|HealthPartners Riverside Clinic, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium-MMCORC, Saint Louis Park, Minnesota, United States|Thomas Jefferson University Hospital-Sidney Kimmel Cancer Network, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,HEPATOCELLULAR CARCINOMA,_SOMATOSTATIN,NCT02799212,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","APHP - Hôpital Beaujon, Clichy, France|Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon, France|APHM - Hôpital de la Timone, Marseille, France|CHU de Bordeaux - Hôpital Haut Lévèque, Pessac, France|CHU Rennes - Hôpital Pontchaillou, Rennes, France|CHU de Toulouse - Hopital Rangueil, Toulouse, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)NCC(O)COc1cccc2ccccc12,GASTRIC CANCER,_PROPRANOLOL,NCT04005365,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xiangya Hospital Central South University, Changsha, Hunan, China",6500454,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)NCC(O)COc1cccc2ccccc12,COLORECTAL NEOPLASMS,_PROPRANOLOL,NCT03919461,Phase 2,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HaEmek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center, Petah-Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel HaShomer, Israel|Asaf Harofeh Medical Center, Tsrifin, Israel",6500454,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,COLORECTAL NEOPLASMS,_ETODOLAC,NCT03919461,Phase 2,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HaEmek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center, Petah-Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel HaShomer, Israel|Asaf Harofeh Medical Center, Tsrifin, Israel",3939178,C07D495/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,57.0,41.0686051048276,2463.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.39,287.3535,62.32,3.0,2.0,3.0,31.94,81.16,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,MYELODYSPLASTIC SYNDROME,_SERTRALINE,NCT02452983,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States",4962128,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,MUCOSITIS,_FOLIC_ACID,NCT03581773,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aarhus University Hospital, Department of oncology, Aarhus, Central Region Of Denmark, Denmark|Department of Oncology, Herlev Hospital, Herlev, Denmark|Department of Oncology, Odense University Hospital, Odense, Denmark",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,OVARIAN CANCER,_ANLOTINIB,NCT03924882,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",8148532,C07D239/88,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,SOFT TISSUE SARCOMA,_ANLOTINIB,NCT03890068,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,HEPATOCELLULAR CARCINOMA,_ANLOTINIB,NCT03945799,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,GASTROINTESTINAL STROMAL TUMORS,_ANLOTINIB,NCT04106024,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,"CARCINOMA, HEPATOCELLULAR",_ANLOTINIB,NCT04066543,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,COLORECTAL NEOPLASMS,_ASCORBIC_ACID,NCT02969681,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",7169381.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,PANCREATIC CANCER,_AZACITIDINE,NCT01845805,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",4058602,C07H19/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,HEAD AND NECK CANCER,_AZACITIDINE,NCT03019003,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",4058602,C07H19/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,METASTATIC COLORECTAL CANCER,_TEMOZOLOMIDE,NCT03832621,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,COLORECTAL CANCER,_TEMOZOLOMIDE,NCT04166435,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale New Haven Hospital, New Haven, Connecticut, United States",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,COLORECTAL CANCER,_OLAPARIB,NCT04166435,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale New Haven Hospital, New Haven, Connecticut, United States",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,BREAST CANCER,_SUNITINIB,NCT02790580,Phase 2,Recruiting,Female,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore, Singapore",6573293,C07D403/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,STOMACH NEOPLASMS,_SUNITINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,STOMACH NEOPLASMS,_IMATINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",5521184,C07D409/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,STOMACH NEOPLASMS,_GEFITINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,GASTROINTESTINAL STROMAL TUMORS,_SUNITINIB,NCT03673501,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of California San Diego Medical Center, La Jolla, California, United States|UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States|Stanford Medicine, Stanford, California, United States|University of Colorado Hospital - Anschutz Cancer Pavillion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Audubon Hospital Campus, Louisville, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, United States|Montefiore Medical Center-Montefiore Medical Park, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University Center for Health and Healing, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert Hospital-Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Sanatorio Allende, Córdoba, Cordoba, Argentina|Instituto Medicao Especializado Alexander Fleming, Buenos Aires, Argentina|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Princess Alexandara Hospital, Woolloongabba, Australia|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Québec, Canada|Clinica San Carlos de Apoquindo Red Salud UC Christs, Santiago, Chile|Fakultni nemocnice v Motole, Prague, Czechia|Institut Bergonnié, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille Cedex, France|Centre Léon Bérard, Lyon, France|Hopital La Timone, Marseille, France|IPC, Marseille, France|IGR, Paris, France|CHU Poitiers-Hopital la Miletrie, Poitiers, France|ICO - Site René Gauducheau, Saint Herblain, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Technische Universitat Dresden, Dresden, Germany|West German Cancer Center, Essen, Germany|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Israel|Rabin Medical Cente, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy|stituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Universita degli Studi di Palermo, Palermo, Italy|Università Campus Bio-Medico di Roma, Rome, Italy|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Antoni van Leeuwenhoek, Amsterdam, Netherlands|The Netherlands Cancer Institute, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Oslo University Hospital, Oslo, Norway|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|National Cancer Centre, Singapore, Singapore|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncología,, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Karolinska universitetssjukhuset, Solna, Sweden|Centre Hospitalier Universitaire Vaudois, Fondation du Centre Pluridisciplinaire d'Oncologi, Lausanne, Switzerland|Universitaetsspital Zuerich, Klinik fuer Onkologie, Zurich, Switzerland|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Kaohsiung Chang Gung Memorial Hospital,, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Chen Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Royal Marsden Hospital - Fulham, London, United Kingdom|University College London Hospitals, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,PANCREATIC NEUROENDOCRINE TUMORS,_SUNITINIB,NCT02282059,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Other|Time Perspective: Prospective,"Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China|Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|SUN Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|The Affiliated Tumour Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Nanjing General Hospital of Nanjing Military Command/Hepatobiliary Surgery Department, Nanjing, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Digestive surgery Department, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shannxi, China|West China Hospital of Sichuan University/Hepatobiliary Pancreatic Surgery, Chengdu, Sichuan, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Oncology department, Hangzhou, Zhejiang, China|The PLA of 307 Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Medical University General Hospital/General Surgery, Tianjin, China",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,GASTRIC CANCER,_DOXORUBICIN,NCT04358341,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jian Xiao, Guangzhou, Guangdong, China",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,GASTRIC CANCER,_IRINOTECAN,NCT04358341,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jian Xiao, Guangzhou, Guangdong, China",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,OVARIAN CANCER,_DOXORUBICIN_HYDROCHLORIDE,NCT04337632,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hunan Cancer Hospital, Changsha, Hunan, China",4003996,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,PROSTATE CANCER,_LUTEIN,NCT04136353,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|GenesisCare Newcastle, Newcastle, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|St Vincent's Public Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Northern Cancer Institute, Sydney, New South Wales, Australia|Sydney Adventist Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Campbelltown hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|ROPART, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Icon Cancer Centre, Southport, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Centre - Bendigo Campus, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Palmerston North Hospital, Palmerston North, New Zealand",3932546.0,C07C11/21,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,23.1298383950389,1374.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.29,568.886,40.46,2.0,2.0,2.0,73.81,195.06,10.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,PROSTATE CANCER,_DAROLUTAMIDE,NCT04136353,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|GenesisCare Newcastle, Newcastle, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|St Vincent's Public Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Northern Cancer Institute, Sydney, New South Wales, Australia|Sydney Adventist Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Campbelltown hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|ROPART, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Icon Cancer Centre, Southport, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Centre - Bendigo Campus, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Palmerston North Hospital, Palmerston North, New Zealand",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,52.403540113760045,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,398.85,119.62,5.0,3.0,3.0,41.86,117.16,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,PROSTATE CANCER,_CURCUMIN,NCT03769766,Phase 3,Recruiting,Male,"40 Years to 89 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UT Southwestern Medical Center, Dallas, Texas, United States",4138212,C09B61/00,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,BREAST CANCER,_CURCUMIN,NCT03980509,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,BREAST CANCER,_VITAMIN_E,NCT04463459,Not Applicable,Recruiting,Female,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"BSMMU, Dhaka, Bangladesh",3932634.0,0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,BREAST CANCER,_METFORMIN,NCT04559308,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beni-suef university, Banī Suwayf, Egypt",6288095.0,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,FAMILIAL ADENOMATOUS POLYPOSIS,_METFORMIN,NCT01725490,Phase 2,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of|Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,COLON CANCER,_METFORMIN,NCT03359681,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Surgery, Slagelse Hospital, Slagelse, Denmark",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)N=C(N)N.Cl,COLON CANCER,_METFORMIN_HYDROCHLORIDE,NCT03359681,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Surgery, Slagelse Hospital, Slagelse, Denmark",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,COLORECTAL CANCER,_PEMETREXED,NCT02588781,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,COLORECTAL CANCER,_ASPIRIN,NCT03957902,Phase 2,Recruiting,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,COLON CANCER,_ASPIRIN,NCT03464305,Phase 3,Recruiting,All,"45 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZ Klina, Brasschaat, Antwerpen, Belgium|AZ Monica, Deurne, Antwerpen, Belgium|Heilige Familie, Rumst, Antwerpen, Belgium|Ziekenhuis Netwerk Antwerpen, Antwerp, East Flanders, Belgium|UZ Antwerpen, Edegem, East-Flanders, Belgium|Sint Jozefkliniek, Bornem, Oost-Vlaanderen, Belgium|AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, Belgium|Gasthuiszusters Ziekenhuizen, Antwerpen, Belgium|Clinique Saint-Luc, Bouge, Belgium|AZ Sint-Lucas, Brugge, Belgium|CHIREC, Brussels, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|AZ Sint-Blasius, Dendermonde, Belgium|AZ Alma, Eeklo, Belgium|AZ Sint-Dimpna, Geel, Belgium|AZ Maria Middelares, Gent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|RZ Heilig Hart, Leuven, Belgium|CH de l'Ardenne, Libramont, Belgium|CHR de la Citadelle, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|CH de Mouscron, Mouscron, Belgium|CHU UCL Namur Site de Sainte-Elisabeth, Namur, Belgium|Clinique Saint-Pierre, Ottignies-Louvain-la-Neuve, Belgium|AZ Glorieux, Ronse, Belgium|AZ Sint-Trudo, Sint-Truiden, Belgium|CHR Verviers, Verviers, Belgium|OLV van Lourdes Ziekenhuis, Waregem, Belgium",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,HEAD AND NECK CANCER,_ASPIRIN,NCT03245489,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,HEAD AND NECK CANCER,_CLOPIDOGREL,NCT03245489,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",4847265,C07D495/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,COLON CANCER,_ICOSAPENT,NCT03661047,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",4377526.0,C07C67/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,15.310375983079698,4159.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.53,302.45099999999996,37.3,2.0,1.0,0.0,35.93,101.07,13.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,COLON CANCER,_ICOSAPENT_ETHYL,NCT03661047,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",8188146,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,BREAST CANCER,_ATORVASTATIN,NCT02958852,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lund University Hospital, Department of Oncology, Lund, Sweden",4681893,C07D405/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,GASTRIC CANCER,_FLUOROURACIL,NCT04379596,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Santa Monica, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, São José do Rio Preto, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Verona, Italy|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Gdańsk, Poland|Research Site, Konin, Poland|Research Site, Warszawa, Poland|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,RECTAL CANCER,_FLUOROURACIL,NCT03299660,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,ADVANCED COLORECTAL CANCER,_IRINOTECAN,NCT04337879,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First Hospital of China Medical University, Shengyang, Liaoning, China",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,BREAST CANCER,_MIDAZOLAM,NCT04172220,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy",8217033,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,OVARIAN CANCER,_ROSUVASTATIN,NCT03532139,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",RE37314,C07D239/42 ,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,RECTAL CANCER,_ROSUVASTATIN,NCT02569645,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada",RE37314,C07D239/42 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CIRRHOSIS,_SIMVASTATIN,NCT02968810,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Cedars Sinai Medical Center, Los Angeles, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Puerto Rico, San Juan, Puerto Rico",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PERIPHERAL NEUROPATHY,_CANDESARTAN,NCT03688633,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CHU Limoges, Limoges, France",5605919,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,WILSON DISEASE,_BUPROPION,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5358970,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,WILSON DISEASE,_BUPROPION_HYDROCHLORIDE,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",RE33994,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,BREAST CANCER,_DEXMEDETOMIDINE,NCT03109990,Not Applicable,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Renji hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China",5344840,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"CARCINOMA, HEPATOCELLULAR",_SORAFENIB,NCT02794337,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India|Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India",7351834.0,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,WILSON DISEASE,_CELECOXIB,NCT04526197,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5972986.0,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,PANCREATIC CANCER,_LOSARTAN,NCT03563248,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Cancer Center, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Newton Wellesley Hospital, Newton, Massachusetts, United States|New York University Langone Medical Center, New York, New York, United States",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,GASTRIC CANCER,_REGORAFENIB,NCT03627728,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,RECTAL CANCER,_REGORAFENIB,NCT02910843,Phase 1,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Claraspital Basel, Basel, Switzerland|Universitätsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"CARCINOMA, HEPATOCELLULAR",_REGORAFENIB,NCT03347292,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Hospital and Clinics, Los Angeles, California, United States|University of Florida Health Sciences Center, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,SOFT TISSUE SARCOMA,_TRAMETINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,SOFT TISSUE SARCOMA,_DABRAFENIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,SOFT TISSUE SARCOMA,_LAPATINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",6391874,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,SOFT TISSUE SARCOMA,_NILOTINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,SOFT TISSUE SARCOMA,_PALBOCICLIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",6936612,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,SOFT TISSUE SARCOMA,_OLAPARIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,SOFT TISSUE SARCOMA,_CAPMATINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,SOFT TISSUE SARCOMA,_CERITINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7153964,C07D239/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,SOFT TISSUE SARCOMA,_GLASDEGIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",8148401,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,45.471159572065105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.68,374.448,96.84,4.0,3.0,4.0,40.98,108.26,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,METASTATIC COLORECTAL CANCER,_TRAMETINIB,NCT03668431,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hosital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institite, Boston, Massachusetts, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,METASTATIC COLORECTAL CANCER,_DABRAFENIB,NCT03668431,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hosital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institite, Boston, Massachusetts, United States",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,BREAST CANCER,_LENVATINIB,NCT03168074,Phase 2,Recruiting,Female,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nationa University Hospital, Singapore, Singapore",7253286,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,BREAST CANCER,_VENETOCLAX,NCT04298918,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Washington University; Division of Oncology, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady; Radioterapeuticka a onkologicka klinika, Praha 10, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Thomayerova nemocnice; Onkologicka klinika 1. LF UK A TN, Praha 4 - Krc, Czechia|Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Pharmacy, Budapest, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz; Onkoradiológia, Nyíregyháza, Hungary|Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet, Pécs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, Hungary|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Szpital Morski im. PCK; Poradnia Onkologiczna, Gdynia, Poland|PRATIA MCM Kraków, Kraków, Poland|Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland|Neuromed, Lublin, Poland|SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY, Olsztyn, Poland|MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Examen sp, Skórzewo, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|Dolnośląskie Centrum Onkologii; Oddział Onkologii Klinicznej i Chemioterapii, Wrocław, Poland|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,MYELODYSPLASTIC SYNDROME,_VENETOCLAX,NCT02942290,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States|University of Chicago /ID# 153673, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 153669, Baltimore, Maryland, United States|Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 153671, Saint Louis, Missouri, United States|Weill Cornell Medical College /ID# 155524, New York, New York, United States|Columbia University Medical Center /ID# 153661, New York, New York, United States|Oregon Health and Science University /ID# 152734, Portland, Oregon, United States|University of Pittsburgh MC /ID# 153662, Pittsburgh, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 152738, Nashville, Tennessee, United States|UT MD Anderson Cancer Center /ID# 153809, Houston, Texas, United States|Concord Repatriation & Gen Hos /ID# 154958, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst /ID# 222846, Darlinghurst, New South Wales, Australia|St George Hospital /ID# 154954, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 222410, Liverpool, New South Wales, Australia|Calvary Mater Newcastle /ID# 154957, Waratah, New South Wales, Australia|Princess Alexandra Hospital /ID# 154990, Woolloongabba, Queensland, Australia|Austin Hospital /ID# 154955, Heidelberg, Victoria, Australia|Alfred Health /ID# 154956, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 222847, Murdoch, Western Australia, Australia|Juravinski Cancer Clinic /ID# 152947, Hamilton, Ontario, Canada|CHU Hotel Dieu /ID# 153828, Nantes CEDEX 1, Pays-de-la-Loire, France|Hopital Saint-Louis /ID# 153827, Paris, France|Universitatsklinikum Mannheim /ID# 153140, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Duesseldorf /ID# 222576, Dusseldorf, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 153141, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gus /ID# 153958, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 153142, Leipzig, Sachsen, Germany|Universitaetsklinikum Halle (S /ID# 153760, Halle, Germany|Klinikum Rechts der Isar /ID# 153139, Munich, Germany|A.O.U. Policlinico S.Orsola-Malpighi /ID# 153763, Bologna, Emilia-Romagna, Italy|Azienda Policlinico Umberto I /ID# 153764, Rome, Lazio, Italy|Norfolk and Norwich Univ Hosp /ID# 156492, Norwich, Norfolk, United Kingdom|Heart of England NHS Foundation Trust /ID# 158810, Birmingham, United Kingdom|King's College Hospital NHS /ID# 156489, London, United Kingdom|Churchill Hospital /ID# 222567, Oxford, United Kingdom",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,BREAST NEOPLASM,_NERATINIB,NCT01670877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama Cancer Center, Birmingham, Alabama, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Southern California Keck School of Medicine, Los Angeles, California, United States|Stanford Medicine Cancer Institute, Stanford, California, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|St. Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center), Chapel Hill, North Carolina, United States|Duke Cancer Institute at Duke University Medical Center, Durham, North Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Baylor College of Medicine, Houston, Texas, United States|BC Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",6288082,C07D215/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,0.0,0.0,1.0,15.0,23.589806772212896,58.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,557.05,112.4,8.0,2.0,4.0,58.1,157.29,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,METASTATIC COLORECTAL CANCER,_NERATINIB,NCT03457896,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Baldwin, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente-Sunset, Los Angeles, California, United States|Kaiser Permanente-West Los Angeles (Cadillac), Los Angeles, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Kaiser Permanente-Sacramento, Sacramento, California, United States|Kaiser Permanente-Medical Group, San Diego, California, United States|Kaiser Permanente-Zion, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-San Jose, San Jose, California, United States|Kaiser Permanente-San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente Medical Center Santa Clara, Santa Clara, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|UF Health Davis Cancer Pavilion and Shands Medical Plaza, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Cancer Care Specialists of Central IL-Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crosslands Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central IL-Swansea, Swansea, Illinois, United States|Trinity Health Michigan, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|St. Joseph Mercy Brighton, Brighton, Michigan, United States|St. Joseph Mercy Canton, Canton, Michigan, United States|St. Joseph Mercy Chelsea, Chelsea, Michigan, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States|Spectrum Health Butterworth, Grand Rapids, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|St. Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Healthcare-Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Thomas Jefferson University Hospital-Sidney Kimmel Cancer Network, Philadelphia, Pennsylvania, United States|Wellmont Cancer Institute, Johnson City, Tennessee, United States|Wellmont Cancer Institute, Kingston, Tennessee, United States|Wellmont Medical Associates-Oncology and Hematology, Bristol, Virginia, United States|Southwest Virginia Regional Cancer Center, Norton, Virginia, United States",6288082,C07D215/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,23.589806772212896,58.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,557.05,112.4,8.0,2.0,4.0,58.1,157.29,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,PROSTATE CANCER,_ABEMACICLIB,NCT03706365,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Arizona Cancer Center, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|St. Bernards Medical Center, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|University of California - San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|Ridley- Tree Cancer Center, Santa Barbara, California, United States|Rocky Mountain Cancer Center, Lone Tree, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Millennium Oncology, Hollywood, Florida, United States|Cancer Care Center of Brevard, Palm Bay, Florida, United States|Northside Hospital Cancer Institute, Marietta, Georgia, United States|Fort Wayne Medical Oncology & Hematology, Inc., Fort Wayne, Indiana, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|Research Medical Center, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C, Albany, New York, United States|Associated Medical Professionals of NY, Syracuse, New York, United States|Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists PC, Tigard, Oregon, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Southwestern Medical Center - Dallas, Dallas, Texas, United States|Texas Oncology Fort Worth, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Scott & White Memorial Hospital & Clinic, Temple, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Southside Cancer Care Centre, Kogarah, New South Wales, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Finsen Institute, Copenhagen, Denmark|Næstved Sygehus, Næstved, Denmark|Studienpraxis Urologie, Nürtingen, Baden-Württemberg, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Asan Medical Center, Seoul, Kr-11, Korea, Republic of|Samsung Medical Center, Seoul, Kr-11, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Canisius-Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Erasmus Medisch Centrum, Rotterdam, South Holland, Netherlands|St. Antonius Ziekenhuis, locatie Nieuwegein, Utrecht, Netherlands|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania|S.C. R.T.C. Radiology Therapeutic Center S.R.L., Otopeni, Ilfov, Romania|SC Gral Medical SRL, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta, Constanta, Romania|Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|University College Hospital - London, London, Greater London, United Kingdom|Charing Cross Hospital, Chelsea, London, United Kingdom|Northampton General Hospital, Northampton, United Kingdom",7855211,C07D401/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BREAST CANCER,_ABEMACICLIB,NCT04565054,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany|Brustzentrum, LMU Klinikum, Ludwig-Maximilians-Universität,, Muenchen, Bayern, Germany|Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus, Moenchengladbach, NRW, Germany",7855211,C07D401/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CN(C)C(=N)N=C(N)N.Cl,BREAST CANCER,_METFORMIN_HYDROCHLORIDE,NCT04170465,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Damanhour University, Beheira, Egypt",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,PROSTATE CANCER,_IBRUTINIB,NCT02643667,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",7514444,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,BREAST NEOPLASM,_DECITABINE,NCT03295552,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",5654333,1,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,PCOS,_DAPAGLIFLOZIN,NCT04213677,Phase 3,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",6956026,A61K47/12,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,BREAST CANCER,_DICLOFENAC,NCT04511832,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"China Medical University Hospital, Taichung, Taiwan",6407079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,PANCREATIC CANCER,_WARFARIN,NCT03536208,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",3932656,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,MYELODYSPLASTIC SYNDROME,_PYRIMETHAMINE,NCT03057990,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",4062940.0,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,BREAST NEOPLASM,_CEFAZOLIN,NCT03742908,Not Applicable,Recruiting,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",3937655,C12Q1/18,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,COLORECTAL CANCER METASTATIC,_LAMIVUDINE,NCT03144804,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts general Hospital, Boston, Massachusetts, United States",5905082,C07D411/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,GASTRIC CANCER,_OLANZAPINE,NCT03575637,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Cancer Hospital & Institute, Beijing, China",5229382.0,C07D495/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,PROSTATE CANCER,_CARVEDILOL,NCT02944201,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",6022562,A61K9/5026,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,BREAST CANCER,_CARVEDILOL,NCT03879629,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,PANCREATIC CANCER,_FENTANYL,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",6169920,A61N1/303,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,PANCREATIC CANCER,_BUPIVACAINE,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",8182835.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)c1cccc(C(C)C)c1O,PANCREATIC CANCER,_PROPOFOL,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",5714520,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,PANCREATIC CANCER,_ROCURONIUM,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",5962536,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,RECTAL CANCER,_ONDANSETRON,NCT03182179,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHUV, Lausanne, Switzerland|Ospedale Regionale di Lugano, Civico e Italiano, Lugano, Switzerland",5344658,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CNC1(c2ccccc2Cl)CCCCC1=O,COLORECTAL CANCER,_KETAMINE,NCT03273231,Not Applicable,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other","Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",3966793,C07D307/52,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,COLORECTAL CANCER,_OXYCODONE,NCT03253133,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut réginal du Cancer de Montpellier, Montpellier, France",5508042,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,GASTRIC CANCER,_BLEOMYCIN,NCT04139070,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Surgery, Zealand University Hospital, Køge, Denmark",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,PROSTATE CANCER,_ROCURONIUM,NCT03808077,Phase 2,Recruiting,Male,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Memorial Sloan - Kettering Cancer Center, New York, New York, United States",5962536,1,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,GASTRIC CANCER,_NEOSTIGMINE,NCT04205097,Not Applicable,Recruiting,All,"19 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Gyeonggido, Korea, Republic of",4439427,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,GASTRIC CANCER,_SUGAMMADEX,NCT04205097,Not Applicable,Recruiting,All,"19 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Gyeonggido, Korea, Republic of",7265099,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,COLORECTAL CANCER,_MITOMYCIN,NCT02614534,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Sant Joan Despí. Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Provincial de Castellón, Castellón De La Plana, Castellón, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario de Gran Canaria ""Dr. Negrín"", Las Palmas De Gran Canaria, Islas Canarias, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz De Tenerife, Islas Canarias, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Torrecárdenas, Almería, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital General Universitario Reina Sofía, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",7806265.0,A61K9/0048,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,NEOPLASMS,_CRIZOTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7230098,C07D413/12,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,NEOPLASMS,_ALECTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",9126931,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,PANCREATIC CANCER,_APATINIB,NCT04415385,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,COLORECTAL CANCER,_APATINIB,NCT04446091,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Zhejiang Province Cancer Hospital, Hangzhou, Zhejiang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,COLORECTAL NEOPLASMS,_APATINIB,NCT03743428,Not Applicable,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Shenzhen People's Hospital, Shenzhen, Guang Dong, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,HEAD AND NECK CANCER,_APATINIB,NCT03654612,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the Second Xiangya Hospital, Changsha, Hunan, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,PROSTATE CANCER,_SAVOLITINIB,NCT03385655,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Jewish General Hospital, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",US-20140255428-A1,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,16.0,15.8360541284215,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,345.37,91.61,6.0,0.0,5.0,35.72,119.06,3.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,OVARIAN CANCER,_TOPOTECAN,NCT03763123,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|The first affiliated hospital,sun yat-sen university, Guangzhou, Guangdong, China|the Affiliated Cancer Hospital of Harbin Medical University, Harbin, Hei Longjiang, China|Hunan Cancer Hospital, Changsha, Hunan, China|Wuhan Union Hospital, Wuhan, Hunan, China",5004758,C07D491/22,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F,COLORECTAL NEOPLASMS,_FLOXURIDINE,NCT04552093,Phase 2|Phase 3,Recruiting,All,"18 Years to 115 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Netherlands",4283394,C07J51/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1811946857225,1401.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.2,246.1924,99.1,5.0,3.0,2.0,20.78,51.26,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,BREAST CANCER,_TALAZOPARIB,NCT04039230,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",8012976,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,PANCREATIC CANCER,_TALAZOPARIB,NCT03637491,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas, California, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States|University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Horizon Oncology Research, LLC, Lafayette, Indiana, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Institut Jules Bordet, Brussels, Belgium|UZ Gent, Gent, Belgium|Singapore National Eye Centre, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|SingHealth Investigational Medicine Unit, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",8012976,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,PANCREATIC CANCER,_BINIMETINIB,NCT03637491,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas, California, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States|University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Horizon Oncology Research, LLC, Lafayette, Indiana, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Institut Jules Bordet, Brussels, Belgium|UZ Gent, Gent, Belgium|Singapore National Eye Centre, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|SingHealth Investigational Medicine Unit, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,BREAST CANCER,_MEGESTROL_ACETATE,NCT03306472,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",5145684.0,B82Y5/00,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,2187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.71,384.51599999999996,60.44,3.0,0.0,4.0,43.51,108.66,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,COLORECTAL CANCER,_ARTESUNATE,NCT03093129,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","108 Military Central Hospital, Hanoi, Vietnam",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,SOFT TISSUE SARCOMA,_PIRARUBICIN,NCT04126811,Phase 2,Recruiting,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China",4818818,C07H15/252,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,29.14228218238561,628.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,627.643,204.3,13.0,5.0,6.0,64.85,157.38,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1,BREAST CANCER,_TOCOTRIENOL,NCT03855423,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Malaya Medical Center, Kuala Lumpur, Malaysia",US-20070293449-A1,A61K9/1272 ,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.68,382.5787,29.46,2.0,1.0,2.0,48.12,122.8,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CCN2c3ncccc3Cc3ccccc3C2C1,BREAST CANCER,_MIRTAZAPINE,NCT02336750,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Fudan University Cancer Hospital, Shanghai, China",5178878.0,A61K9/0056,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,GASTROINTESTINAL STROMAL TUMORS,_AXITINIB,NCT04258956,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maria Sklodowska-Curie National Research Institue of Oncology, Warsaw, Poland",6534524,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,16.7231359986858,54.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.17,386.47,70.67,3.0,2.0,4.0,42.58,115.14,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,HEPATOCELLULAR CARCINOMA,_TIVOZANIB,NCT03970616,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|University of California - Irvine, Orange, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States|The University of Texas Health Science Center at Tyler (UTHealth), Tyler, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",US-20040229876-A1,C07D335/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,84.0,34.760467360726,23.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,454.86300000000006,107.74,5.0,2.0,4.0,44.26,120.85,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,BREAST CANCER,_CHLORHEXIDINE,NCT02395614,Not Applicable,Recruiting,Female,"18 Years to 81 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",5538353,A45D34/04,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,PROSTATIC NEOPLASMS,_ZOLPIDEM,NCT03436745,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",6761910.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
O=c1[nH]c(=O)n(C2CCCO2)cc1F,GASTRIC CANCER,_TEGAFUR,NCT03006705,Phase 3,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anhui Province Clinical Site, Anhui Province, China|Beijing Clinical Site1, Beijing, China|Beijing Clinical Site2, Beijing, China|Cuangdong Province Clinical Site, Cuangdong Province, China|Guangdong Province Clinical Site1, Guangdong, China|Guangdong Province Clinical Site2, Guangdong, China|Henan Province Clinical Site1, Henan, China|Henan Province Clinical Site2, Henan, China|Jiangsu Province Clinical Site1, Jiangsu Province, China|Jiangsu Province Clinical Site3, Jiangsu Province, China|Jiangsu Province Clinical Site4, Jiangsu Province, China|Jiangsu Province Clinical Site5, Jiangsu Province, China|Jiangxi Province Clinical Site2, Jiangxi, China|Jilin Province Clinical Site, Jilin, China|Shanghai Clinical Site2, Shanghai, China|Shanxi Province Clinical Site, Shanxi, China|Tianjin Clinical Site1, Tianjin, China|Tianjin Clinical Site2, Tianjin, China|Zhejiang Province Clinical Site, Zhejiang, China|Zhengjiang Province Clinical Site, Zhengjiang Province, China|Aichi Clinical Site1, Nagoya, Aichi, Japan|Aichi Clinical Site2, Nagoya, Aichi, Japan|Chiba Clinical Site, Kamogawa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Ehime Clinicla Site, Matsuyama, Ehime, Japan|Gifu Clinical Site, Ōgaki, Gifu, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Takasaki, Gunma, Japan|Hiroshima Clinical Site, Fukuyama, Hiroshima, Japan|Hokkaido Clinical Site 3, Hakodate, Hokkaido, Japan|Hokkaido Clinical Site 1, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Ishikawa Clinical Site, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Miyagi Clinical Site, Osaki, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Okayama Clinical Site, Kurashiki, Okayama, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Osaka Clinical Site, Ōsaka-sayama, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site 1, Fukuoka, Japan|Fukuoka Clinical Site 2, Fukuoka, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site1, Hiroshima, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site3, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site1, Osaka, Japan|Osaka Clinical Site2, Osaka, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site4, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamagata Clinical Site, Yamagata, Japan|Busan Clinical Site1, Busan, Korea, Republic of|Busan Clinical Site2, Busan, Korea, Republic of|Busan Clinical Site3, Busan, Korea, Republic of|Daegu Clinical Site1, Daegu, Korea, Republic of|Daegu Clinical Site2, Daegu, Korea, Republic of|Daegu Clinical Site3, Daegu, Korea, Republic of|Daejeon Clinical Site 1, Daejeon, Korea, Republic of|Daejeon Clinical Site 2, Daejeon, Korea, Republic of|Gwangju Clinical Site, Gwangju, Korea, Republic of|Gyeonggi-do Clinical Site1, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site2, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site3, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site4, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site5, Gyeonggi-do, Korea, Republic of|Jeollabuk-do Clinical Site, Jeollabuk-do, Korea, Republic of|Seoul Clinical Site 8, Seoul, Korea, Republic of|Seoul Clinical Site 9, Seoul, Korea, Republic of|Seoul Clinical Site1, Seoul, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site7, Seoul, Korea, Republic of|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|New Taipei Clinical Site, New Taipei, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site2, Tainan, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site1, Taipei, Taiwan|Taipei Clinical Site2, Taipei, Taiwan",3948897,C07D405/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,29.897944516314503,918.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.09,200.169,58.64,3.0,1.0,2.0,17.52,44.5,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,RECTAL CANCER,_FOLINIC_ACID,NCT02704520,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aberdeen Royal Infirmary - NHS Grampion, Aberdeen, Aberdeenshire, United Kingdom|Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom|University Hospital of North Midlands NHS Trust - Royal Stoke, Stoke-on-Trent, Staffordshire, United Kingdom|Salisbury NHS Foundation Trust, Salisbury, Wiltshire, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|NHS Lanarkshire - Hairmyres Hospital, East Kilbride, United Kingdom|Diana Princess of Wales Hospital, Grimsby, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.8,473.4393,215.55,12.0,7.0,3.0,44.63,126.46,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,COLORECTAL CANCER METASTATIC,_FOLINIC_ACID,NCT03751176,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain|Hospital de Granollers, Granollers, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital General Universitario de Elche, Alicante, Elche, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|H. Universitari Sant Joan de Reus, Reus, Tarragona, Spain|Hospital de La Ribera de Alzira, Alzira, Valencia, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universtiario la Paz, Madrid, Spain|CIOCC Sanchinarro, Madrid, Spain|Complejo Hospitalario de Navarra, Navarro, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.8,473.4393,215.55,12.0,7.0,3.0,44.63,126.46,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,ADVANCED COLORECTAL CANCER,_FOLINIC_ACID,NCT04252456,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"A.O. Treviglio-Caravaggio, P.le Ospedale n1, Treviglio, Bergamo, Italy|A.O. Humanitas Gavazzeni, Bergamo, BG, Italy|Policlinico Universitario D.Casula, Monserrato, Cagliari, Italy|A.O. Polo Oncologico Vito Fazzi, Lecce, LE, Italy|ASST-Rhodense, Rho, Milano, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|AUSL di Piacenza, Piacenza, PC, Italy|Centro Riferimento, Aviano, PN, Italy|Azienda Ospedaliera San Carlo, Potenza, PZ, Italy|Ospedale Papa Giovanni XXIII, Bergamo, Italy|Fondazione Poliambulanza, Via Bissolati 57, Brescia, Italy|IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Istituto Europeo di Oncologia, Milano, Italy|A.O.U. Policlinico di Modena, Modena, Italy|A.O. S.Giovanni Calabita Fatebenefratelli, Roma, Italy|Ospedale San Bortolo, Vicenza, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.8,473.4393,215.55,12.0,7.0,3.0,44.63,126.46,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,SOFT TISSUE SARCOMA,_TRABECTEDIN,NCT02367924,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Other|Time Perspective: Prospective,"Dokusan GmbH und Co. KG; Praxisklinik Herne / Onkologie, Herne, Nordrhein-Westfalen, Germany|MVZ Marien-Hospital-Wesel GmbH, Wesel, Nordrhein-Westfalen, Germany|Onkologische Gemeinschaftspraxis Dr. med. Mohm & Dr. med. Prange-Krex, Dresden, Sachsen, Germany|Praxis Dr. med. Jens Uhlig, Naunhof, Sachsen, Germany|Praxis für Innere Medizin, Hämatologie u. Onkologie, Bremen, Germany",8895557,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,RECTAL CANCER,_EPACADOSTAT,NCT03516708,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",WO-2010005958-A2,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1,COLORECTAL CANCER,_MEBENDAZOLE,NCT03925662,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Cairo, Egypt",4009266,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,19.9429146389042,198.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.95,295.2927,84.08,4.0,2.0,3.0,31.1,81.5,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,BREAST CANCER,_RUCAPARIB,NCT03911453,Early Phase 1,Recruiting,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center, Tucson, Arizona, United States",6495541,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,OVARIAN CANCER,_ZAFIRLUKAST,NCT04339140,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",4859692,C07D249/18,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
FC(F)(F)C(F)(F)C(F)(F)F,HEPATOCELLULAR CARCINOMA|LIVER CANCER,_PERFLUTREN,NCT03199274,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",6723303,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
FS(F)(F)(F)(F)F,CIRRHOSIS,_SULFUR_HEXAFLUORIDE,NCT03407001,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"M D Anderson Cancer Center, Houston, Texas, United States",5686060,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,11.0,31.0150105751658,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,146.05,0.0,0.0,0.0,0.0,7.11,18.44,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)=O)cc1,COLORECTAL NEOPLASMS,_SULINDAC,NCT01349881,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Highlands Oncology Group-Rogers, Rogers, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|East Bay Radiation Oncology Center, Castro Valley, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States|Enloe Medical Center, Chico, California, United States|University Oncology Associates, Clovis, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Epic Care-Dublin, Dublin, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Valley Medical Oncology Consultants-Fremont, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|El Camino Hospital, Mountain View, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Hematology and Oncology Associates-Oakland, Oakland, California, United States|Tom K Lee Inc, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|East Bay Medical Oncology Hematology Medical Associates Inc-Pleasant Hill, Pleasant Hill, California, United States|Valley Medical Oncology Consultants, Pleasanton, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Epic Care Cyberknife Center, Walnut Creek, California, United States|Presbyterian Intercommunity Hospital, Whittier, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|South Florida Baptist Hospital, Plant City, Florida, United States|Saint Anthony's Hospital Cancer Care Center, Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute of Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Joseph Regional Medical Center, Lewiston, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Mac Neal Hospital, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Presence Saint Joseph Hospital-Chicago, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|OSF Saint Anthony Medical Center, Rockford, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Michiana Hematology Oncology PC-Crown Point, Crown Point, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Premier Oncology Hematology Associates, Merrillville, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|Porter Memorial Hospital, Valparaiso, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|MercyOne Waterloo Medical Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Newman Regional Health, Emporia, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Providence Medical Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Saint Elizabeth Fort Thomas, Fort Thomas, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Saint Claire Regional Medical Center, Morehead, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|Lallie Kemp Regional Medical Center, Independence, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Kaiser Permanente-Woodlawn Medical Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Western Maryland Regional Medical Center, Cumberland, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg, Maryland, United States|Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States|MedStar Montgomery Medical Center, Olney, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Boston Veteran's Affairs Medical Center, Jamaica Plain, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Riverwood Healthcare Center, Aitkin, Minnesota, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|The West Clinic - Corinth, Corinth, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|The West Clinic - Southaven, Southaven, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Veteran's Affairs Medical Center - Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States|Great Plains Health Callahan Cancer Center, North Platte, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Omaha, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Urology Cancer Center PC, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center Cancer Center, Scottsbluff, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Exeter Hospital, Exeter, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Chilton Medical Center, Pompton, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Inspira Medical Center Woodbury, Woodbury, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Hematology Oncology Associates of Central New York-Liverpool, Liverpool, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Hematology Oncology Associates of Central New York-Rome, Rome, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Gaston Hematology and Oncology Associates-Belmont, Belmont, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Carolina Surgical Clinic of Charlotte PA, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|Gaston Hematology and Oncology Associates, Gastonia, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Cleveland Hematology and Oncology Associates PC, Shelby, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lancaster Radiation Oncology, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|South Pointe Hospital, Warrensville Heights, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Easton Hospital, Easton, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Phoenixville Hospital, Phoenixville, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Oncology - Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Charleston, South Carolina, United States|Charleston Oncology - Saint Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|The West Clinic - Wolf River, Germantown, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|The West Clinic - Mid-Town, Memphis, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Hendrick Medical Center, Abilene, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|Audie L Murphy VA Hospital, San Antonio, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|White River Junction Veteran Administration Medical Center, White River Junction, Vermont, United States|Kaiser Permanente-Burke Medical Center, Burke, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Seattle Cancer Care Alliance at EvergreenHealth, Kirkland, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|Capital Medical Center, Olympia, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Pacific Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Saint Mary's Medical Center, Huntington, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Ascension Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",4207340,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,17.7416374052855,1478.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.96,356.411,54.37,3.0,1.0,3.0,37.2,99.56,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
NCCCC(N)(C(=O)O)C(F)F,COLORECTAL NEOPLASMS,_EFLORNITHINE,NCT01349881,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Highlands Oncology Group-Rogers, Rogers, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|East Bay Radiation Oncology Center, Castro Valley, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States|Enloe Medical Center, Chico, California, United States|University Oncology Associates, Clovis, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Epic Care-Dublin, Dublin, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Valley Medical Oncology Consultants-Fremont, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|El Camino Hospital, Mountain View, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Hematology and Oncology Associates-Oakland, Oakland, California, United States|Tom K Lee Inc, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|East Bay Medical Oncology Hematology Medical Associates Inc-Pleasant Hill, Pleasant Hill, California, United States|Valley Medical Oncology Consultants, Pleasanton, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Epic Care Cyberknife Center, Walnut Creek, California, United States|Presbyterian Intercommunity Hospital, Whittier, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|South Florida Baptist Hospital, Plant City, Florida, United States|Saint Anthony's Hospital Cancer Care Center, Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute of Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Joseph Regional Medical Center, Lewiston, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Mac Neal Hospital, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Presence Saint Joseph Hospital-Chicago, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|OSF Saint Anthony Medical Center, Rockford, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Michiana Hematology Oncology PC-Crown Point, Crown Point, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Premier Oncology Hematology Associates, Merrillville, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|Porter Memorial Hospital, Valparaiso, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|MercyOne Waterloo Medical Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Newman Regional Health, Emporia, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Providence Medical Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Saint Elizabeth Fort Thomas, Fort Thomas, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Saint Claire Regional Medical Center, Morehead, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|Lallie Kemp Regional Medical Center, Independence, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Kaiser Permanente-Woodlawn Medical Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Western Maryland Regional Medical Center, Cumberland, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg, Maryland, United States|Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States|MedStar Montgomery Medical Center, Olney, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Boston Veteran's Affairs Medical Center, Jamaica Plain, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Riverwood Healthcare Center, Aitkin, Minnesota, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|The West Clinic - Corinth, Corinth, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|The West Clinic - Southaven, Southaven, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Veteran's Affairs Medical Center - Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States|Great Plains Health Callahan Cancer Center, North Platte, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Omaha, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Urology Cancer Center PC, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center Cancer Center, Scottsbluff, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Exeter Hospital, Exeter, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Chilton Medical Center, Pompton, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Inspira Medical Center Woodbury, Woodbury, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Hematology Oncology Associates of Central New York-Liverpool, Liverpool, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Hematology Oncology Associates of Central New York-Rome, Rome, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Gaston Hematology and Oncology Associates-Belmont, Belmont, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Carolina Surgical Clinic of Charlotte PA, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|Gaston Hematology and Oncology Associates, Gastonia, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Cleveland Hematology and Oncology Associates PC, Shelby, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lancaster Radiation Oncology, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|South Pointe Hospital, Warrensville Heights, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Easton Hospital, Easton, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Phoenixville Hospital, Phoenixville, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Oncology - Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Charleston, South Carolina, United States|Charleston Oncology - Saint Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|The West Clinic - Wolf River, Germantown, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|The West Clinic - Mid-Town, Memphis, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Hendrick Medical Center, Abilene, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|Audie L Murphy VA Hospital, San Antonio, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|White River Junction Veteran Administration Medical Center, White River Junction, Vermont, United States|Kaiser Permanente-Burke Medical Center, Burke, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Seattle Cancer Care Alliance at EvergreenHealth, Kirkland, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|Capital Medical Center, Olympia, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Pacific Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Saint Mary's Medical Center, Huntington, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Ascension Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",4330559,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,15.408940635331302,178.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,182.171,89.34,4.0,3.0,0.0,15.8,37.73,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,PROSTATE CANCER,_TESTOSTERONE,NCT03716739,Phase 2,Recruiting,Male,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",5152997,A61K9/7084,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,PROSTATE CANCER,_TESTOSTERONE_CYPIONATE,NCT03716739,Phase 2,Recruiting,Male,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",5340584,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,32.0,18.661574159633602,315.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.1,412.61400000000003,43.37,2.0,0.0,5.0,49.87,119.36,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,PROSTATE CANCER,_TESTOSTERONE_ENANTHATE,NCT02090114,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sibley Memorial Hospital, Washington, District of Columbia, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",8021335,A61M5/30,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,FAMILIAL ADENOMATOUS POLYPOSIS,_NICLOSAMIDE,NCT04296851,Phase 2,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",4283400,A23K10/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,319.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.49,327.12,95.15,4.0,2.0,2.0,28.47,80.51,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,COLORECTAL CANCER METASTATIC,_LOPERAMIDE,NCT03705442,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Department of Radiotherapy and Oncology, Rijeka, Primorsko-goranska, Croatia",6103260,8,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,36.9617445943448,375.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.44,477.038,43.78,3.0,1.0,4.0,52.67,139.32,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,HEPATOCELLULAR CARCINOMA,_INDOCYANINE_GREEN,NCT04258566,Phase 1,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)C(=O)O,PROSTATE CANCER,_PYRUVATE,NCT02913131,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC(=O)C(=O)O,BREAST CANCER,_PYRUVATE,NCT03121989,Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,BREAST CANCER,_PACRITINIB,NCT04520269,Phase 1|Phase 2,Recruiting,All,"21 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore",WO-2010068181-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,SPONTANEOUS BACTERIAL PERITONITIS,_NORFLOXACIN,NCT04161768,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Sherief Abd-Elsalam, Tanta, Egypt",4146719,C07D215/56,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,13.2733731698802,646.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.47,319.3308,72.88,6.0,2.0,3.0,32.26,85.48,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1ccc2cc3ccc(N)cc3nc2c1,BARRETT'S ESOPHAGUS,_PROFLAVINE,NCT02018367,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Baylor College of Medicine, Houston, Texas, United States",4189423,C07D209/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.661574159633602,291.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1,209.2465,64.93,3.0,2.0,3.0,23.17,65.46,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)CCC=C1c2ccccc2COc2ccccc21,BREAST CANCER,_DOXEPIN,NCT02447211,Phase 2,Recruiting,Female,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of",6211229,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,BREAST CANCER,_TOMIVOSERTIB,NCT04261218,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,METASTATIC COLORECTAL CANCER,_FRUQUINTINIB,NCT03977090,Phase 1,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,393.399,95.71,5.0,1.0,4.0,40.64,106.25,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,COLORECTAL CANCER,_FRUQUINTINIB,NCT04431791,,Recruiting,All,"Child, Adult, Older Adult",Other,Observational Model: Cohort|Time Perspective: Other,"Beijing Cancer Hospital, Beijing, Beijing, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,393.399,95.71,5.0,1.0,4.0,40.64,106.25,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,PCOS,_SALSALATE,NCT03229408,Phase 2,Recruiting,Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Frank González, Chicago, Illinois, United States",3954533,C06B23/007,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,PANCREATIC CANCER,_METHYLNALTREXONE,NCT04083651,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Bausch Site 001, Omaha, Nebraska, United States",6559158,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,43.0,31.2778496478367,15.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.59,356.441,66.76,4.0,2.0,6.0,38.04,107.42,2.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C(O)c1cc(O)c2c(c1)C(C1c3cc(C(=O)O)cc(O)c3C(=O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc31)c1cccc(OC3OC(CO)C(O)C(O)C3O)c1C2=O,COLON CANCER,_SENNOSIDES,NCT03475680,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Service de chirurgie Colorectale / Hôpital Beaujon, Clichy, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.94,862.7460000000003,347.96,20.0,12.0,8.0,81.49,205.44,9.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,OVARIAN CANCER,_BRIVANIB,NCT03895788,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jing Wang, Changsha, Hunan, China",US-20040072832-A1,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,20.1400439434074,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.32,370.384,84.67,4.0,2.0,4.0,37.82,110.02,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,_ETELCALCETIDE,NCT03633708,Phase 3,Recruiting,All,"up to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Kolkata, West Bengal, India|Research Site, Seoul, Korea, Republic of|Research Site, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Seremban, Negri Sembilan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Singapore, Singapore|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey",8999932,C07K7/08,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,56.280416435655695,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.4,1048.26,557.71,23.0,22.0,0.0,108.23,303.63,36.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,MYELODYSPLASTIC SYNDROME,_IMETELSTAT,NCT02598661,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|CBCC Global Research, Inc, Bakersfield, California, United States|UCLA Ronald Regan Medical Center, Los Angeles, California, United States|Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Franciscan Health, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, New York, New York, United States|Columbia Presbyterian, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic Taussig Cancer, Cleveland, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|Prairie lakes Healthcare system, Inc, Watertown, South Dakota, United States|Tennessee Oncology at Centennial Medical Center, Nashville, Tennessee, United States|Texas Oncology/Methodist Charlton Cancer Center, Dallas, Texas, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|ZNA Middelheim, Antwerpen, Belgium|ZNA Stuivenberg- Middelheim, Antwerpen, Belgium|AZ Klina, Brasschaat, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|GZA Ziekenhuizen - Campus Sint, Wilrijk, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada|University of Alberta Hospital - Hematology Research, Edmonton, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|Fakultni nemocnice Brno, Brno, Brno-město, Czechia|FN Hradec Kralove, Hradec Králové, Czechia|FN Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|CHU de Grenoble - Hôpital Albe, La Tronche, Isère, France|CHRU Nancy Brabois, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France|CHU de Poitiers, Poitiers, Vienne, France|CHU d'Angers, Angers, France|CHRU de Lille - Hopital Claude Huriez - Maladies du Sang, Lille, France|CHU de Limoges, Hopital Dupuytren, Limoges, France|CHU de Nice Hopital de l Archet, Nice, France|Hopital Saint-Louis, Paris Cedex 10, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France|CHU Bretonneau, Tours Cedex, France|University Hospital Freiburg, Freiburg, Baden-Württemberg, Germany|Fachärztliche Gemeinschaftspraxis mit Schwerpunkt, Dresden, Sachsen, Germany|University Hospital Leipzig, Leipzig, Sachsen, Germany|Studienzentrum für Hämatologie, Onkologie,Diabetologie, Endoskopie und Fußambulanz, Aschaffenburg, Germany|University Hospital Bonn, Bonn, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Duesseldorf, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Johannes Gutenberg Universität, Mainz, Germany|Klinikum rechts der Isar an der Technischen Universität München, München, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Kaplan Medical Center, Reẖovot, Hagalil Saint, Israel|The Edith Wolfson Medical Center, H̱olon, HaMerkaz, Israel|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Ha'Emek Medical Center, Afula, HaZafon, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Tel-Aviv, Israel|The Chaim Sheba Medical Center, Tel HaShomer, Tel-Aviv, Israel|Carmel MC, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Istituto Clinico Humanitas Rozzano, IRCCS, Rozzano, Milano, Italy|Irccs Crob, Rionero In Vulture, Potenza, Italy|AOU Ospedali Riuniti Umberto I G.M. Lancisi G. Salesi, Ancona, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|A.O. Ospedale Niguarda Ca' Granda, Milano, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|A.O. Ospedali Riuniti Marche Nord Presidio Ospedaliero S. Salvatore di Pesaro-Stabilim. di Muraglia, Pesaro, Italy|Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria, Reggio Calabria, Italy|A.O. Universitaria Policlinico Tor Vergata, Roma, Italy|AO S. Andrea, Università degli Studi di Roma La Sapienza, Roma, Italy|Ospedale di Circolo, PO Varese, Varese, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei Uni, Seoul, Korea, Republic of|Meander Medisch Centrum, Amersfoort, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Radboud Umcn, Nijmegen, Netherlands|Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Russian Federation|City Clinical Hospital, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|FGU-Russian Research Institut, Saint Petersburg, Russian Federation|Oncologic Dispensary No.2, Sochi, Russian Federation|H.U.Pta.del Mar, Cadiz, Cádiz, Spain|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|Hospital Universitario Doctor, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.2,4610.18,1587.05,74.0,45.0,35.0,442.86,1045.35,95.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,CIRRHOSIS,_CATECHIN,NCT03278925,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"MedStar Georgetown University Hospital, Washington, District of Columbia, United States",4094969,A01N25/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,24.0,35.9103883036612,1741.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,PANCREATIC CANCER,_SECRETIN,NCT03404661,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Control|Time Perspective: Prospective,"Mayo Clinic in Florida, Jacksonville, Florida, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,COLORECTAL CANCER,_TIPIRACIL,NCT03974594,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tangdu Hospital,Fourth Military Medical University, Xi'an, Shanxi, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,67.81248074909136,7.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.21,242.662,85.29,4.0,3.0,2.0,22.48,69.89,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F,COLORECTAL CANCER,_TRIFLURIDINE,NCT03974594,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tangdu Hospital,Fourth Military Medical University, Xi'an, Shanxi, China",5744475,C07D239/553,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,17.183104375859802,772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.45,296.1999,99.1,5.0,3.0,2.0,23.07,56.34,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,BREAST CANCER,_ALPELISIB,NCT03056755,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic (Arizona), Phoenix, Arizona, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of Calif Irvine Medical Center, Orange, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Cancer Research Collaboration, Inc, Santa Ana, California, United States|Yale University Yale Cancer Center, New Haven, Connecticut, United States|Miami Cancer Center at Mercy Hospital, Miami, Florida, United States|Advent Health Cancer Institute, Orlando, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Louisville Hospital/James Brown Cancer Ctr. SC, Louisville, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Holy Cross Hospital Pharmacy, Silver Spring, Maryland, United States|Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Josephine Ford Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States|Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States|Texas Oncology P A SC-3, Dallas, Texas, United States|Texas Oncology Houston Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology P A Plano East, Plano, Texas, United States|Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|UT Health San Antonio, San Antonio, Texas, United States|Virginia Oncology Associates SC, Norfolk, Virginia, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Troisdorf, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Jalisco, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,34.431918519887475,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,441.47,101.21,4.0,2.0,3.0,42.75,105.85,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,METASTATIC MELANOMA,_NIRAPARIB,NCT03925350,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Pacific Medical Center Research Institute, San Francisco, California, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC MELANOMA,_CYCLOPHOSPHAMIDE,NCT03475134,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHUV Oncology Department, Lausanne, Vaud, Switzerland",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC MELANOMA,_FLUDARABINE,NCT03475134,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHUV Oncology Department, Lausanne, Vaud, Switzerland",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,HEMATOLOGICAL MALIGNANCY,_CYCLOPHOSPHAMIDE,NCT03344705,Phase 1,Recruiting,All,"4 Years to 75 Years   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Third Hospital, Beijing, Beijing, China",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,HEMATOLOGICAL MALIGNANCY,_FLUDARABINE,NCT03344705,Phase 1,Recruiting,All,"4 Years to 75 Years   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Third Hospital, Beijing, Beijing, China",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,HEMATOLOGICAL MALIGNANCY,_TACROLIMUS,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5260301,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,HEMATOLOGICAL MALIGNANCY,_BUSULFAN,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5430057,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,HEMATOLOGICAL MALIGNANCY,_MYCOPHENOLATE_MOFETIL,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,METASTATIC BREAST CANCER,_GEMCITABINE,NCT03901339,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Avondale, Arizona, United States|Arizona Oncology Associates, PC, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center, Orange, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Laura and Isaac Perlmutter Cancer Center/NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|The West Clinic, PC dba West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Chirec Cancer Institute, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Hopital de Mercy, Ars-Laquenexy, France|Institut Sainte Catherine, Avignon, France|Hôpital Jean-Minjoz, Besançon, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Hospices Civils de Lyon, Pierre-Bénite, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Gynakologisches Zentrum Bonn, Bonn, Germany|Marienhospital Bottrop, Bottrop, Germany|Städtisches Klinikum Dessau, Dessau, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany|Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|Gynakologisch-Onkologische Praxis Hannover, Hannover, Germany|Nationales Centrum für Tumorerkrankungen - Heidelberg, Heidelberg, Germany|Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany|Universitätsmedizin Mannheim, Mannheim, Germany|Ospedale di Desio, Desio, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|IFO Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Complejo Hospitalario Universitario A Coruna, A Coruña, Spain|Hospital Quirónsalud Barcelona Instituto Oncologico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Provincial de Castellón, Castillón, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Instituto Oncologico Bureau (IOB), Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Royal Cornwall Hospital NHS Trust, Cornwell, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE CANCER,_OLAPARIB,NCT03810105,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Chicago, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,METASTATIC MELANOMA,_MELPHALAN,NCT01920516,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, Pesaro, PU, Italy",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,METASTATIC BREAST CANCER,_DOXORUBICIN,NCT04159818,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antoni van Leeuwenhoek, Amsterdam, Netherlands",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,HEMATOLOGICAL MALIGNANCY,_BORTEZOMIB,NCT03850366,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henry Ford hospital, Detroit, Michigan, United States",6083903.0,C07K5/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,METASTATIC MELANOMA,_COBIMETINIB,NCT04109456,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MD Anderson, Houston, Texas, United States",7803839,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1,COVID-19|SARS-COV-2,_PYRIDOSTIGMINE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",3931205,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],COVID-19|SARS-COV-2,_PYRIDOSTIGMINE_BROMIDE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",5298504,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,METASTATIC BREAST CANCER,_IMIQUIMOD,NCT03982004,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4689338,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,METASTATIC BREAST CANCER,_DISULFIRAM,NCT04265274,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Institute, Bratislava, Slovakia",3932346,C08F2/50,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,RECURRENT PROSTATE CANCER,_VERTEPORFIN,NCT03067051,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keith Cengel, Philadelphia, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust, London, United Kingdom",5214036.0,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,BREAST CANCER,_SAPACITABINE,NCT03641755,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Broad Institute of MIT, Cambridge, Massachusetts, United States",US-20050014716-A1,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,32.7488,2.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,PROSTATE CANCER,_PIMONIDAZOLE,NCT02095249,Not Applicable,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",5674693,G01N33/57492,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.678494424936794,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.58,254.29,84.43,5.0,1.0,2.0,25.32,65.83,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,METASTATIC BREAST CANCER,_ERDAFITINIB,NCT03238196,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California San Francicso, San Francisco, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Baptist Memorial Hospital MEMPHIS, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,45.0,24.31261422205795,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,446.555,77.33,7.0,1.0,4.0,51.0,139.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,NEWLY DIAGNOSED MULTIPLE MYELOMA,_PREDNISONE,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",6488960,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,NEWLY DIAGNOSED MULTIPLE MYELOMA,_MELPHALAN,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8410077,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,NEWLY DIAGNOSED MULTIPLE MYELOMA,_CARFILZOMIB,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,DIFFUSE LARGE B CELL LYMPHOMA,_PREDNISONE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",6488960,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,DIFFUSE LARGE B CELL LYMPHOMA,_CYCLOPHOSPHAMIDE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,DIFFUSE LARGE B CELL LYMPHOMA,_GEMCITABINE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,DIFFUSE LARGE B CELL LYMPHOMA,_EPIRUBICIN,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",4950738.0,A61K41/0042,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,DIFFUSE LARGE B CELL LYMPHOMA,_VINDESINE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,HEMATOLOGIC NEOPLASMS,_CYCLOPHOSPHAMIDE,NCT01374841,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"European Institute of Oncology, Milan, Italy",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,DIFFUSE LARGE B CELL LYMPHOMA,_METHOTREXATE,NCT04214626,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,DIFFUSE LARGE B CELL LYMPHOMA,_LENALIDOMIDE,NCT04214626,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_METHOTREXATE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_VINCRISTINE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6723338,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_DEXAMETHASONE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,PERIPHERAL T CELL LYMPHOMA,_METHOTREXATE,NCT03321890,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,ACUTE MYELOID LEUKEMIA,_TACROLIMUS,NCT03467386,Phase 1,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,LYMPHOMA,_BUSULFAN,NCT03151876,Phase 2,Recruiting,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing cancer hospital, Beijing, Beijing, China|Peking university third hospital, Beijing, Beijing, China|The first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China|Southwest Hospital, Chongqing, Chongqing, China|General Hospital of Lanzhou military command, Lanzhou, Gansu, China|Henan cancer hospital, Zhengzhou, Henan, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu province hospital, Nanjing, Jiangsu, China|Rui jin hospital Shanghai jiao tong University, Shanghai, Shanghai, China|Tong Ren Hospital, Shanghai, Shanghai, China|Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Southwest Medical University, Nanchong, Sichuan, China|Blood diseases hospital, Chinese academy of medica, Tianjin, Tianjing, China|The first affiliated hospital of Xinjiang medical Universtiy, Ürümqi, Xinjiang, China|Kunming General Hospital of Chengdu Military Area, Kunming, Yunnan, China",5430057,2,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,LYMPHOMA,_CLADRIBINE,NCT03151876,Phase 2,Recruiting,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing cancer hospital, Beijing, Beijing, China|Peking university third hospital, Beijing, Beijing, China|The first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China|Southwest Hospital, Chongqing, Chongqing, China|General Hospital of Lanzhou military command, Lanzhou, Gansu, China|Henan cancer hospital, Zhengzhou, Henan, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu province hospital, Nanjing, Jiangsu, China|Rui jin hospital Shanghai jiao tong University, Shanghai, Shanghai, China|Tong Ren Hospital, Shanghai, Shanghai, China|Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Southwest Medical University, Nanchong, Sichuan, China|Blood diseases hospital, Chinese academy of medica, Tianjin, Tianjing, China|The first affiliated hospital of Xinjiang medical Universtiy, Ürümqi, Xinjiang, China|Kunming General Hospital of Chengdu Military Area, Kunming, Yunnan, China",7888328.0,7,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,PERIPHERAL T CELL LYMPHOMA,_FLUDARABINE,NCT04083495,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,PERIPHERAL T CELL LYMPHOMA,_BENDAMUSTINE,NCT04083495,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,OVARIAN CANCER,_PALBOCICLIB,NCT03936270,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil|AC Camargo Cancer Center, São Paulo, Brazil|Hospital Beneficência Portuguesa, São Paulo, Brazil|Hospital Pérola Byington, São Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil",6936612,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,PROSTATE CANCER,_PALBOCICLIB,NCT02905318,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Jewish General Hospital, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",6936612,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,MULTIPLE MYELOMA,_VINORELBINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,MULTIPLE MYELOMA,_GEMCITABINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,DIFFUSE LARGE B-CELL LYMPHOMA,_VINORELBINE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,DIFFUSE LARGE B-CELL LYMPHOMA,_MITOXANTRONE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",3977953,C12C3/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,DIFFUSE LARGE B-CELL LYMPHOMA,_DEXAMETHASONE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,DIFFUSE LARGE B-CELL LYMPHOMA,_THALIDOMIDE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",6235756,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,DIFFUSE LARGE B-CELL LYMPHOMA,_GEMCITABINE,NCT04182204,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|The Cancer Institute at St Francis Hospital, East Hills, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Millennium Oncology, Houston, Texas, United States|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Centre Henri Becquerel; Service Hématologie, Rouen, France|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Cork University Hospital, Cork, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,DIFFUSE LARGE B-CELL LYMPHOMA,_VEDOTIN,NCT04182204,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|The Cancer Institute at St Francis Hospital, East Hills, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Millennium Oncology, Houston, Texas, United States|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Centre Henri Becquerel; Service Hématologie, Rouen, France|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Cork University Hospital, Cork, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,NK/T CELL LYMPHOMA,_GEMCITABINE,NCT04230330,Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Centre Singapore, Singapore, Singapore",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,NK/T CELL LYMPHOMA,_DEXAMETHASONE,NCT04230330,Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Centre Singapore, Singapore, Singapore",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,ACUTE MYELOID LEUKEMIA,_ENTINOSTAT,NCT01305499,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale School of Medicine, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,ACUTE LYMPHOBLASTIC LEUKEMIA,_METHYLPREDNISOLONE,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_ACETAMINOPHEN,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_DIPHENHYDRAMINE,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",8263647,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,MULTIPLE MYELOMA,_METHYLPREDNISOLONE,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,MULTIPLE MYELOMA,_RUXOLITINIB,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,ACUTE MYELOID LEUKEMIA,_MYCOPHENOLATE_MOFETIL,NCT02782546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,ACUTE LYMPHOBLASTIC LEUKEMIA,_CLADRIBINE,NCT03318419,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",7888328.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,DIFFUSE LARGE B CELL LYMPHOMA,_CYTARABINE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",5455044,A61K9/127,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,DIFFUSE LARGE B CELL LYMPHOMA,_MELPHALAN,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,DIFFUSE LARGE B CELL LYMPHOMA,_ETOPOSIDE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4701327,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=NN(CCCl)C(=O)NCCCl,DIFFUSE LARGE B CELL LYMPHOMA,_CARMUSTINE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4028410,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,MYELODYSPLASTIC SYNDROME,_CYTARABINE,NCT03412266,Phase 2,Recruiting,All,"1 Year to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Institute of Hematology,Beijing, Beijing, Beijing, China",5455044,A61K9/127,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,ACUTE MYELOID LEUKEMIA,_ELTROMBOPAG,NCT03603795,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHU ANGERS - Maladies du sang, Angers, France|CH de la Côte Basque - Hématologie, Bayonne, France|CHU Estaing, Clermont-Ferrand, France|CHU Grenoble - Hématologie Clinique, Grenoble, France|Institut Paoli-Calmettes - Hématologie 2, Marseille, France|Hôpital Saint-Eloi - Hématologie Clinique, Montpellier, France|HOPITAL E. MULLER - Hématologie, Mulhouse, France|CHU HOTEL DIEU - Hématologie Clinique, Nantes, France|CHU Caremeau, Nîmes, France|CHU La Milétrie - Hématologie Clinique, Poitiers, France|CHU Pontchaillou, Rennes, France|CHU Hautepierre - Hématologie, Strasbourg, France|Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie, Toulouse, France|Sponsor FILO, Tours, France|CHU de Brabois, Vandœuvre-lès-Nancy, France",6280959,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,ACUTE MYELOID LEUKEMIA,_MELPHALAN,NCT02771197,Phase 2,Recruiting,All,"18 Years to 78 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,MULTIPLE MYELOMA,_HYDROXYCHLOROQUINE,NCT04163107,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo, Norway|St. Olavs Hospital, Department of Hematology, Trondheim, Norway",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,MULTIPLE MYELOMA,_ACETAMINOPHEN,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,MULTIPLE MYELOMA,_DIPHENHYDRAMINE,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8263647,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,MULTIPLE MYELOMA,_MONTELUKAST,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CNNCc1ccc(C(=O)NC(C)C)cc1,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,_PROCARBAZINE,NCT03495960,Phase 2,Recruiting,All,70 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aarhus University Hospital, Aarhus, Denmark|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Bari IRCCS Istituto Tumori, Bari, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, Meldola, Italy|Milano, IRCCS Ospedale San Raffaele, Milan, Italy|Milano - Îstituto Besta, Milan, Italy|Milano Niguarda, Milan, Italy|Modena, Policlinico Universitario, Modena, Italy|Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi, Pescara, Italy|Piacenza, Piacenza, Italy|Ravenna - Ospedale di Ravenna - IRST, Ravenna, Italy|Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy|Roma - Unicampus-Bio, Roma, Italy|S. Giovanni Rotondo - Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy|Siena - Azienda Ospedaliera Universitaria Senese, Siena, Italy|Terni - Ospedale di Terni, Terni, Italy|Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, Torino, Italy|Tricase - Ospedale ""Card. G. Panico"", Tricase, Italy|Udine, Azienda Ospedaliera Universitaria, Udine, Italy|Basel - Universitätsspital, Basel, Switzerland|IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Bern - Inselspital, Bern, Switzerland|St. Gallen - Kantonsspital, Saint Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland",3993072,A61M31/002,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0
Cn1nnc2c(C(N)=O)ncn2c1=O,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,_TEMOZOLOMIDE,NCT03495960,Phase 2,Recruiting,All,70 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aarhus University Hospital, Aarhus, Denmark|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Bari IRCCS Istituto Tumori, Bari, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, Meldola, Italy|Milano, IRCCS Ospedale San Raffaele, Milan, Italy|Milano - Îstituto Besta, Milan, Italy|Milano Niguarda, Milan, Italy|Modena, Policlinico Universitario, Modena, Italy|Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi, Pescara, Italy|Piacenza, Piacenza, Italy|Ravenna - Ospedale di Ravenna - IRST, Ravenna, Italy|Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy|Roma - Unicampus-Bio, Roma, Italy|S. Giovanni Rotondo - Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy|Siena - Azienda Ospedaliera Universitaria Senese, Siena, Italy|Terni - Ospedale di Terni, Terni, Italy|Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, Torino, Italy|Tricase - Ospedale ""Card. G. Panico"", Tricase, Italy|Udine, Azienda Ospedaliera Universitaria, Udine, Italy|Basel - Universitätsspital, Basel, Switzerland|IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Bern - Inselspital, Bern, Switzerland|St. Gallen - Kantonsspital, Saint Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland",5260291,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=P1(NCCCl)OCCCN1CCCl,DIFFUSE LARGE B CELL LYMPHOMA,_IFOSFAMIDE,NCT03736616,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Swedish Cancer Institute, Seattle, Washington, United States",5252341,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,DIFFUSE LARGE B CELL LYMPHOMA,_ACALABRUTINIB,NCT03736616,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Swedish Cancer Institute, Seattle, Washington, United States",7459554,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,LYMPHOMA,_DEXAMETHASONE,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",6284804,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,LYMPHOMA,_IBRUTINIB,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",7514444,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=S(=O)(O)CCS,LYMPHOMA,_MESNA,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,WALDENSTRÖM MACROGLOBULINEMIA,_DEXAMETHASONE,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,WALDENSTRÖM MACROGLOBULINEMIA,_ZANUBRUTINIB,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.836054128421528,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,471.561,102.48,4.0,2.0,5.0,51.75,146.25,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,PERIPHERAL T CELL LYMPHOMA,_AZACITIDINE,NCT04480125,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, China",4058602,C07H19/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,MANTLE CELL LYMPHOMA,_LENALIDOMIDE,NCT04109872,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Retrospective,"Hospital Universitario Virgen Macarena, Sevilla, Spain",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,DIFFUSE LARGE B-CELL LYMPHOMA,_LENALIDOMIDE,NCT04404283,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St Louis, Saint Louis, Missouri, United States",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,NON HODGKIN LYMPHOMA,_LENALIDOMIDE,NCT02180711,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Innovative Clinical Research, Whittier, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Center, Louisville, Kentucky, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Clinical Research Alliance, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,NON HODGKIN LYMPHOMA,_ACALABRUTINIB,NCT02180711,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Innovative Clinical Research, Whittier, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Center, Louisville, Kentucky, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Clinical Research Alliance, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",7459554,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,_POMALIDOMIDE,NCT04191616,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Cincinnati, Ohio, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Hamburg, Germany|Research Site, Tubingen, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Ancona, Italy|Research Site, Brescia, Italy|Research Site, Lecce, Italy|Research Site, Roma, Italy",5635517,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,LYMPHOMA,_RUXOLITINIB,NCT02974647,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,HODGKIN LYMPHOMA,_RUXOLITINIB,NCT03681561,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois Cancer Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Wisconsin, Madison, Wisconsin, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,MANTLE CELL LYMPHOMA,_DOXORUBICIN_HYDROCHLORIDE,NCT03710772,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4003996,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,CARCINOMA|NON-SMALL-CELL LUNG,_PEMETREXED,NCT03952403,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cancer Hospital Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_ASPIRIN,NCT04160546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Català d´oncologia Badalona (ICO), Badalona, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen de La Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_PONATINIB,NCT04160546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Català d´oncologia Badalona (ICO), Badalona, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen de La Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",8114874,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,ACUTE LYMPHOBLASTIC LEUKEMIA,_PENTOXIFYLLINE,NCT02451774,Phase 2|Phase 3,Recruiting,All,"1 Year to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Civil de Guadalajara ""Dr. Juan I. Menchaca"", Guadalajara, Jalisco, Mexico",4189469,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,LYMPHOMA,_SIMVASTATIN,NCT04514029,Early Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,DIFFUSE LARGE B CELL LYMPHOMA,_BORTEZOMIB,NCT03129828,Phase 1|Phase 2,Recruiting,All,"61 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany",6083903.0,C07K5/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,DIFFUSE LARGE B CELL LYMPHOMA,_IBRUTINIB,NCT03129828,Phase 1|Phase 2,Recruiting,All,"61 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,ACUTE MYELOID LEUKEMIA,_BORTEZOMIB,NCT04173585,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Heidelberg, Internal Medicine V, Heidelberg, Baden-Württemberg, Germany",6083903.0,C07K5/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,ACUTE MYELOID LEUKEMIA,_DASATINIB,NCT02013648,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitätsklinik für Innere Medizin V, Innsbruck, Austria|Krankenhaus der Barmherzigen Schwestern, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Universitätsklinik der PMU, Salzburg, Austria|Hanuschkrankenhaus, Wien, Austria|MVZ Osthessen, Fulda, Hessen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany|Helios Klinikum Bad Saarow, Klinik für Hämatologie, Bad Saarow, Germany|Klinikum am Urban, Berlin, Germany|Klinikum Neukölln, Berlin, Germany|Charité Universitätsmedizin Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Medizinische Klinik und Poliklinik III, Bonn, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Klinikum Bremen Mitte gGmbH, Bremen, Germany|Klinikum Darmstadt Medizinische Klinik V, Darmstadt, Germany|St. Johannes Hospital, Dortmund, Germany|Universitätsklinikum Medizinische Klinik und Poliklinik, Düsseldorf, Germany|Klinikum Esslingen, Esslingen, Germany|Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Wilhelm-Anton-Hospital gGmbH, Goch, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Hanau GmbH, Hanau, Germany|Klinikum Region Hannover GmbH, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK-Kliniken GmbH, Heilbronn, Germany|Marienhospital Klinikum der Ruhr-Universität, Herne, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|Gemeinschaftspraxis Hämato-Onkologie im Caritas Krankenhaus, Lebach, Germany|Klinikum Lippe GmbH, Lemgo, Germany|Märkische Kliniken GmbH, Lüdenscheid, Germany|Univ-Klinikum der Otto-von Guericke-Universität, Magdeburg, Germany|III. Medizinische Klinik und Poliklinik Universitätsmedizin der Johannes Gutenberg-Universität, Mainz, Germany|Johannes Wesling Klinikum, Minden, Germany|Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany|Klinikum rechts der Isar der TU, München, Germany|Ortenau Klinikum, Offenburg, Germany|PIUS Hospital, Oldenburg, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Klinikum Passau, Passau, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Caritasklinkum Saarbrücken St. Theresia, Saarbrücken, Germany|Klinikum Stuttgart, Stuttgart, Germany|Vinzenz von Paul Kliniken gGmbH Marienhospital, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier, Germany|Medizinische Universitätsklinik, Tübingen, Germany|Universitätsklinikum Ulm Zentrum für Innere Medizin, Ulm, Germany|Schwarzwald-Baar Klinikum, Villingen Schwenningen, Germany|Kliniken Essen Süd, Werden, Germany|HELIOS Klinikum, Wuppertal, Germany",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"MYELOID LEUKEMIA, CHRONIC",_DASATINIB,NCT02890784,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uniklinik der RWTH Aachen, Aachen, Germany|Gesundheitszentrum St. Marien GmbH, Amberg, Germany|Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany|OnkoBer, Berlin, Germany|Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany|Universitätsklinikum Bonn, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Bremen, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Gemeinschaftspraxis Mohm/Prange-Krex, Dresden, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|Helios St. Johannes Klinik Duisburg, Duisburg, Germany|Gemeinschaftspraxis Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Katholisches Karl-Leisner Klinikum, Goch, Germany|MVZ Onkologische Kooperation Harz, Goslar, Germany|ConMed GmbH, Göttingen, Germany|Hämato-Onkologische Gemeinschaftspraxis Halberstadt, Halberstadt, Germany|Universitätsklinikum Halle/S., Halle, Germany|Asklepios MVZ Onkologie, Hamburg, Germany|MediProjekt GbR, Hannover, Germany|St. Bernward Krankenhaus Hildesheim, Hildesheim, Germany|Universitätsklinikum Jena, Jena, Germany|Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR, Kaiserslautern, Germany|Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|St. Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany|Onkologische Gemeinschaftspraxis, Kassel, Germany|Klinikum Kassel, Kassel, Germany|Städtisches Krankenhaus Kiel GmbH, Kiel, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|InVo Institut für Versorgungsforschung, Koblenz, Germany|MVZ Hämatologie und Onkologie, Krefeld, Germany|Onkologische Schwerpunktpraxis, Kronach, Germany|Onkologisches Zentrum, Lebach, Germany|Studienzentrum UnterEms, Leer, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin Mannheim, Mannheim, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany|Rotkreuzklinikum München, München, Germany|Gemeinschaftspraxis Hämatologie/ Onkologie, München, Germany|Universitätsklinikum Münster, Münster, Germany|Hämatologisch-onkologische Schwerpunktpraxis, Neustadt Am Rübenberge, Germany|Klinikum Passau, Passau, Germany|Kreiskliniken Reutlingen GmbH, Reutlingen, Germany|Universitätsmedizin Rostock, Rostock, Germany|Klinikum Südstadt Rostock, Rostock, Germany|Hämatologie-Onkologie Stolberg, Stolberg, Germany|Klinikum Mutterhaus der, Trier, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Rems-Murr-Klinik Winnenden, Winnenden, Germany",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,MULTIPLE MYELOMA,_TRAMETINIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,MULTIPLE MYELOMA,_DABRAFENIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_IDELALISIB,NCT03742323,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario A Coruña, A Coruña, Spain|Hospital ICO Badalona, Badalona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital ICO Hospitalet, Hospitalet de Llobregat, Spain|Hospital 12 de Octubre, Madrid, Spain|H. Morales Meseguer, Murcia, Spain|H. Virgen de la Victoria, Mála, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santander, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Clínico Valencia, Valencia, Spain|Hospital Universitario y Politécnico la Fe, Valencia, Spain",6800620,C07D473/38,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,MANTLE CELL LYMPHOMA,_VENETOCLAX,NCT03523975,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Michgan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,DIFFUSE LARGE B CELL LYMPHOMA,_COPANLISIB,NCT04263584,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Halle, Halle (Saale), Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital Muenster, Muenster, Germany|Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany|Hospital Stuttgart - Stuttgart Cancer Center, Stuttgart, Germany|University Hospital Ulm, Ulm, Germany",7511041,C07D471/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,MANTLE CELL LYMPHOMA,_CARFILZOMIB,NCT03891355,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy|Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O., Bolzano, Italy|ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy|Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia, Genova, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy|IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia, Pavia, Italy|Ospedale Guglielmo da Saliceto - U.O.Ematologia, Piacenza, Italy|Ospedale delle Croci - Ematologia, Ravenna, Italy|Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia, Reggio Emilia, Italy|Policlinico Umberto I - Università ""La Sapienza"" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione, Roma, Italy|AOU Senese - U.O.C. Ematologia, Siena, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy|A.O. C. Panico - U.O.C Ematologia e Trapianto, Tricase, Italy|Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy|Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - SOC Clinica Ematologica, Udine, Italy|AOU Integrata di Verona - U.O. Ematologia, Verona, Italy",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,MULTIPLE MYELOMA,_CARFILZOMIB,NCT03989414,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Colorado Blood Cancer Institute, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta - Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Charles University General Hospital, Praha 2, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Hopital Claude Huriez CHRU Lille, Lille cedex, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse Cedex 9, France|CHRU Hopital Bretonneau, Tours cedex, France|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Hopsital Germans Trias I Pujol, Badalona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,MULTIPLE MYELOMA,_CC-220,NCT02773030,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Winthrop Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital Weil Cornell Medical College, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Prisma Health Cancer Institute, Greenville, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McGill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|CHRU Hopital Claude Huriez, Lile Cedax, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU La Miletrie, Poitiers Cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia, Rome, Italy|Osp. S.Giovanni Battista Le Molinette, Torino, Italy|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Nagoya City University Hospital, Nagoya, Japan|Tohoku University Hospital, Sendai, Japan|VU University Medical Center, Amsterdam, Netherlands|Maastricht University Medical Center, Maastrich, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Val d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Genesis Care, Oxford, United Kingdom|The Institut of Cancer Research, Sutton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",WO-2014025958-A2,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,449.50699999999995,88.18,6.0,1.0,5.0,47.73,122.29,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,MANTLE CELL LYMPHOMA,_IXAZOMIB,NCT03616782,Phase 2,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kosin University Gospel Hospital, Busan, Western, Korea, Republic of",7442830,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,NON-HODGKIN'S LYMPHOMA,_IBRUTINIB,NCT03198026,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,PERIPHERAL T CELL LYMPHOMA,_DUVELISIB,NCT03372057,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|University of California - Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Ohio State Univeristy, Columbia, Ohio, United States|Toledo Cancer Center, Toledo, Ohio, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor Research Institute - Charles Sammons Cancer Center, Dallas, Texas, United States|Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV, Halle, Sachsen-Anhalt, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo, Bergamo, Italy|A.O.di Bologna Policl.S.Orsola, Bologna, Italy|Ieo, Irccs, Milano, Italy|Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Italy|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",8193182,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,HODGKIN LYMPHOMA,_DECITABINE,NCT03250962,Phase 2,Recruiting,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China",5654333,1,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,NON HODGKIN LYMPHOMA,_DECITABINE,NCT04337606,Phase 1|Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,DIFFUSE LARGE B CELL LYMPHOMA,_BENDAMUSTINE,NCT02753062,Phase 2,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,MULTIPLE MYELOMA,_BENDAMUSTINE,NCT04083898,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_BENDAMUSTINE,NCT02763319,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"MorphoSys Research Site, Anaheim, California, United States|MorphoSys Research Site, Bakersfield, California, United States|Morphosys Research Site, Burbank, California, United States|Morphosys Research Site, Fresno, California, United States|MorphoSys Research Site, Los Angeles, California, United States|MorphoSys Research Site, Whittier, California, United States|MorphoSys Research Site, Plainville, Connecticut, United States|MorphoSys Research Site, Skokie, Illinois, United States|MorphoSys Research Site, Detroit, Michigan, United States|MorphoSys Research Site, Rochester, Minnesota, United States|MorphoSys Research Site, Hattiesburg, Mississippi, United States|Morphosys Research site, Jackson, Mississippi, United States|Morphosys Research Site, Morristown, New Jersey, United States|MorphoSys Research Site, New York, New York, United States|MorphoSys Research Site, Stony Brook, New York, United States|MorphoSys Research Site, Oklahoma City, Oklahoma, United States|MorphoSys Research Site, Knoxville, Tennessee, United States|Morphosys Research Site, Lubbock, Texas, United States|MorphoSys Research Site, Adelaide, Australia|MorphoSys Research Site, Albury, Australia|MorphoSys Research Site, Bedford Park, Australia|MorphoSys Research Site, Box Hill, Australia|MorphoSys Research Site, Concord, Australia|MorphoSys Research Site, Frankston, Australia|MorphoSys Research SIte, Garran, Australia|MorphoSys Research Site, Geelong, Australia|MorphoSys Research Site, Gosford, Australia|MorphoSys Research Site, Nedlands, Australia|MorphoSys Research Site, South Brisbane, Australia|MorphoSys Research Site, St. Albans, Australia|MorphoSys Research Site, Innsbruck, Austria|Morphosys Research Site, Edmonton, Alberta, Canada|MorphoSys Research Site, Winnipeg, Manitoba, Canada|MorphoSys Research Site, Saint John, New Brunswick, Canada|Morphosys Research Site, Saint John's, Newfoundland and Labrador, Canada|MorphoSys Research Site, Kingston, Ontario, Canada|MorphoSys Research Site, Greenfield Park, Quebec, Canada|Morphosys Research Site, Montréal, Quebec, Canada|MorphoSys Research Site, Saskatoon, Canada|MorphoSys Research Site, Zagreb, Croatia|MorphoSys Research Site, Hradec Kralove, Czechia|Morphosys Research site, Olomouc, Czechia|Morphosys Research Site, Prague, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Oulu, Finland|MorphoSys Research Site, Tampere, Finland|MorphoSys Research Site, Grenoble, France|MorphoSys Research Site, Le Mans, France|MorphoSys Research Site, Aachen, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Düsseldorf, Germany|MorphoSys Research Site, Giessen, Germany|Morphosys Research Site, Homburg, Germany|MorphoSys Research Site, Leipzig, Germany|MorphoSys Research Site, Mainz, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Mutlangen, Germany|Morphosys Research Site, Münster, Germany|MorphoSys Research Site, Rostock, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys, Traunstein, Germany|MorphoSys, Budapest, Hungary|MorphoSys Research Site, Debrecen, Hungary|MorphoSys Research Site, Győr, Hungary|MorphoSys, Szeged, Hungary|MorphoSys Research Site, Haifa, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Kfar Saba, Israel|MorphoSys Research Site, Tel Aviv, Israel|MorphoSys Research Site, Alessandria, Italy|MorphoSys Research Site, Bologna, Italy|MorphoSys Research Site, Campobasso, Italy|MorphoSys Research Site, Cona, Italy|MorphoSys Research Site, Genova, Italy|MorphoSys Research Site, Lecce, Italy|MorphoSys Research Site, Meldola, Italy|MorphoSys Research Site, Monza, Italy|MorphoSys Research Site, Napoli, Italy|Morphosys Research Site, Novara, Italy|MorphoSys Research Site, Orbassano, Italy|MorphoSys Research Site, Parma, Italy|MorphoSys Research Site, Pavia, Italy|MorphoSys Research Site, Pisa, Italy|MorphoSys Research Site, Ravenna, Italy|MorphoSys Research Site, Reggio Emilia, Italy|MorphoSys Research Site, Rimini, Italy|MorphoSys Research Site, Rome, Italy|MorphoSys Research Site, Rome, Italy|Morphosys Research Site, Terni, Italy|MorphoSys Research Site, Turin, Italy|Morphosys Research Site, Turin, Italy|MorphoSys Research Site, Busan, Korea, Republic of|MorphoSys Research Site, Goyang-si, Korea, Republic of|MorphoSys Research Site, Incheon, Korea, Republic of|MorphoSys Research Site, Jeonju, Korea, Republic of|MorphoSys Research Site, Seongnam, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Ulsan, Korea, Republic of|MorphoSys Research Site, Addington, New Zealand|MorphoSys Research Site, Auckland, New Zealand|MorphoSys Research Site, Grafton, New Zealand|Morphosys Research Site, Bydgoszcz, Poland|MorphoSys Research Site, Gdynia, Poland|MorphoSys Research Site, Kraków, Poland|MorphoSys Research Site, Legnica, Poland|MorphoSys Research Site, Lodz, Poland|MorphoSys Research Site, Lublin, Poland|Morphosys Research Site, Warszawa, Poland|MorphoSys Research Site, Wrocław, Poland|MorphoSys Research Site, Braga, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Matosinhos, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Pragal, Portugal|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Iaşi, Romania|MorphoSys Research Site, Belgrade, Serbia|MorphoSys Research Site, Kragujevac, Serbia|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Cadiz, Spain|MorphoSys Research Site, Girona, Spain|MorphoSys Research Site, L'Hospitalet De Llobregat, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Palma de Mallorca, Spain|MorphoSys Research Site, Pamplona, Spain|MorphoSys Research Site, Pozuelo De Alarcón, Spain|MorphoSys, Sabadell, Spain|MorphoSys Research Site, Salamanca, Spain|MorphoSys Research Site, Valencia, Spain|Morphosys Research Site, Chang Hua, Taiwan|Morphosys Research Site, Hualien City, Taiwan|Morphosys Research Site, Taichung City, Taiwan|MorphoSys Research Site, Adana, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Bornova, Turkey|MorphoSys Research Site, Gaziantep, Turkey|MorphoSys Research Site, İzmir, Turkey|MorphoSys Research Site, Manisa, Turkey|MorphoSys Research Site, Samsun, Turkey|Morphosys Research Site, Birmingham, United Kingdom|MorphoSys Research Site, Leeds, United Kingdom|MorphoSys Research Site, Southend on Sea, United Kingdom",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,"LYMPHOMA, T-CELL, CUTANEOUS",_DOXYCYCLINE,NCT03116659,Early Phase 1,Recruiting,All,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States",5789395.0,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,16.0,23.1298383950389,2.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,"LYMPHOMA, T-CELL, CUTANEOUS",_IMIQUIMOD,NCT03116659,Early Phase 1,Recruiting,All,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States",4689338,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCC(CCC)C(=O)O,ACUTE MYELOID LEUKEMIA,_VALPROIC_ACID,NCT01369368,Phase 1|Phase 2,Unknown status,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haukeland University Hospital, Bergen, Norway",6419953.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,CHRONIC LYMPHOCYTIC LEUKEMIA,_LAMIVUDINE,NCT03528941,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Other|Time Perspective: Retrospective,"AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione, Cona, Ferrara, Italy|AOU Consorziale Policlinico - UO Ematologia con Trapianto, Bari, Italy|ASST degli Ospedali Civili di Brescia - UO Ematologia, Brescia, Italy|AO Brotzu, Presidio Ospedaliero A.Businco - SC Ematologia e CTMO, Cagliari, Italy|CTC U.O. di Ematologia con Trapianto di midollo osseo - Catania, Catania, Italy|AO di Catanzaro ""Pugliese - Ciaccio"", Presidio Ospedaliero ""Ciaccio - De Lellis"" - Ematologia, Catanzaro, Italy|IRCCS AOU San Martino - UO Ematologia e Trapianti, Genova, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico - Ematologia, Milano, Italy|IRCCS Ospedale San Raffaele - Unità neoplasie linfocitarie B, Milano, Italy|AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy|Fondazione IRCCS Policlinico San Matteo - OU Ematologia, Pavia, Italy|AOU Pisana - UO Ematologia Universitaria, Pisa, Italy|AOU Policlinico Tor Vergata - UOC Trapianto cellule staminali, Roma, Italy|Fondazione Policlinico Universitario A. Gemelli IRCCS - Area Ematologica, Roma, Italy|Policlinico Universitario Campus Bio Medico - UOC Ematologia e Trapianto di cellule staminali, Roma, Italy|AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia, Torino, Italy",5905082,C07D411/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,MULTIPLE MYELOMA,_PLERIXAFOR,NCT03406091,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy",RE42152,C07D401/14 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,LYMPHOMA,_ETOPOSIDE_PHOSPHATE,NCT02106988,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,ACUTE MYELOID LEUKEMIA,_PIOGLITAZONE,NCT02942758,Phase 2,Unknown status,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Regensburg, Regensburg, Germany",4687777,C07D213/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,CHRONIC MYELOID LEUKEMIA,_PIOGLITAZONE,NCT02889003,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de Versailles, Le Chesnay, France|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|CHU de Nantes, Nantes, France|CHU de Rennes, Rennes, France",4687777,C07D213/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CN(C)/N=N/c1[nH]cnc1C(N)=O,HODGKIN LYMPHOMA,_DACARBAZINE,NCT03033914,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",4722834,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,28.0,22.965563974619602,1554.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.32,182.187,99.73,5.0,2.0,1.0,17.78,49.71,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],CENTRAL NERVOUS SYSTEM LYMPHOMA,_SODIUM_THIOSULFATE,NCT00293475,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CENTRAL NERVOUS SYSTEM LYMPHOMA,_MANNITOL,NCT00293475,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",3932678,A23L27/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,CHRONIC LYMPHOCYTIC LEUKEMIA,_UMBRALISIB,NCT04016805,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TG Therapeutics Investigational Trial Site, Boston, Massachusetts, United States|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, United States|TG Therapeutics Investigational Trial Site, New York, New York, United States",US-20140011819-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,27.13813425327001,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.2,571.56,105.15,7.0,1.0,6.0,56.6,163.22,6.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,ACUTE MYELOID LEUKEMIA,_RIBAVIRIN,NCT03760666,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",6172046,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHRONIC MYELOID LEUKEMIA,_BOSUTINIB,NCT03831776,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aalborg university hospital, Aalborg, Denmark|Aarhus ..., Aarhus, Denmark|Copenhagen ..., Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Comprehensive Cancer Center, Hematology, Helsinki, Finland|Haukeland Universitetssjukehus, Bergen, Norway|Oslo Universitetssykehus, Oslo, Norway|Stavanger Universitetssjukehus, Stavanger, Norway|Universitetssykehuset Nord Norge, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Göteborg ...., Göteborg, Sweden|Universitetssjukhuset Linköping, Linköping, Sweden|Skåne University Hospital, Lund, Sweden|Karolinska Universitetssjukhus, Stockholm, Sweden|Sundsvall ..., Sundsvall, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|University Hospital, Uppsala, Sweden|Universitetssjukhuset Örebro, Örebro, Sweden",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHRONIC MYELOGENOUS LEUKEMIA,_BOSUTINIB,NCT02501330,,Recruiting,All,"Child, Adult, Older Adult",Industry,Observational Model: Case-Only|Time Perspective: Prospective,"Shibuya-ku, Japan",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,MULTIPLE MYELOMA,_RIMIDUCID,NCT03288493,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of California Davis, Davis, California, United States|University of California San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wayne State - Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,BREAST CANCER,_TUCIDINOSTAT,NCT04465097,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,DIFFUSE LARGE B-CELL LYMPHOMA,_TUCIDINOSTAT,NCT04231448,Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University Cancer Hospital, Beijing, Beijing, China|Shanghai JiaoTong University School of Medicine，Ruijin Hospital, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_RADOTINIB,NCT03722420,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital(北京大学人民医院), Beijing, China",US-20080096899-A1,A61P35/00 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,42.0542516273434,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,530.515,110.51,7.0,2.0,5.0,52.47,150.32,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,ACUTE MYELOID LEUKEMIA,_GLASDEGIB,NCT04051996,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Yale Cancer Center/Smilow, New Haven, Connecticut, United States",8148401,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,45.471159572065105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.68,374.44800000000004,96.84,4.0,3.0,4.0,40.98,108.26,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,PERIPHERAL T CELL LYMPHOMA,_FENRETINIDE,NCT02495415,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas, Southwestern, Dallas, Texas, United States",4190594,C07D213/87,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,HEMATOLOGICAL MALIGNANCY,_TENALISIB,NCT03711604,Phase 1|Phase 2,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Division of Hematology, University of Colorado,, Denver, Colorado, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Medivest - Institute of Hematology and Transfusiology, Tbilisi, Georgia",US-20140364447-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,415.42800000000005,92.79,6.0,2.0,5.0,41.59,116.09,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",_TENALISIB,NCT04204057,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Multiprofile Hospital for Active Treatment ""Dr Georgi Stranski"" Ltd.,, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv Ivan Rilski"" Ltd, Sofia, Bulgaria|Ltd. M.Zodelava Hematology Centre, Tbilisi, Georgia|Medivest - Institute of Hematology and Transfusiology, Tbilisi, Georgia|Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzow, Poland|Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus, Łódź, Poland",US-20140364447-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,415.42800000000005,92.79,6.0,2.0,5.0,41.59,116.09,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ERDAFITINIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,45.0,24.31261422205795,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,446.555,77.33,7.0,1.0,4.0,51.0,139.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ENASIDENIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,6.111008439598348,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,473.38300000000004,108.74,8.0,3.0,3.0,41.41,118.37,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,ACUTE MYELOID LEUKEMIA,_ENASIDENIB,NCT04075747,Phase 1,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Stanford University School of Medicine- Standford Cancer Institute, Palo Alto, California, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,6.111008439598348,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,473.38300000000004,108.74,8.0,3.0,3.0,41.41,118.37,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,DIFFUSE LARGE B CELL LYMPHOMA,_ZANUBRUTINIB,NCT04460248,Phase 2,Recruiting,All,75 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.836054128421528,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,471.561,102.48,4.0,2.0,5.0,51.75,146.25,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,ENDOMETRIAL POLYP,_PROGESTERONE,NCT03309709,Phase 3,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Ospedale Pugliese Ciaccio, Catanzaro, Calabria, Italy|Federico II University, Naples, Italy",5543150.0,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[O-],"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ACETATE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_PREDNISONE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",6488960,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ABIRATERONE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ABIRATERONE_ACETATE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,28.6494589211277,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_NIRAPARIB,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",8859562,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_EXEMESTANE,NCT02666105,Phase 2,Recruiting,Female,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Health System, Albert Lea, Minnesota, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Sanford Worthington Medical Center, Worthington, Minnesota, United States",4808616,C07J1/0011,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,BRAIN TUMOR,_LETROZOLE,NCT03122197,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Cincinnati, Cincinnati, Ohio, United States",4978672,C07D213/57,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PARKINSON'S DISEASE,_PREDNISONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,PARKINSON'S DISEASE,_METHYLPREDNISOLONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,PARKINSON'S DISEASE,_SIROLIMUS,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,METASTATIC PROSTATE CANCER,_PREDNISONE,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",6488960,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,METASTATIC PROSTATE CANCER,_CABAZITAXEL,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",5438072,3,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,METASTATIC PROSTATE CANCER,_DOCETAXEL,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",4814470,C07D305/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,METASTATIC PROSTATE CANCER,_ABIRATERONE,NCT04262154,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_DOCETAXEL,NCT02923258,Phase 2|Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai ninth people's hospital, Shanghai, Shanghai, China",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NEOPLASM METASTASIS,_DOCETAXEL,NCT00781612,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States|Comp Cancer Centers of Nevada, Los Angeles, California, United States|Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UCLA Oncology Office; Oncology, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, United States|Univ of Colorado Canc Ctr, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Christina Care Institutional Review Board, Newark, Delaware, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States|Univ of Miami Health Systems, Miami, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Loyola University Med Center, Maywood, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Midwestern Regional Medical Center; Office of Research, Zion, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Hematology-Oncology; Associates of the Quad Cities, Bettendorf, Iowa, United States|Oncology Assoc of Cedar Rapids; Iowa Cancer Care, Cedar Rapids, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center; Anne Arundel Health System, Annapolis, Maryland, United States|Johns Hopkins Univ Med Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute; Breast Oncology, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, Pa, Minneapolis, Minnesota, United States|University of Minnesota., Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Capitol Comprehensive CA Care, Jefferson City, Missouri, United States|St. John's Mercy Medical Ctr; David C. Pratt Cancer Center, Saint Louis, Missouri, United States|Mercy Clinic Cancer & Hematology, Springfield, Missouri, United States|St. Barnabas Health Care Sys, Livingston, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|NS-Long Island Jewish Hlth Sys, Lake Success, New York, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States|Northwest Cancer Specialists - Portland (N Broadway), Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Vanderbilt Ingram Cancer Ctr, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|US Oncology Research Pharm., Irving, Texas, United States|US Oncology, Irving, Texas, United States|USO, Plano, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|US Oncology Research, Inc., The Woodlands, Texas, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|Uni of Washington Medical Center; Dept of Oncology, Seattle, Washington, United States|Univ of WA Medical Center, Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Kaiser Franz Josef Spital, 1. Medizinische Abteilung, Wien, Austria|UZ Gent, Gent, Belgium|Sint Augustinus Wilrijk, Apotheek, Wilrijk, Belgium|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, BA, Brazil|Trymed Clinical Research, Belo Horizonte, MG, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Oncologia de Porto Alegre - CliniOnco, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia, Santo Andre, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Complex Oncology Center - Plovdiv First Internal Chemotherapy Department, Plovdiv, Bulgaria|SHATO - Sofia, Sofia, Bulgaria|British Columbia Cancer Agency Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, Canada|Ottawa Regional Cancer Centre; Civic Hospital Division, Ottawa, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Chile|Beijing Cancer Hospital, Beijing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Fudan University Shanghai Cancer Center, Shanghai, China|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Centre Francois Baclesse; Comite Sein, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Institut régional du Cancer Montpellier, Montpellier, France|Hopital Tenon, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany|Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche, Berlin, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln, Köln, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde, Muenchen, Germany|gSUND Gynäkologie Kompetenzzentrum Stralsund; Frauenheilkunde & Geburtshilfe, Stralsund, Germany|Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker, Würzburg, Germany|Grupo Angeles, Guatemala City, Guatemala|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary|Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary|Markusovszky Hospital, Szombathely, Hungary|Shaare Zedek Medical Center, Jerusalem, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, Israel|Ospedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma, Emilia-Romagna, Italy|RCCS - Centro di Riferimento; Oncologia Medica B, Aviano (PN), Friuli-Venezia Giulia, Italy|Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Civile; Oncologia Medica, Sassari, Sardegna, Italy|Humanitas Centro Catanese Di Oncologia; Oncologia Medica, Misterbianco (CT), Sicilia, Italy|A.O. Universitaria Pisana; Oncologia, Pisa, Toscana, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|Hiroshima University Hospital; Breast Surgery, Hiroshima, Japan|Hyogo Cancer Center; Breast Surgery, Hyogo, Japan|Saitama Medical University International Medical Center; Breast Oncology, Saitama, Japan|Kyungpook National University Medical Center; Oncology, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Consultorio de Medicina Especializada, Mexico, Mexico CITY (federal District), Mexico|Centro de Investigacion; Clinica Del Pacifico, Acapulco, Mexico|Instituto Nacional de Cancer, D.f., Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Private Health Organization Acibadem Sistina Hospital, Skopje, North Macedonia|Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway|Centro Hemato Oncologico Panama, Panama, Panama|Instituto;Oncologico Miraflores, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Cebu Cancer Institute; Perpetual Succour Hospital, Cebu City, Philippines|Veterans Memorial Medical Ctr; Cancer Research Centre, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Świętokrzyskie Centrum Onkologii; Dział Chemioterapii, Kielce, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|City Oncology Dispensary, St Petersburg, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital de Jerez de la Frontera; Servicio de Oncologia, Jerez de La Frontera, Cadiz, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital Severo Ochoa; Servicio de Oncologia, Leganes, Madrid, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Mälarsjukhuset; Onkologkliniken Sörmland, Eskilstuna, Sweden|Universitaetsspital Zuerich, Zürich, Switzerland|National Cheng Kung Uni Hospital; Surgery, Tainan, Taiwan|Chi-Mei Medical Center, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan|Bumrungrad International Hosp, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Ninewells Hospital, Dundee, United Kingdom|Western General Hospital; Clinical Oncology, Edinburgh, United Kingdom|Diana Princess of Wales Hosp., Grimsby, United Kingdom|Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|Poole General Hospital, Poole, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|Abertawe and Bro Morgannwg NHS Trust; Clinical Researdh Institute, Swansea, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NEOPLASM METASTASIS,_PACLITAXEL,NCT00781612,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States|Comp Cancer Centers of Nevada, Los Angeles, California, United States|Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UCLA Oncology Office; Oncology, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, United States|Univ of Colorado Canc Ctr, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Christina Care Institutional Review Board, Newark, Delaware, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States|Univ of Miami Health Systems, Miami, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Loyola University Med Center, Maywood, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Midwestern Regional Medical Center; Office of Research, Zion, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Hematology-Oncology; Associates of the Quad Cities, Bettendorf, Iowa, United States|Oncology Assoc of Cedar Rapids; Iowa Cancer Care, Cedar Rapids, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center; Anne Arundel Health System, Annapolis, Maryland, United States|Johns Hopkins Univ Med Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute; Breast Oncology, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, Pa, Minneapolis, Minnesota, United States|University of Minnesota., Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Capitol Comprehensive CA Care, Jefferson City, Missouri, United States|St. John's Mercy Medical Ctr; David C. Pratt Cancer Center, Saint Louis, Missouri, United States|Mercy Clinic Cancer & Hematology, Springfield, Missouri, United States|St. Barnabas Health Care Sys, Livingston, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|NS-Long Island Jewish Hlth Sys, Lake Success, New York, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States|Northwest Cancer Specialists - Portland (N Broadway), Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Vanderbilt Ingram Cancer Ctr, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|US Oncology Research Pharm., Irving, Texas, United States|US Oncology, Irving, Texas, United States|USO, Plano, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|US Oncology Research, Inc., The Woodlands, Texas, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|Uni of Washington Medical Center; Dept of Oncology, Seattle, Washington, United States|Univ of WA Medical Center, Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Kaiser Franz Josef Spital, 1. Medizinische Abteilung, Wien, Austria|UZ Gent, Gent, Belgium|Sint Augustinus Wilrijk, Apotheek, Wilrijk, Belgium|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, BA, Brazil|Trymed Clinical Research, Belo Horizonte, MG, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Oncologia de Porto Alegre - CliniOnco, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia, Santo Andre, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Complex Oncology Center - Plovdiv First Internal Chemotherapy Department, Plovdiv, Bulgaria|SHATO - Sofia, Sofia, Bulgaria|British Columbia Cancer Agency Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, Canada|Ottawa Regional Cancer Centre; Civic Hospital Division, Ottawa, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Chile|Beijing Cancer Hospital, Beijing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Fudan University Shanghai Cancer Center, Shanghai, China|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Centre Francois Baclesse; Comite Sein, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Institut régional du Cancer Montpellier, Montpellier, France|Hopital Tenon, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany|Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche, Berlin, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln, Köln, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde, Muenchen, Germany|gSUND Gynäkologie Kompetenzzentrum Stralsund; Frauenheilkunde & Geburtshilfe, Stralsund, Germany|Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker, Würzburg, Germany|Grupo Angeles, Guatemala City, Guatemala|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary|Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary|Markusovszky Hospital, Szombathely, Hungary|Shaare Zedek Medical Center, Jerusalem, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, Israel|Ospedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma, Emilia-Romagna, Italy|RCCS - Centro di Riferimento; Oncologia Medica B, Aviano (PN), Friuli-Venezia Giulia, Italy|Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Civile; Oncologia Medica, Sassari, Sardegna, Italy|Humanitas Centro Catanese Di Oncologia; Oncologia Medica, Misterbianco (CT), Sicilia, Italy|A.O. Universitaria Pisana; Oncologia, Pisa, Toscana, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|Hiroshima University Hospital; Breast Surgery, Hiroshima, Japan|Hyogo Cancer Center; Breast Surgery, Hyogo, Japan|Saitama Medical University International Medical Center; Breast Oncology, Saitama, Japan|Kyungpook National University Medical Center; Oncology, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Consultorio de Medicina Especializada, Mexico, Mexico CITY (federal District), Mexico|Centro de Investigacion; Clinica Del Pacifico, Acapulco, Mexico|Instituto Nacional de Cancer, D.f., Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Private Health Organization Acibadem Sistina Hospital, Skopje, North Macedonia|Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway|Centro Hemato Oncologico Panama, Panama, Panama|Instituto;Oncologico Miraflores, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Cebu Cancer Institute; Perpetual Succour Hospital, Cebu City, Philippines|Veterans Memorial Medical Ctr; Cancer Research Centre, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Świętokrzyskie Centrum Onkologii; Dział Chemioterapii, Kielce, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Nr 3, Rybnik, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|City Oncology Dispensary, St Petersburg, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital de Jerez de la Frontera; Servicio de Oncologia, Jerez de La Frontera, Cadiz, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital Severo Ochoa; Servicio de Oncologia, Leganes, Madrid, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Mälarsjukhuset; Onkologkliniken Sörmland, Eskilstuna, Sweden|Universitaetsspital Zuerich, Zürich, Switzerland|National Cheng Kung Uni Hospital; Surgery, Tainan, Taiwan|Chi-Mei Medical Center, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan|Bumrungrad International Hosp, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Ninewells Hospital, Dundee, United Kingdom|Western General Hospital; Clinical Oncology, Edinburgh, United Kingdom|Diana Princess of Wales Hosp., Grimsby, United Kingdom|Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|Poole General Hospital, Poole, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|Abertawe and Bro Morgannwg NHS Trust; Clinical Researdh Institute, Swansea, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NON-SMALL CELL LUNG CANCER METASTATIC,_DOCETAXEL,NCT04154956,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 8400015, Newnan, Georgia, United States|Investigational Site Number 8400004, Tinley Park, Illinois, United States|Investigational Site Number 8400016, Grand Rapids, Michigan, United States|Investigational Site Number 8400014, Greenville, South Carolina, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 8400013, The Woodlands, Texas, United States|Investigational Site Number 0320004, Buenos Aires, Argentina|Investigational Site Number 0320009, Caba, Argentina|Investigational Site Number 0320012, Capital Federal, Argentina|Investigational Site Number 0320008, Pergamino, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0320003, Viedma, Argentina|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 0560005, Brugge, Belgium|Investigational Site Number 0560002, Bruxelles, Belgium|Investigational Site Number 0560004, Edegem, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Liège, Belgium|Investigational Site Number 0760023, Blumenau, Brazil|Investigational Site Number 0760008, Curitiba, Brazil|Investigational Site Number 0760002, Fortaleza, Brazil|Investigational Site Number 0760012, Porto Alegre, Brazil|Investigational Site Number 0760022, Sao Paulo, Brazil|Investigational Site Number 0760020, Sao Paulo, Brazil|Investigational Site Number 0760007, Sao Paulo, Brazil|Investigational Site Number 0760001, São José Do Rio Preto, Brazil|Investigational Site Number 0760010, São Paulo, Brazil|Investigational Site Number 1000008, Burgas, Bulgaria|Investigational Site Number 1000007, Plovdiv, Bulgaria|Investigational Site Number 1000004, Sofia, Bulgaria|Investigational Site Number 1000003, Sofia, Bulgaria|Investigational Site Number 1000001, Sofia, Bulgaria|Investigational Site Number 1240003, Greenfield Park, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520009, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520005, Temuco, Chile|Investigational Site Number 1520001, Viña Del Mar, Chile|Investigational Site Number 1560026, Beijing, China|Investigational Site Number 1560010, Changchun, China|Investigational Site Number 1560024, Fuzhou, China|Investigational Site Number 1560001, Guangzhou, China|Investigational Site Number 1560037, Guangzhou, China|Investigational Site Number 1560017, Guangzhou, China|Investigational Site Number 1560034, Guangzhou, China|Investigational Site Number 1560025, Hangzhou, China|Investigational Site Number 1560033, Hangzhou, China|Investigational Site Number 1560021, Hangzhou, China|Investigational Site Number 1560018, Hangzhou, China|Investigational Site Number 1560011, Hangzhou, China|Investigational Site Number 1560014, Hefei, China|Investigational Site Number 1560028, Jinan, China|Investigational Site Number 1560035, Nanchang, China|Investigational Site Number 1560019, Nanjing, China|Investigational Site Number 1560006, Wuhan, China|Investigational Site Number 1560016, Zhanjiang, China|Investigational Site Number 1560041, Zhengzhou, China|Investigational Site Number 1560040, Zhengzhou, China|Investigational Site Number 2500010, Bordeaux Cedex, France|Investigational Site Number 2500008, Caen Cedex 05, France|Investigational Site Number 2500006, Creteil, France|Investigational Site Number 2500001, Marseille Cedex 20, France|Investigational Site Number 2500003, Rennes Cedex 09, France|Investigational Site Number 2500002, Saint-Mande, France|Investigational Site Number 2500004, Villejuif Cedex, France|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760003, Oldenburg, Germany|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3480008, Farkasgyepü, Hungary|Investigational Site Number 3480005, Kaposvár, Hungary|Investigational Site Number 3760005, Jerusalem, Israel|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Orbassano, Italy|Investigational Site Number 3920011, Bunkyo-Ku, Japan|Investigational Site Number 3920012, Fukuoka-Shi, Japan|Investigational Site Number 3920017, Himeji-Shi, Japan|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 3920006, Kanazawa-Shi, Japan|Investigational Site Number 3920008, Kurume-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920015, Nagoya-Shi, Japan|Investigational Site Number 3920009, Natori-Shi, Japan|Investigational Site Number 3920013, Osaka Sayama-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920014, Sakai-Shi, Japan|Investigational Site Number 3920016, Sapporo-Shi, Japan|Investigational Site Number 3920004, Sunto-Gun, Japan|Investigational Site Number 3920010, Ube-Shi, Japan|Investigational Site Number 3920007, Wakayama-Shi, Japan|Investigational Site Number 3920005, Yokohama-Shi, Japan|Investigational Site Number 4100008, Busan-gwangyeoksi, Korea, Republic of|Investigational Site Number 4100005, Cheongju-Si, Korea, Republic of|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100007, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 4840002, Cdmx, Mexico|Investigational Site Number 4840004, Guadalajara, Mexico|Investigational Site Number 4840003, México, Mexico|Investigational Site Number 5280003, 'S Hertogenbosch, Netherlands|Investigational Site Number 5280004, Breda, Netherlands|Investigational Site Number 5280005, Utrecht, Netherlands|Investigational Site Number 6160004, Olsztyn, Poland|Investigational Site Number 6160003, Radom, Poland|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6200002, Almada, Portugal|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200004, Lisboa, Portugal|Investigational Site Number 6200006, Porto, Portugal|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7240007, Barcelona, Spain|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240001, Hospitalet De Llobregat, Spain|Investigational Site Number 7240009, Madrid / Madrid, Spain|Investigational Site Number 7240106, Madrid, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240010, Majadahonda, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240006, Pamplona, Spain|Investigational Site Number 7240011, Sevilla, Spain|Investigational Site Number 7240008, Valencia, Spain|Investigational Site Number 7920008, Adana, Turkey|Investigational Site Number 7920002, Adana, Turkey|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Istanbul, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920009, Malatya, Turkey",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,CASTRATION-RESISTANT PROSTATIC CANCER,_DOCETAXEL,NCT04404140,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tucson, Arizona, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, France|Gustave Roussy, Villejuif CEDEX, France|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland",4814470,C07D305/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,LUNG CANCER,_NIRAPARIB,NCT03891615,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PANCREATIC ADENOCARCINOMA,_NIRAPARIB,NCT03404960,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,OVARIAN NEOPLASMS,_NIRAPARIB,NCT03955471,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Solvang, California, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Maplewood, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Harrison, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Willow Grove, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States",8859562,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,METASTATIC PROSTATE CANCER,_ENZALUTAMIDE,NCT04179864,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Institute of Urology - Northwest, Tucson, Arizona, United States|San Bernardino Urological Associates, San Bernardino, California, United States|The Urology Center Of Colorado, Denver, Colorado, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Norton Cancer Institute - Broadway, Louisville, Kentucky, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Oncology Consultants - Texas Medical Center, Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,METASTATIC PROSTATE CANCER,_TAZEMETOSTAT,NCT04179864,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Institute of Urology - Northwest, Tucson, Arizona, United States|San Bernardino Urological Associates, San Bernardino, California, United States|The Urology Center Of Colorado, Denver, Colorado, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Norton Cancer Institute - Broadway, Louisville, Kentucky, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Oncology Consultants - Texas Medical Center, Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States",8410088,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,PROSTATE ADENOCARCINOMA,_ENZALUTAMIDE,NCT03829930,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"George Washington University - Medical Faculty Associates, Washington, District of Columbia, United States",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC RENAL CELL CARCINOMA,_CYCLOPHOSPHAMIDE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC RENAL CELL CARCINOMA,_FLUDARABINE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_CYCLOPHOSPHAMIDE,NCT04227275,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Insitute, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States",3987166,7,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_FLUDARABINE,NCT04227275,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Insitute, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States",7547776,C07H19/16,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,RHABDOMYOSARCOMA,_CYCLOPHOSPHAMIDE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,RHABDOMYOSARCOMA,_VINCRISTINE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",6723338,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS,_CYCLOPHOSPHAMIDE,NCT02953184,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Hospital of Jilin University, Changchun, Jilin, China",3987166,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS,_DOXORUBICIN,NCT02953184,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Hospital of Jilin University, Changchun, Jilin, China",5013556,C07F9/5537,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,RETINOBLASTOMA,_CYCLOPHOSPHAMIDE,NCT02870907,Phase 2,Recruiting,All,2 Months to 10 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chr Felix Guyon, Saint-Denis, La Réunion, France|Hopital Nord Chu Amiens, Amiens, France|Chu Angers, Angers, France|Hopital Jean Minioz, Besancon, France|Chu R; Pellegrin, Bordeaux, France|Chu Morvan, Brest, France|CHU CAEN, Caen, France|Chu Estaing, Clermont Ferrand, France|Chu Bocage, Dijon, France|Chu de Grenoble, Grenoble, France|Centre Oscar Lambret, Lille, France|Chu Limoges, Limoges, France|Centre Leon Berard, Lyon, France|Hopital D'Enfants La Timone, Marseille, France|Hopital Arnaud de Villeneuve, Montpellier, France|Chu Nantes, Nantes, France|Chu de Nice, Nice, France|Institut Curie, Paris, France|Chu de Poitiers, Poitiers, France|Chur de Reims, Reims, France|Chu de Rennes, Rennes, France|Chu de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Hoptial Hautepierre, Strasbourg, France|Chu Toulouse, Toulouse, France|Chu Tours, Tours, France|Chu Nancy, Vandoeuvre Les Nancy, France",3987166,7,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
S=P(N1CC1)(N1CC1)N1CC1,RETINOBLASTOMA,_THIOTEPA,NCT02870907,Phase 2,Recruiting,All,2 Months to 10 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chr Felix Guyon, Saint-Denis, La Réunion, France|Hopital Nord Chu Amiens, Amiens, France|Chu Angers, Angers, France|Hopital Jean Minioz, Besancon, France|Chu R; Pellegrin, Bordeaux, France|Chu Morvan, Brest, France|CHU CAEN, Caen, France|Chu Estaing, Clermont Ferrand, France|Chu Bocage, Dijon, France|Chu de Grenoble, Grenoble, France|Centre Oscar Lambret, Lille, France|Chu Limoges, Limoges, France|Centre Leon Berard, Lyon, France|Hopital D'Enfants La Timone, Marseille, France|Hopital Arnaud de Villeneuve, Montpellier, France|Chu Nantes, Nantes, France|Chu de Nice, Nice, France|Institut Curie, Paris, France|Chu de Poitiers, Poitiers, France|Chur de Reims, Reims, France|Chu de Rennes, Rennes, France|Chu de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Hoptial Hautepierre, Strasbourg, France|Chu Toulouse, Toulouse, France|Chu Tours, Tours, France|Chu Nancy, Vandoeuvre Les Nancy, France",4766149,7,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,OSTEOSARCOMA,_CYCLOPHOSPHAMIDE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,OSTEOSARCOMA,_METHOTREXATE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_CAPECITABINE,NCT02524275,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States|Omaha Veterans Administration Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,GLIOBLASTOMA,_CAPECITABINE,NCT02669173,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,BREAST NEOPLASM MALIGNANT FEMALE,_CAPECITABINE,NCT04198727,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Clinique Saint Jean, Cagnes-sur-Mer, France|Centre Azuréen de Cancérologie, Mougins, France|Clinique St Georges, Nice, France|Centre Antoine Lacassagne, Nice, France|Hôpital Princesse Grâce, Monaco, Monaco",4966891,C07H19/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,HEAD AND NECK NEOPLASMS,_CAPECITABINE,NCT03678649,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_PALBOCICLIB,NCT03389477,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",6936612,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,FEMALE BREAST CARCINOMA,_PALBOCICLIB,NCT02942355,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Levine Cancer Institute, Charlotte, North Carolina, United States",6936612,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,FEMALE BREAST CARCINOMA,_ANASTROZOLE,NCT02942355,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Levine Cancer Institute, Charlotte, North Carolina, United States",RE36617,C07D239/26,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,LUNG CANCER,_PALBOCICLIB,NCT03170206,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",6936612,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,LUNG CANCER,_BINIMETINIB,NCT03170206,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,"CARCINOMA, RENAL CELL",_EVEROLIMUS,NCT04195750,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama - Birmingham ( Site 1538), Birmingham, Alabama, United States|St Joseph Heritage Healthcare ( Site 1531), Santa Rosa, California, United States|University Of Colorado ( Site 1540), Aurora, Colorado, United States|UCHealth Highlands Ranch Hospital ( Site 1560), Highlands Ranch, Colorado, United States|Sibley Memorial Hospital ( Site 1559), Washington, District of Columbia, United States|Northwest Georgia Oncology Centers PC ( Site 1520), Marietta, Georgia, United States|The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States|Dana Farber Cancer Institute ( Site 1505), Boston, Massachusetts, United States|Henry Ford Cancer Center ( Site 1511), Detroit, Michigan, United States|Hattiesburg Clinic ( Site 1509), Hattiesburg, Mississippi, United States|St. Vincent Frontier Cancer Center ( Site 1549), Billings, Montana, United States|University of Rochester Medical Center ( Site 1543), Rochester, New York, United States|University of North Carolina at Chapel Hill ( Site 1537), Chapel Hill, North Carolina, United States|Oncology Hematology Care, Inc. ( Site 1524), Cincinnati, Ohio, United States|Cleveland Clinic ( Site 1504), Cleveland, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523), Tulsa, Oklahoma, United States|Oregon Health & Science University ( Site 1553), Portland, Oregon, United States|Abramson Cancer Center ( Site 1525), Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center ( Site 1506), Philadelphia, Pennsylvania, United States|Medical University of South Carolina ( Site 1518), Charleston, South Carolina, United States|Henry Joyce Cancer Clinic ( Site 1544), Nashville, Tennessee, United States|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 1653), Sao Paulo, Brazil|Sociedad de Investigaciones Medicas Limitadas ( Site 0004), Temuco, Araucania, Chile|Sociedad Medica Aren y Bachero Limitada ( Site 0003), Santiago, Region M. De Santiago, Chile|Fundacion Centro de Investigacion Clinica CIC ( Site 1703), Medellin, Antioquia, Colombia|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1709), Valledupar, Cesar, Colombia|Administradora Country SA - Clinica del Country ( Site 1701), Bogota, Distrito Capital De Bogota, Colombia|Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1702), Bogota, Distrito Capital De Bogota, Colombia|Oncologos del Occidente S.A. ( Site 1708), Pereira, Risaralda, Colombia|Masarykuv onkologicky ustav ( Site 0105), Brno, Brno-mesto, Czechia|Fakultni nemocnice Ostrava ( Site 0103), Ostrava, Moravskoslezsky Kraj, Czechia|Fakultni nemocnice Hradec Kralove ( Site 0106), Hradec Kralove, Czechia|Fakultni nemocnice Olomouc ( Site 0104), Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady ( Site 0102), Praha 10, Czechia|Herlev Hospital ( Site 0251), Herlev, Hovedstaden, Denmark|Aarhus University Hospital Skejby ( Site 0250), Aarhus, Midtjylland, Denmark|Tampereen yliopistollinen sairaala ( Site 0300), Tampere, Pirkanmaa, Finland|Kuopion Yliopistollinen Sairaala ( Site 0304), Kuopio, Pohjois-Savo, Finland|HYKS. ( Site 0302), Helsinki, Uusimaa, Finland|TYKS T-sairaala Syopatautien pkl ( Site 0301), Turku, Varsinais-Suomi, Finland|HUS Hopital Hautepierre ( Site 0350), Strasbourg, Bas-Rhin, France|Centre Francois Baclesse ( Site 0360), Caen, Calvados, France|CHU Besancon - Hopital Jean Minjoz ( Site 0351), Besancon, Doubs, France|Institut de Cancerologie du Gard - CHU Caremeau ( Site 0352), Nimes, Gard, France|Centre Hospitalier Lyon Sud ( Site 0354), Pierre Benite, Rhone, France|Gustave Roussy ( Site 0353), Villejuif, Val-de-Marne, France|Universitaetsklinikum Jena ( Site 0402), Jena, Thuringen, Germany|Prince of Wales Hospital ( Site 1050), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 1051), Hong Kong, Hong Kong|Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0502), Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Onkologiai Intezet ( Site 0503), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0504), Debrecen, Hungary|Medical Oncology Ospedale San Donato ( Site 0609), Arezzo, Italy|Policlinico S. Orsola-Malpighi ( Site 0606), Bologna, Italy|Fondazione Salvatore Maugeri IRCCS ( Site 0600), Pavia, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0607), Roma, Italy|Azienda Ospedaliera Santa Maria ( Site 0602), Terni, Italy|Azienda Ospedaliera Universitaria di Verona ( Site 0605), Verona, Italy|National Cancer Center Hospital East ( Site 1001), Kashiwa, Chiba, Japan|National Cancer Center Hospital ( Site 1003), Tokyo, Japan|Toranomon Hospital ( Site 1004), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 1000), Tokyo, Japan|Keio University Hospital ( Site 1002), Tokyo, Japan|National Cancer Center ( Site 1204), Gyeonggi-do, Kyonggi-do, Korea, Republic of|Chungnam National University Hospital ( Site 1205), Daejeon, Taejon-Kwangyokshi, Korea, Republic of|Korea University Anam Hospital ( Site 1203), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1202), Seoul, Korea, Republic of|Asan Medical Center ( Site 1200), Seoul, Korea, Republic of|Samsung Medical Center ( Site 1201), Seoul, Korea, Republic of|Akershus universitetssykehus ( Site 0851), Lorenskog, Akershus, Norway|Helse Bergen HF - Haukeland Universitetssykehus ( Site 0854), Bergen, Hordaland, Norway|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1151), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|SBIH City clinical hospital named after D.D. Pletniov ( Site 1160), Moscow, Moskva, Russian Federation|N.N. Blokhin NMRCO ( Site 1156), Moscow, Moskva, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 1155), Moscow, Moskva, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 1163), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1157), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 1150), Omsk, Omskaya Oblast, Russian Federation|SBHI SPb Clinical Research Centre of specialized types of medical care ( Site 1159), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City clinical oncological dispensary ( Site 1154), Sankt-Petersburg, Sankt-Peterburg, Russian Federation|Instituto Catalan de Oncologia - ICO ( Site 1251), L Hospitalet De Llobregat, Barcelona, Spain|Instituto Valenciano de Oncologia - IVO ( Site 1254), Valencia, Valenciana, Comunitat, Spain|Hospital Universitari Vall d Hebron ( Site 1250), Barcelona, Spain|Hospital Ramon y Cajal ( Site 1253), Madrid, Spain|Hospital General Universitario 12 de Octubre ( Site 1252), Madrid, Spain|National Cheng Kung University Hospital ( Site 1103), Tainan, Taiwan|National Taiwan University Hospital ( Site 1100), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1101), Taipei, Taiwan|Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1302), Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1305), Istanbul, Turkey|Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi ( Site 1303), Istanbul, Turkey|MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 1453), Dnipropetrovsk, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 1452), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Kyiv City Clinical Oncology Center ( Site 1450), Kyiv, Kyivska Oblast, Ukraine|Western General Hospital ( Site 1400), Edinburgh, Edinburgh, City Of, United Kingdom",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,RHABDOMYOSARCOMA,_VINORELBINE,NCT04299113,Phase 1,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,RHABDOMYOSARCOMA,_MOCETINOSTAT,NCT04299113,Phase 1,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,LUNG ADENOCARCINOMA,_VINORELBINE,NCT03891173,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Dnipropetrovsk City Multi-field Clinical Hospital #4, Dnipro, Ukraine|Sumy Regional Clinical Oncological Centre, Sumy, Ukraine|Vinnytsya Regional Clinical Oncological Centre, Vinnytsia, Ukraine",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,BLADDER CANCER,_GEMCITABINE,NCT02885974,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor Clinic, Houston, Texas, United States|Harris Health System - Smith Clinic, Houston, Texas, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,BLADDER CANCER,_CELECOXIB,NCT02885974,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor Clinic, Houston, Texas, United States|Harris Health System - Smith Clinic, Houston, Texas, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,LUNG CANCER,_GEMCITABINE,NCT02428764,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,PANCREATIC ADENOCARCINOMA,_GEMCITABINE,NCT03703089,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia mason medical Center, Seattle, Washington, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NON SMALL CELL LUNG CANCER,_PACLITAXEL,NCT02477826,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology ""Prof.Dr.Alexandru Trestioreanu"" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_PACLITAXEL,NCT04164238,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,SMALL CELL LUNG CANCER,_PACLITAXEL,NCT04210037,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Flinders Medical Centre, Bedford Park, South Australia, Australia",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,BLADDER CANCER,_PACLITAXEL,NCT04060459,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,PANCREATIC ADENOCARCINOMA,_PACLITAXEL,NCT03703063,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia mason medical Center, Seattle, Washington, United States",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,_PACLITAXEL,NCT04416035,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anhui Provincial Center Hospital, Hefei, Anhui, China|Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China|Wuhan Fourth Hospital, Wuhan, Hubei, China|The Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China|FAW General Hospital of Jilin Province, Changchun, Jilin, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai East Hospital, Shanghai, Shanghai, China|Shanghai Fifth People's Hospital, Fudan University, Shanghai, Shanghai, China|Nanchong Central Hospital, Nanchong, Sichuan, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,ADVANCED NON-SQUAMOUS NSCLC,_PACLITAXEL,NCT04325698,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Affiliated Hospital of Hebei University, Baoding, Hebei, China|Henan Cancer Hostipal, Zhengzhou, Henan, China|Xuzhou Central Hospital/ Medical Oncology Department, Xuzhou, Jiangsu, China|Jinan Central Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,SQUAMOUS CELL CARCINOMA,_PACLITAXEL,NCT03719924,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chu Amiens, Amiens, France|Institut Sainte Catherine, Avignon, France|Hopital Européen, Marseille, France|Ch Le Raincy, Montfermeil, France|Chu Saint Louis, Paris, France|Ch Perpignan, Perpignan, France|Chu de Poitiers, Poitiers, France|Chu Rouen, Rouen, France|Ch Duchenne, Saint-Malo, France",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,NON SMALL CELL LUNG CANCER,_OLAPARIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,NON SMALL CELL LUNG CANCER,_VISTUSERTIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",US-20090099174-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,32.7488,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.22,462.55400000000003,92.71,8.0,1.0,5.0,51.35,133.06,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,NON SMALL CELL LUNG CANCER,_CEDIRANIB,NCT03334617,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Santa Monica, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",WO-2001074360-A1,A61K45/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,BREAST NEOPLASM,_OLAPARIB,NCT03740893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Christie Hospital NHS Trust, Manchester, England, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom|Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_OLAPARIB,NCT03022409,Phase 1,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Toulouse, France|Research Site, Changhua City, Taiwan|Research Site, Taipei, Taiwan|Research Site, London, United Kingdom",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,METASTATIC COLORECTAL CANCER,_OLAPARIB,NCT04456699,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago ( Site 1357), Chicago, Illinois, United States|Illinois Cancer Care, PC ( Site 1352), Peoria, Illinois, United States|James Graham Brown Cancer Center ( Site 1393), Louisville, Kentucky, United States|Cancer & Hematology Centers of Western Michigan ( Site 1358), Grand Rapids, Michigan, United States|Washington University in St. Louis ( Site 1384), Saint Louis, Missouri, United States|CHI Health St. Francis ( Site 1406), Grand Island, Nebraska, United States|Southeast Nebraska Cancer Center ( Site 1353), Lincoln, Nebraska, United States|Providence Portland Medical Center ( Site 1400), Portland, Oregon, United States|Allegheny Singer Research Institute ( Site 1364), Pittsburgh, Pennsylvania, United States|West Cancer Center - East Campus ( Site 1396), Germantown, Tennessee, United States|Vanderbilt University Medical Center ( Site 1362), Nashville, Tennessee, United States|Baylor Scott & White Medical Center - Temple ( Site 1397), Temple, Texas, United States|Royal Brisbane and Women s Hospital ( Site 0054), Herston, Queensland, Australia|Monash Health ( Site 0050), Clayton, Victoria, Australia|Kyungpook National University Chilgok Hospital ( Site 0956), Daegu, Taegu-Kwangyokshi, Korea, Republic of|Korea University Anam Hospital ( Site 0955), Seoul, Korea, Republic of|Seoul National University Hospital ( Site 0950), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0951), Seoul, Korea, Republic of|Asan Medical Center ( Site 0952), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0954), Seoul, Korea, Republic of|The Catholic University of Korea St. Mary s Hospital ( Site 0953), Seoul, Korea, Republic of|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1202), Istanbul, Turkey|Prof. Dr. Cemil Tascioglu Sehir Hastanesi ( Site 1216), Istanbul, Turkey|Istanbul Medeniyet Universitesi Goztepe EAH ( Site 1214), Istanbul, Turkey|Kartal Dr. Lutfi Kirdar Egitim ve Arast Hast ( Site 1211), Istanbul, Turkey|Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi ( Site 1204), Izmir, Turkey|Medical Center Asklepion LLC ( Site 1309), Khodosivka, Kyivska Oblast, Ukraine",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE CANCER METASTATIC,_OLAPARIB,NCT03434158,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|ICO L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario i Politècnic La Fe, Valencia, Spain",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_METHYLPREDNISOLONE,NCT03661567,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,POST-DURAL PUNCTURE HEADACHE,_LIDOCAINE,NCT03560349,Phase 2,Enrolling by invitation,Female,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States",5234957.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,METASTATIC MELANOMA,_VANCOMYCIN,NCT03817125,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Angeles Clinic and Research Institute, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",10188697,A61K9/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,LEUKEMIA,_MYCOPHENOLATE_MOFETIL,NCT04547049,Phase 3,Recruiting,All,"14 Years to 60 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China|The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, China|Jinhua Hospital of Zhejiang University, Jinhua, China|Ningbo Hospital of Zhejiang University, Ningbo, China|The Affiliated People's Hospital of Ningbo University, Ningbo, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
S=P(N1CC1)(N1CC1)N1CC1,LEUKEMIA,_THIOTEPA,NCT03342196,Phase 2,Recruiting,All,"1 Year to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4766149,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,LEUKEMIA,_CLADRIBINE,NCT01515527,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7888328.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,LEUKEMIA,_DECITABINE,NCT01515527,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,NON SMALL CELL LUNG CANCER,_VEDOTIN,NCT03539536,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Alabama /ID# 212939, Mobile, Alabama, United States|Mayo Clinic Arizona /ID# 218550, Phoenix, Arizona, United States|Highlands Oncology Group /ID# 215600, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center - LaJolla /ID# 218258, La Jolla, California, United States|University of California, Los Angeles /ID# 203219, Los Angeles, California, United States|Sutter Medical Center Sacramen /ID# 203299, Sacramento, California, United States|Univ of Colorado Cancer Center /ID# 203212, Aurora, Colorado, United States|Rocky Mountain Cancer Centers - Denver Midtown /ID# 215789, Denver, Colorado, United States|Mayo Clinic /ID# 218488, Jacksonville, Florida, United States|Straub Clinic and Hospital /ID# 217905, Honolulu, Hawaii, United States|Northwestern University Feinberg School of Medicine /ID# 203239, Chicago, Illinois, United States|University of Chicago /ID# 203216, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston Hospital /ID# 215583, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 203228, Harvey, Illinois, United States|Joliet Oncology-Hematology Associates, LTD /ID# 203238, Joliet, Illinois, United States|Goshen Center for Cancer Care /ID# 215584, Goshen, Indiana, United States|Univ Kansas Med Ctr /ID# 216804, Kansas City, Kansas, United States|Cancer Center of Kansas /ID# 203235, Wichita, Kansas, United States|Baptist Health /ID# 203283, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 203284, Louisville, Kentucky, United States|Central Maine Medical Center /ID# 216583, Lewiston, Maine, United States|Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 203248, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 215646, Ann Arbor, Michigan, United States|Henry Ford Hospital - West Bloomfield /ID# 203220, West Bloomfield, Michigan, United States|Mayo Clinic - Rochester /ID# 215603, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 203217, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center /ID# 203292, Billings, Montana, United States|Univ Nebraska Med Ctr /ID# 203388, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center /ID# 203350, Lebanon, New Hampshire, United States|Atlantic Health System /ID# 203404, Morristown, New Jersey, United States|Overlook Medical Center /ID# 211160, Summit, New Jersey, United States|University of New Mexico /ID# 208339, Albuquerque, New Mexico, United States|Univ Hosp Cleveland /ID# 215648, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 203301, Portland, Oregon, United States|Penn State University and Milton S. Hershey Medical Center /ID# 221844, Hershey, Pennsylvania, United States|Allegheny General Hospital /ID# 215585, Pittsburgh, Pennsylvania, United States|Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr /ID# 203281, Nashville, Tennessee, United States|Houston Methodist Hospital - Scurlock Tower /ID# 213268, Houston, Texas, United States|Baylor Scott & White Medical Center- Temple /ID# 216578, Temple, Texas, United States|Virginia Cancer Specialists /ID# 203224, Fairfax, Virginia, United States|University of Washington /ID# 206056, Seattle, Washington, United States|Medical College of Wisconsin /ID# 210062, Milwaukee, Wisconsin, United States|The Kinghorn Cancer Centre /ID# 207666, Darlinghurst, New South Wales, Australia|Newcastle Private Hospital /ID# 206600, Lambton Heights, New South Wales, Australia|The Tweed Hospital /ID# 206601, Tweed Heads, New South Wales, Australia|UZ Antwerp /ID# 217430, Edegem, Belgium|AZ Groeninge /ID# 217431, Kortrijk, Belgium|Cross Cancer Institute /ID# 204540, Edmonton, Alberta, Canada|The Ottawa Hospital /ID# 205579, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre /ID# 204423, Toronto, Ontario, Canada|CISSS de la Monteregie /ID# 211356, Greenfield Park, Quebec, Canada|Anhui Provincial Hospital /ID# 212096, Hefei, Anhui, China|Fujian Provincial Cancer Hospital /ID# 210808, Fuzhou, Fujian, China|Jilin Cancer Hosptial /ID# 210563, Changchun, Jilin, China|Fudan University Shanghai Cancer Center /Id# 210084, Shanghai, Shanghai, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 211154, Hangzhou, Zhejiang, China|Zhejiang Cancer hospital /ID# 210085, Hangzhou, Zhejiang, China|Beijing Cancer Hospital /ID# 210133, Beijing, China|West China Hospital, Sichuan University /ID# 210022, Chengdu, China|Shanghai Chest Hospital /ID# 210930, Shanghai, China|Henan Cancer Hospital /ID# 210961, Zhengzhou Henan, China|CHU Hopital Nord /ID# 209854, Marseille, Bouches-du-Rhone, France|Institut Bergonie /ID# 216207, Bordeaux, Gironde, France|Institut Curie /ID# 207046, Paris CEDEX 05, Ile-de-France, France|Centre Leon Berard /ID# 205107, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 205149, Villejuif, Val-de-Marne, France|Hopital Louis Pradel /ID# 216209, Bron, France|CHRU de Lille - Hopital Albert Calmette /ID# 205105, Lille, France|Nouvel Hopital Civil (NHC) /ID# 208080, Strasbourg, France|KH Martha-Maria Halle Dolau /ID# 205442, Halle (Saale), Sachsen-Anhalt, Germany|Vivantes Klinikum Neukolln /ID# 205928, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 207789, Gauting, Germany|Evangelisches Krankenhaus Hamm /ID# 208043, Hamm, Germany|Klinikum Kassel /ID# 205443, Kassel, Germany|Pius Hospital Oldenburg /ID# 211615, Oldenburg, Germany|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 205528, Athens, Greece|Metropolitan Hospital /ID# 205529, Athens, Greece|University General Hospital of Heraklion PA.G.N.I /ID# 205530, Heraklion, Greece|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 204878, Miskolc, Borsod-Abauj-Zemplen, Hungary|Torokbalinti Tudogyogyintezet /ID# 204883, Budapest, Pest, Hungary|Semmelweis Egyetem /ID# 204434, Budapest, Hungary|Veszprem Megyei Tudogyogyintez /ID# 213950, Farkasgyepu, Hungary|Matrahaza Gyogyintezet /ID# 204432, Kékesteto, Hungary|St. James's Hospital /ID# 205104, Dublin 8, Dublin, Ireland|Cork University Hospital /ID# 205103, Cork, Ireland|St Vincent's University Hosp /ID# 205102, Dublin, Ireland|Soroka Medical Center /ID# 204898, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 215322, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 204866, Haifa, Israel|Meir Medical Center /ID# 204255, Kfar Saba, Israel|Sheba Medical Center /ID# 204254, Ramat Gan, Israel|IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 205601, Meldola, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 215918, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 205163, Rome, Lazio, Italy|AO San Giuseppe Moscati /ID# 204707, Avellino, Italy|A.O.U. San Luigi Gonzaga /ID# 204706, Orbassano, Italy|Azienda Ospedaliero Uni Parma /ID# 204983, Parma, Italy|National Hospital Organization Kyushu Cancer Center /ID# 206061, Fukuoka-shi, Fukuoka, Japan|Kinki-Chuo Chest Medical Center /ID# 216461, Kita-ku, Osaka, Japan|Shizuoka Cancer Center /ID# 205065, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital /ID# 205066, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of JFCR /ID# 216463, Koto-ku, Tokyo, Japan|Hiroshima Citizens Hospital /ID# 218087, Hiroshima, Japan|Niigata Cancer Center Hospital /ID# 216462, Niigata-shi, Japan|Osaka Inter. Cancer Institute /ID# 210735, Osaka, Japan|Sendai Kousei Hospital /ID# 216460, Sendai, Japan|Kanagawa Cancer Center /ID# 205068, Yokohama, Japan|National Cancer Center /ID# 204241, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 204237, Seongnam, Gyeonggido, Korea, Republic of|Chungbuk National Univ Hosp /ID# 205680, Cheongju, Korea, Republic of|Chonnam National University Hwasun Hospital /ID# 206951, Jeonnam, Korea, Republic of|Asan Medical Center /ID# 204236, Seoul, Korea, Republic of|Antoni van Leeuwenhoek /ID# 216657, Amsterdam, Noord-Holland, Netherlands|Meander Medisch Centrum /ID# 217756, Amersfoort, Netherlands|Ziekenhuis St. Jansdal /ID# 216658, Harderwijk, Netherlands|VA Caribbean Healthcare System /ID# 206336, San Juan, Puerto Rico|Puerto Rico Hematology Oncolog /ID# 206337, San Juan, Puerto Rico|Institutul Oncologic /ID# 206320, Cluj Napoca, Romania|Oncomed SRL /ID# 205616, Timisoara, Romania|""Avicenna"" medical center /ID# 212397, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Tatarstan Cancer Center /ID# 206463, Kazan, Tatarstan, Respublika, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 206520, Volgograd, Volgogradskaya Oblast, Russian Federation|Arkhangelsk clinical oncology /ID# 216418, Arkhangelsk, Russian Federation|LLC Evimed /ID# 216473, Chelyabinsk, Russian Federation|Univercity Headache Clynic,LTD /ID# 212080, Moscow, Russian Federation|PMI Euromedservice /ID# 206390, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 216262, Pyatigorsk, Russian Federation|OOO Centre of Palliative Medicine De Vita /ID# 212900, Saint Petersburg, Russian Federation|St.Petersburg City Cancer Center /ID# 206405, Sankt-Peterburg, Russian Federation|Hospital Clínico Universitario de Santiago /ID# 204367, Santiago de Compostela, A Coruna, Spain|Instituto Catalan de Oncologia (ICO) Badalona /ID# 216106, Badalona, Barcelona, Spain|Hospital Regional Universitario de Malaga /ID# 216081, Málaga, Malaga, Spain|Hospital Universitario y Politecnico La Fe /ID# 203862, Valencia, Valenciana, Spain|Hospital Vall d'Hebron /ID# 206997, Barcelona, Spain|Hospital Univ Ramon y Cajal /ID# 203922, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 203913, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 216058, Sevilla, Spain|National Cheng Kung University Hospital /ID# 205307, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 205100, Taipei City, Taipei, Taiwan|Dalin Tzu Chi General Hospital /ID# 205309, Dalin Township, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 205831, Kaohsiung, Taiwan|Taipei Med Univ Shuang Ho Hosp /ID# 215356, New Taipei City, Taiwan|Taichung Veterans General Hosp /ID# 205308, Taichung City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 205424, Taoyuan City, Taiwan|Adana Sehir Egitim ve Arastirma Hastanesi /ID# 206000, Adana, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi /ID# 205243, Ankara, Turkey|Akdeniz Universitesi Tip Fakul /ID# 205238, Antalya, Turkey|Trakya University Medical Facu /ID# 205242, Edirne, Istanbul, Turkey|Istanbul Medeniyet Universites /ID# 215082, Istanbul, Turkey|Dr. Suat Seren Gogus Has /ID# 215083, Izmir, Turkey|Heart of England NHS Foundation Trust /ID# 206209, Birmingham, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 205890, Oxford, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,PANCREATIC ADENOCARCINOMA,_LEUCOVORIN,NCT03193190,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Helen Diller Fam Comp Can Ctr, San Francisco, California, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States|Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Hillman Cancer Center;Medical Oncology, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Charite - Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hosp. G. U Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
O=c1[nH]cc(F)c(=O)[nH]1,PANCREATIC ADENOCARCINOMA,_FLUOROURACIL,NCT03193190,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Helen Diller Fam Comp Can Ctr, San Francisco, California, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States|Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Hillman Cancer Center;Medical Oncology, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Charite - Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hosp. G. U Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,NON SMALL CELL LUNG CANCER,_ETOPOSIDE,NCT03840902,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California Irvine Medical Center, Orange, California, United States|UCLA Hematology Oncology - Main Site - 2020 Santa Monica, Santa Monica, California, United States|University of Colorado Health - Memorial Hospital - Memorial Hospital, Colorado Springs, Colorado, United States|Lynn Cancer Institute Center, Boca Raton, Florida, United States|Holy Cross Hospital - Michael and Dianne Bienes CCC, Fort Lauderdale, Florida, United States|Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|American Health Network of Indiana, LLC, Indianapolis, Indiana, United States|Baptist Health Lexington Oncology Associates, Lexington, Kentucky, United States|University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Hematology Oncology Center of Nyack Hospital, Nyack, New York, United States|FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States|Centro Polivalente de Asistencia e Inv. Clinica CER, San Juan, Argentina|Bendigo Hospital, Bendigo, Australia|The Townsville Hospital, Douglas, Australia|Calvary Central Districts Hospital, Elizabeth Vale, Australia|St Vincent's Hospital Melbourne - PARENT, Fitzroy, Australia|Austin Health, Heidelberg Heights, Australia|Centro de Investigacion Pergamino SA, Pergamino, Australia|Prince of Wales Hospital, Randwick, Australia|Sunshine Hospital, St Albans, Australia|South West Healthcare - South West Oncology, Warrnambool, Australia|UZ Leuven, Leuven, Belgium|Clinique et Maternite St Elisabeth Namur, Namur, Belgium|CHU Mont-Godinne, Yvoir, Belgium|Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil|HGB - Hospital Giovanni Battista - Mãe de Deus Center - Centro de Pesquisa Clínica - Instituto do Câncer, Porto Alegre, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Brazil|COI - Clínicas Oncológicas Integradas, Rio de Janeiro, Brazil|A. C. Camargo Cancer Center - Fundação Antônio Prudente, São Paulo, Brazil|ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Brazil|BC Cancer Agency Center for the Southern Interior, Kelowna, Canada|Fakultni nemocnice Olomouc - Dept of Onkologicka klinika, Olomouc, Czechia|Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire, Marseille cedex 20, France|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris - Service d'Oncologie Médicale, Paris Cedex 05, France|CHU Nantes - Hôpital Guillaume et René Laënnec - Service de Pneumologie, Saint Herblain, France|Nippon Medical School Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Japan|Saitama Medical University International Medical Center - Dept of Respiratory Medicine, Hidaka-shi, Japan|National Cancer Center Hospital East - Dept of Respiratory Medicine, Kashiwa-shi, Japan|Kobe City Hospital Organization Kobe City Medical Center General Hospital - Dept of Respiratory Medicine, Kobe-shi, Japan|Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine, Koto-ku, Japan|Kurume University Hospital - Dept of Lung Cancer Center, Kurume-shi, Japan|Aichi Cancer Center Hospital - Dept of Respiratory Medicine, Nagoya-shi, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka-shi, Japan|Kindai University Hospital (13859), Osakasayama-shi, Japan|Shizuoka Cancer Center, Sunto-gun, Japan|Kanagawa Cancer Center - Dept of Respiratory Medicine, Yokohama-shi, Japan|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Netherlands|Meander Medisch Centrum - Dep of Pulmonology, Amersfoort, Netherlands|Amphia Ziekenhuis - PARENT - Parent, Breda, Netherlands|Martini ziekenhuis, Groningen, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|St. Antonius Ziekenhuis - Dept Pulmonology - Nieuwegein, Nieuwegein, Netherlands|St. Elisabeth Ziekenhuis - Parent, Tilburg, Netherlands|ISALA Klinieken Locatie Sophia, Zwolle, Netherlands|Hospital del Mar - Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia, L'Hospitalet de Llobregat, Spain|Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid, Spain|Clinica Universidad de Navarra (MAD) - Oncology Service, Madrid, Spain|Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Nuestra Señora de Valme - Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio - Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen Macarena - Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Liou Ying, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",4701327,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,OSTEOSARCOMA,_ETOPOSIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=P1(NCCCl)OCCCN1CCCl,OSTEOSARCOMA,_IFOSFAMIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",5252341,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,OSTEOSARCOMA,_LENVATINIB,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,HEPATOCELLULAR CARCINOMA,_IDARUBICIN,NCT04178642,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UH Montpellier, Montpellier, France",4534971,A61K47/42,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,"CARCINOMA, HEPATOCELLULAR",_IDARUBICIN,NCT03727633,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU d'Angers, Angers, France|CHU de Dijon, Dijon, France|CHU de Montpellier, Montpellier, France|CHU de Nice, Nice, France",4534971,A61K47/42,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,ACUTE MYELOBLASTIC LEUKEMIA,_IDARUBICIN,NCT01296178,Not Applicable,Recruiting,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital La Fe, Valencia, Spain",4534971,A61K47/42,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,PROSTATE CANCER RECURRENT,_HYDROXYCHLOROQUINE,NCT04011410,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center - University of Kentucky, Lexington, Kentucky, United States",4181725,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,PROSTATE CANCER RECURRENT,_HYDROXYCHLOROQUINE_SULFATE,NCT04011410,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center - University of Kentucky, Lexington, Kentucky, United States",5318960,A61K47/44,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,"CARCINOMA, NON-SMALL-CELL LUNG",_ACETAMINOPHEN,NCT04165096,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States|City of Hope ( Site 0014), Duarte, California, United States|University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States|MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States|Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States|Cleveland Clinic ( Site 0006), Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,"CARCINOMA, NON-SMALL-CELL LUNG",_DIPHENHYDRAMINE,NCT04165096,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States|City of Hope ( Site 0014), Duarte, California, United States|University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States|MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States|Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States|Cleveland Clinic ( Site 0006), Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas, United States",8263647,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,NON SMALL CELL LUNG CANCER,_SELUMETINIB,NCT03392246,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University, Durham, North Carolina, United States",7425637,C07D401/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,NEUROFIBROMATOSIS TYPE 1,_SELUMETINIB,NCT04495127,Phase 1,Recruiting,All,"3 Years to 18 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Minato-ku, Japan|Research Site, Setagaya-ku, Japan|Research Site, Yufu-shi, Japan",7425637,C07D401/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CUSHING DISEASE,_DEXAMETHASONE,NCT03974789,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"CHU de Nimes, Nîmes, France",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,SMALL CELL LUNG CANCER,_ACETAZOLAMIDE,NCT03467360,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Antoine Lacassagne, Nice, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
C[N+](C)(C)CCO,PROSTATE ADENOCARCINOMA,_CHOLINE,NCT03404648,Phase 3,Enrolling by invitation,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,PROSTATE ADENOCARCINOMA,_GADOBUTROL,NCT03404648,Phase 3,Enrolling by invitation,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",5980864,C07D257/02,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,103.722869052752,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.35,604.72,181.08,9.0,3.0,4.0,45.39,143.47,10.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,GLIOBLASTOMA,_ANLOTINIB,NCT04119674,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang cancer hospital, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,LUNG CANCER,_ANLOTINIB,NCT03983928,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,THYROID CANCER,_ANLOTINIB,NCT04309136,Phase 2,Recruiting,All,"14 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fudan University Shanghai Cancer Center, Shanghai, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,LUNG NEOPLASMS,_ANLOTINIB,NCT03940404,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Observational Model: Case-Only|Time Perspective: Prospective,"First People's Hospital of Hangzhou, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,BLADDER CANCER,_ASCORBIC_ACID,NCT04046094,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",7169381.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,GLIOBLASTOMA MULTIFORME,_ASCORBIC_ACID,NCT02344355,Phase 2,"Active, not recruiting",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",7169381.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,GLIOBLASTOMA MULTIFORME,_TEMOZOLOMIDE,NCT02344355,Phase 2,"Active, not recruiting",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,GLIOBLASTOMA MULTIFORME,_PAZOPANIB,NCT02331498,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Antoine Lacassagne, Nice, Cedex 2, France",7105530,C07D231/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,KIDNEY CANCER,_PAZOPANIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",7105530,C07D231/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,KIDNEY CANCER,_SUNITINIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,KIDNEY CANCER,_TEMSIROLIMUS,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",5362718,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,SMALL CELL LUNG CANCER,_TEMOZOLOMIDE,NCT04400188,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital of Sichuan University, Chengdu, Sichuan, China",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,GLIOMA,_TEMOZOLOMIDE,NCT03257618,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut regional du Cancer - Val d Aurelle, Montpellier, France",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,OSTEOSARCOMA,_SUNITINIB,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,OSTEOSARCOMA,_LOSARTAN,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",5210079,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,RENAL CELL CARCINOMA,_SUNITINIB,NCT02919371,Phase 1|Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,GLIOBLASTOMA,_FLUDEOXYGLUCOSE,NCT04315584,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Virginia, Charlottesville, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,"CARCINOMA, NON-SMALL-CELL LUNG",_TYROSINE,NCT03799094,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clifford Hospital, Guangzhou, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,NSCLC,_TYROSINE,NCT04318938,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,THYROID CANCER,_TYROSINE,NCT04521348,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_RUXOLITINIB,NCT03153982,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center, Tucson, Arizona, United States|University of California, San Francisco, San Francisco, California, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,LEUKEMIA,_RUXOLITINIB,NCT02723994,Phase 2,Recruiting,All,"1 Year to 21 Years   (Child, Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Anaheim (Satellite Site), Anaheim, California, United States|Kaiser Permanente Downey (Satellite Site), Downey, California, United States|Kaiser Permanente Fontana (Satellite Site), Fontana, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Miller Children's at Long Beach Medical Center, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucille Packard Child Hospital END, Palo Alto, California, United States|Kaiser Permanente San Diego (Satellite Site), San Diego, California, United States|Rady Children's Hospital, San Diego, California, United States|UCSF Pediatric Hematology/Oncology, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Alfred I. duPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|Adventist Health System/Sunbelt Inc d/b/a/Florida Hospital, Altamonte Springs, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic - of the Nemours Foundation, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic, Pensacola, Florida, United States|All Children's Hospital Johns Hopkins Medicine, Saint Petersburg, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|Saint Mary's Medical Center, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Kapiolani Medical Center for Women and Children/Univ of HI, Honolulu, Hawaii, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|St. Vincent Children's Hospital, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|CS Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Helen Devos Children's Hospital, Grand Rapids, Michigan, United States|Bronson Methodist Hospital Ped, Kalamazoo, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Children's Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Children's Hospital Critical Care, Omaha, Nebraska, United States|Children's Specialty Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St Joseph's Regional Medical Center, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, The Children's Hospital at Montefiore, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cohen Children's Medical Center of NY - PRIME, New Hyde Park, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Medical Center - Charlotte, Charlotte, North Carolina, United States|Wake Forest University Health Center, Winston-Salem, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation - Central, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Medical Center of Dayton, Dayton, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Children's Blood and Cancer Center, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Children's Hospital & Regional Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Midwest Children's Cancer Center, Wauwatosa, Wisconsin, United States|Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's & Women's Hospital Center, Vancouver, British Columbia, Canada|McMaster University Health Sciences Center, Hamilton, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada|Montreal Children's Hospital, Montréal, Quebec, Canada|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",7598257,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,RETINOBLASTOMA,_DOXORUBICIN,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=S(=O)(O)CCS,RETINOBLASTOMA,_MESNA,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,RETINOBLASTOMA,_TOPOTECAN,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5004758,C07D491/22,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,BASAL CELL CARCINOMA,_DOXORUBICIN,NCT03646188,Phase 1,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Center for Clinical and Cosmetic Research, Aventura, Florida, United States",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,"CARCINOMA, NON-SMALL-CELL LUNG",_ZOLEDRONIC_ACID,NCT03958565,,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Other|Time Perspective: Prospective,"University of Colorado Hospital, Aurora, Colorado, United States",4939130.0,C07F9/65031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,LUNG CANCER,_AFATINIB,NCT01553942,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",6251912,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,LUNG CANCER,_PEMETREXED,NCT01553942,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=N)NC(=N)N,NON SMALL CELL LUNG CANCER,_METFORMIN,NCT03874000,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)N=C(N)N.Cl,NON SMALL CELL LUNG CANCER,_METFORMIN_HYDROCHLORIDE,NCT03874000,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_METFORMIN,NCT02949700,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States|Harris Health System - Smith Clinic, Houston, Texas, United States",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,GLIOBLASTOMA,_METFORMIN,NCT03151772,Early Phase 1,Terminated,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sahlgrenska University Hospital, Göteborg, Sweden",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,GLIOBLASTOMA,_DISULFIRAM,NCT03151772,Early Phase 1,Terminated,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sahlgrenska University Hospital, Göteborg, Sweden",3932346,C08F2/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,"CARCINOMA, NON-SMALL-CELL LUNG",_METFORMIN,NCT04170959,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Antwerp, Edegem, Antwerp, Belgium",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,GLIOBLASTOMA MULTIFORME,_METFORMIN,NCT02780024,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Neurological Institute - McGill University Health Centre, Montréal, Quebec, Canada",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,NON-SMALL CELL LUNG CANCER METASTATIC,_PEMETREXED,NCT04163432,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,LUNG NEOPLASMS,_PEMETREXED,NCT03380468,Phase 2|Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fudan University Cancer Center, Shanghai, Shanghai, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,NON-SQUAMOUS NSCLC,_PEMETREXED,NCT03802240,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shanghai Chest Hospital, Shanghai, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,ERECTILE DYSFUNCTION|PROSTATE CANCER,_PENTOXIFYLLINE,NCT03406169,Phase 3,Recruiting,Male,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brooke Army Medical Center, San Antonio, Texas, United States",4189469,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,ERECTILE DYSFUNCTION|PROSTATE CANCER,_SILDENAFIL,NCT03406169,Phase 3,Recruiting,Male,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brooke Army Medical Center, San Antonio, Texas, United States",5250534.0,C07D487/04,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,COLORECTAL CANCER,_ATORVASTATIN,NCT04151355,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Faculty of Pharmacy, Cairo, Egypt",4681893,C07D405/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_FLUOROURACIL,NCT03340896,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Bretonneau, Service CORad Pôle Henry S Kaplan, Tours, France",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,PANCREATIC ADENOCARCINOMA,_IRINOTECAN,NCT03665441,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University, Durham, North Carolina, United States|Institut de Cancerologie, Brest, France",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,SMALL CELL LUNG CANCER,_IRINOTECAN_HYDROCHLORIDE,NCT04381910,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,ACTINIC KERATOSIS,_DIGOXIN,NCT03684772,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Human Drug Research, Leiden, Netherlands",3933997.0,G01N31/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,ACTINIC KERATOSIS,_FUROSEMIDE,NCT03684772,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Human Drug Research, Leiden, Netherlands",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,POST-TRAUMATIC HEADACHE,_PSILOCYBIN,NCT03806985,Phase 1,Recruiting,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","VA Connecticut Healthcare System, West Haven, Connecticut, United States",6126924,A61Q19/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,16.263167621511702,94.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.25,284.2481,85.79,4.0,3.0,2.0,27.73,73.3,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,POST-DURAL PUNCTURE HEADACHE,_DEXMEDETOMIDINE,NCT04327726,Not Applicable,Recruiting,Female,21 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Zagazig University Hospitals, Zagazig, Sharkia, Egypt",5344840,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,PHEOCHROMOCYTOMA,_DEXMEDETOMIDINE,NCT04320589,Phase 2,Recruiting,All,"12 Years to 69 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, Egypt",5344840,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,ABDOMINAL CANCER,_DEXMEDETOMIDINE,NCT03762785,Phase 1|Phase 2,Recruiting,All,3 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","South Egypt Cancer Institute, Assiut, Egypt",5344840,4,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,GLIOBLASTOMA MULTIFORME,_VALGANCICLOVIR,NCT04116411,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SE01 Karolinska University Hospital, Solna, Stockholm, Sweden",6083953,C07D473/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,NON SMALL CELL LUNG CANCER,_CABOZANTINIB,NCT04131543,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OU di Oncologia Medica- Azienda ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy|U.O di Oncologia Medica Policlinico V.Emanuele-G.Rodolico, Catania, Italy|Oncologia Medica 2 -Policlinico San Martino, Genova, Italy|S.S. di Oncologia Medica toraco-polmonare - Fondazione IRCCS - Istituto Nazionale Tumori, Milano, Italy|U.O.C Pneumologia ad Indirizzo Oncologico -AORN Ospedali dei Colli Monaldi-Cotugno-CTO, Napoli, Italy|UOC di Oncologia Medica 2 - IOV Istituto Oncologico Veneto, Padova, Italy|UOC di Oncologia Medica- Azienda Ospidaliero Universitaria di Parma, Parma, Italy|US di Oncologia Medica - A.O. di Perugia, Perugia, Italy|UO Pneumologia - A.O.U Pisana, Pisa, Italy|S.C. di Oncologia Medica - IFO - Istituto Regina Elena, Roma, Italy|UOC di Oncologia Medica - Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"CARCINOMA, NON-SMALL-CELL LUNG",_CABOZANTINIB,NCT04471428,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tucson, Arizona, United States|Stanford University, Palo Alto, California, United States|Kaiser Permanente - San Diego, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Florida Hospital, Orlando, Florida, United States|Cancer Care Centers of Brevard, Rockledge, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy, Illinois, United States|Regional Cancer Care Associates, Bethesda, Maryland, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Oncology Associates of Oregon, P.C, Eugene, Oregon, United States|Consultants in Medical Oncology and Hematology, Broomall, Pennsylvania, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Oncology and Hematology Associates of Southwest Virginia, Inc.,-Blacksburg, Blacksburg, Virginia, United States|Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States|Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia|Townsville Hospital, Townsville, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia|Affinity Oncology, Nedlands, Western Australia, Australia|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria|Ordensklinikum Linz Elisabethinen, Linz, Austria|Lhk Feldkirch; Interne Medizin Abt., Rankweil, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Clinique de l'Europe, Amiens, France|CHU Angers,Service de Pneumologie, Angers, France|CHU de Grenoble, Grenoble, France|Hopital Dupuytren; Pneumologie, Limoges, France|Hôpital Saint Joseph; Oncologie Medicale, Marseille, France|Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque; Service d oncologie, Montpellier, France|Centre Hospitalier de Mulhouse - Hopital Emile Muller, Mulhouse, France|Hopital Tenon;Pneumologie, Paris, France|Zentralklinik Bad Berka GmbH; Pneumologie, Bad Berka, Germany|Kliniken Essen Mitte Evang. Huyssens Stiftung/Knappschaft GmbH, Essen, Germany|Universitaetsklinikum Giessen und Marburg GmbH; Medizinische Klinik IV und V, Gießen, Germany|KRH Klinikum Siloah-Oststadt-Heidehaus, Hannover, Germany|Klinikum Koeln-Merheim; Lungenklinik, Köln, Germany|Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz, Germany|Universitaetsklinikum Giessen und Marburg, Marburg, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Med. Versorgungszentrum Weiden, Abteilung für Onkologie, Weiden, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Henri Dunant Hospital; Oncology Dept., Athens, Greece|Uoa Sotiria Hospital; Oncology, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|AORN Ospedali dei Colli Ospedale Monaldi; UOC Pneumologia ad indirizzo Oncologico, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|IRCCS AOU San Martino - IST, Genova, Liguria, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|Instituto Europeo di Oncologia, Milan, Lombardia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy|Ospedale Vito Fazzi, Lecce, Puglia, Italy|A.O.U Careggi, Florence, Toscana, Italy|Hyogo Cancer Center, Hyogo, Japan|Sendai Kousei Hospital, Miyagi, Japan|Osaka International Cancer Institute, Osaka, Japan|Kinki-Chuo Chest Medical Center, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Samsung Changwon Hospital, Gyeongsangnam-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Centrum Onkologii w Gliwicach; II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Szpital Wojewódzki im. Mikołaja Kopernika; Oddział Dzienny Chemioterapii, Koszalin, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Hospital Pulido Valente; Servico de Pneumologia, Lisboa, Portugal|Hospital Pedro Hispano; Servico de Oncologia, Matosinhos, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|Hospital CUF Porto; Servico Pneumologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|CHVNG/E_Unidade 1; Servico de Pneumologia, Vila Nova De Gaia, Portugal|Regional Clinical Oncology Hospital, Yaroslavl, Jaroslavl, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|GBUZ Leningradskaya state clinical hospital, St. Petersburg, Russian Federation|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, La Coruna, LA Coruña, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe; Oncologia, Valencia, Spain|Addenbrookes Hospital, Cambridge, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Castle Hill Hospital; The Queen's Centre for Oncology & Haematology, Hull, United Kingdom|Barts & London School of Med; Medical Oncology, London, United Kingdom|University College London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,METASTATIC RENAL CELL CARCINOMA,_CABOZANTINIB,NCT03149822,Phase 1|Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States|Memorial Hospital Central, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|UCHealth Lone Tree Medical Center, Lone Tree, Colorado, United States",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"CARCINOMA, RENAL CELL",_CABOZANTINIB,NCT04338269,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, Flagstaff, Arizona, United States|University of Arizona, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Health System, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California Davis, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|New York University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology - Willowbrook, Houston, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists - Gainsville, Gainesville, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Medico Austral OMI, Ciudad Autonoma Buenos Aires, Argentina|Orange Hospital, Orange, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Bendigo Cancer Centre, Bendigo, Victoria, Australia|Box Hill Hospital; Oncology, Box Hill, Victoria, Australia|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut de cancerologie du Gard, Nimes, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie, Frankfurt, Germany|Universitaetsklinikum Freiburg; Urology, Freiburg, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie, Hamburg, Germany|Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie u. Stammzelltransplantation, Hannover, Germany|Universitaetsklinikum Muenster; Urology, Muenster, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Attikon University General Hospital, Athens, Greece|Athens Medical Center; Dept. of Oncology, Athens, Greece|University Hospital of Larissa;Department of Medical Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); SOC Oncologia Medica A, Aviano (PN), Friuli-Venezia Giulia, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS); Day Hospital Oncologico Multidisciplinare, Candiolo (TO), Piemonte, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Kyushu University Hospital, Fukuoka, Japan|Hokkaido University Hospital, Hokkaido, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Yokohama City University Hospital, Kanagawa, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Keio University Hospital, Tokyo, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Wojewódzki Szpital Zespolony im.L.Rydygiera; Oddzial Chemioterapii Nowotworów, Toruń, Poland|Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Warszawa, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wrocław, Poland|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|TSBHI Altai Territorial oncological dispensary, Barnaul, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Medical Center Avicenna; Urology, Novosibirsk, Russian Federation|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Alvaro Cunqueiro; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario de Burgos; Oncología, Burgos, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Royal Blackburn Hospital, Blackburn, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|ROYAL MARSDEN HOSPITAL; DEPT OF MEDICAL ONCOLOGY; The Bob Champion Unit, Sutton, United Kingdom",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,BLADDER CANCER,_CABOZANTINIB,NCT04289779,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,NON SMALL CELL LUNG CANCER,_VEMURAFENIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7504509,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,39.0,50.9579252140701,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.95,489.92199999999997,91.92,4.0,2.0,4.0,48.1,121.97,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,NON SMALL CELL LUNG CANCER,_COBIMETINIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7803839,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,NON SMALL CELL LUNG CANCER,_ENTRECTINIB,NCT03178552,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",8299057,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,51.7464424320827,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.03,560.65,85.52,6.0,3.0,6.0,60.41,161.24,7.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,THYROID CANCER,_REGORAFENIB,NCT02657551,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,NON SMALL CELL LUNG CANCER,_TRAMETINIB,NCT03087448,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Davis, Davis, California, United States|University of California, San Francisco, San Francisco, California, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,NON SMALL CELL LUNG CANCER,_CERITINIB,NCT03087448,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Davis, Davis, California, United States|University of California, San Francisco, San Francisco, California, United States",7153964,C07D239/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,"CARCINOMA, NON-SMALL-CELL LUNG",_TRAMETINIB,NCT04452877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Tianjin, China",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,"CARCINOMA, NON-SMALL-CELL LUNG",_DABRAFENIB,NCT04452877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Tianjin, China",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,METASTATIC MELANOMA,_TRAMETINIB,NCT02392871,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,METASTATIC MELANOMA,_DABRAFENIB,NCT02392871,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,MENINGIOMA,_TRAMETINIB,NCT03631953,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assistance Publique Hôpitaux de Marseille, Marseille, France",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,MENINGIOMA,_ALPELISIB,NCT03631953,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assistance Publique Hôpitaux de Marseille, Marseille, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,34.431918519887475,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,441.47,101.21,4.0,2.0,3.0,42.75,105.85,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,NON SMALL CELL LUNG CANCER,_LENVATINIB,NCT03829332,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alaska Clinical Research Center ( Site 0511), Anchorage, Alaska, United States|Ironwood Cancer & Research Centers ( Site 0541), Chandler, Arizona, United States|CBCC Global Research, Inc. ( Site 0532), Bakersfield, California, United States|Scripps Cancer Center ( Site 0521), La Jolla, California, United States|Florida Hospital ( Site 0526), Orlando, Florida, United States|Northwest Georgia Oncology Centers PC ( Site 0518), Marietta, Georgia, United States|Illinois Cancer Care, PC ( Site 0557), Peoria, Illinois, United States|Parkview Cancer Center ( Site 0542), Fort Wayne, Indiana, United States|University of Kentucky School of Medicine & Hospitals ( Site 0517), Lexington, Kentucky, United States|Anne Arundel Medical Center Oncology and Hematology ( Site 0514), Annapolis, Maryland, United States|Munson Medical Center ( Site 0512), Traverse City, Michigan, United States|Park Nicollet Frauenshuh Cancer Center ( Site 0554), Saint Louis Park, Minnesota, United States|University of Missouri Health Care ( Site 0555), Columbia, Missouri, United States|Billings Clinic Cancer Center ( Site 0508), Billings, Montana, United States|Cone Health Cancer Center at Alamance Regional ( Site 0527), Greensboro, North Carolina, United States|Genesis Cancer Care Center ( Site 0559), Zanesville, Ohio, United States|Oregon Health Sciences University ( Site 0544), Portland, Oregon, United States|Central Texas Veterans Healthcare System ( Site 0533), Temple, Texas, United States|Orange Health Services ( Site 0002), Orange, New South Wales, Australia|Wollongong Private Hospital ( Site 0005), Wollongong, New South Wales, Australia|The Prince Charles Hospital ( Site 0011), Chermside, Queensland, Australia|Ballarat Oncology and Haematology Services ( Site 0008), Wendouree, Victoria, Australia|St John of God Murdoch Medical Clinic ( Site 0001), Perth, Western Australia, Australia|Cross Cancer Institute ( Site 0400), Edmonton, Alberta, Canada|Lions Gate Hospital ( Site 0407), North Vancouver, British Columbia, Canada|William Osler Health System (Brampton Civic Hospital) ( Site 0402), Brampton, Ontario, Canada|Windsor Regional Cancer Program ( Site 0404), Windsor, Ontario, Canada|McGill University Health Centre ( Site 0418), Montreal, Quebec, Canada|Anhui Provincial Hospital ( Site 0108), Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University ( Site 0113), Hefei, Anhui, China|Peking Union Medical College Hospital ( Site 0105), Beijing, Beijing, China|Beijing Cancer Hospital ( Site 0102), Beijing, Beijing, China|Beijing Chest Hospital Capital Medical University ( Site 0111), Beijing, Beijing, China|Xiangya Hospital of Central South University ( Site 0115), Changsha, Hunan, China|Hunan Cancer Hospital ( Site 0104), Changsha, Hunan, China|The First Hospital of Jilin University ( Site 0110), Chang chun, Jilin, China|Zhongshan Hospital Fudan University ( Site 0100), Shanghai, Shanghai, China|Shanghai Chest Hospital ( Site 0112), Shanghai, Shanghai, China|The First Affiliated Hospital Zhejiang University ( Site 0106), Hangzhou, Zhejiang, China|Hangzhou First People's Hospital ( Site 0109), Hangzhou, Zhejiang, China|2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0114), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 0116), Hangzhou, Zhejiang, China|Fundacion Centro de Investigacion Clinica CIC ( Site 0366), Medellin, Antioquia, Colombia|Hospital General de Medellin Luz Castro de Gutierrez ( Site 0368), Medellin, Antioquia, Colombia|Biomelab S A S ( Site 0365), Barranquilla, Atlantico, Colombia|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0374), Valledupar, Cesar, Colombia|Oncomedica S.A. ( Site 0372), Monteria, Cordoba, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0369), Cali, Valle Del Cauca, Colombia|AS Ida-Tallinna Keskhaigla ( Site 0161), Tallinn, Harjumaa, Estonia|SA Pohja-Eesti Regionaalhaigla ( Site 0162), Tallin, Harjumaa, Estonia|SA Tartu Ulikooli Kliinikum ( Site 0160), Tartu, Tartumaa, Estonia|CHU Jean Minjoz ( Site 0167), Besancon, Doubs, France|Institut Curie - Centre Rene Huguenin ( Site 0181), Saint-Cloud, Hauts-de-Seine, France|ICM Val D Auerelle ( Site 0177), Montpellier, Herault, France|CHU de Grenoble - Hopital Michallon ( Site 0169), La Tronche, Isere, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0185), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier de la Cote Basque ( Site 0173), Bayonne, Pyrenees-Atlantiques, France|CHU de Rouen ( Site 0174), Rouen, Seine-Maritime, France|CHU Amiens Sud ( Site 0182), Amiens, Somme, France|Centre hospitalier Toulon Sainte-Musse ( Site 0172), Toulon, Var, France|Institut Curie ( Site 0166), Paris, France|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0207), Gyula, Bekes, Hungary|CRU Hungary KFT ( Site 0209), Miskolc, Borsod-Abauj-Zemplen, Hungary|Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0202), Miskolc, Borsod-Abaúj-Zemplén, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 0213), Gyor, Győr-Moson-Sopron, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0203), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Tudogyogyintezet Torokbalint ( Site 0205), Torokbalint, Pest, Hungary|Semmelweis Egyetem ( Site 0210), Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0217), Kaposvar, Hungary|Bnei Zion Medical Center ( Site 0227), Haifa, Heifa, Israel|Soroka Medical Center ( Site 0222), Beer Sheva, Southern, Israel|Sheba Medical Center ( Site 0220), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0225), Tel Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0223), Haifa, Israel|Meir Medical Center ( Site 0221), Kfar-Saba, Israel|Rabin Medical Center ( Site 0224), Petah Tikva, Israel|Barzilai Medical Center ( Site 0226), Ashkelon, Ḥeifā, Israel|Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 0233), Roma, Lazio, Italy|Presidio Ospedaliero San Vincenzo ( Site 0231), Taormina, Messina, Italy|Centro di Riferimento Oncologico CRO ( Site 0235), Aviano, Pordenone, Italy|Azienda Ospedaliera San Giuseppe Moscati ( Site 0234), Avellino, Italy|Universita Magna Grecia ( Site 0230), Catanzaro, Italy|A.O. Universitaria Careggi ( Site 0236), Firenze, Italy|Ospedale Santa Maria delle Croci ( Site 0232), Ravenna, Italy|Policlinico Gemelli di Roma ( Site 0237), Roma, Italy|Aichi Cancer Center Hospital ( Site 0018), Nagoya, Aichi, Japan|Kurume University Hospital ( Site 0025), Kurume, Fukuoka, Japan|Hyogo Cancer Center ( Site 0021), Akashi, Hyogo, Japan|Kanagawa Cardiovascular and Respiratory Center ( Site 0026), Yokohama, Kanagawa, Japan|Kanagawa Cancer Center ( Site 0023), Yokohama, Kanagawa, Japan|Miyagi Cancer Center ( Site 0028), Natori, Miyagi, Japan|Sendai Kousei Hospital ( Site 0022), Sendai, Miyagi, Japan|Kindai University Hospital ( Site 0017), Osakasayama, Osaka, Japan|National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0027), Sakai, Osaka, Japan|National Hospital Organization Kyushu Medical Center ( Site 0015), Fukuoka, Japan|Kyushu University Hospital ( Site 0030), Fukuoka, Japan|Okayama University Hospital ( Site 0020), Okayama, Japan|Osaka International Cancer Institute ( Site 0019), Osaka, Japan|Toranomon Hospital ( Site 0016), Tokyo, Japan|Juntendo University Hospital ( Site 0029), Tokyo, Japan|Nippon Medical School Hospital ( Site 0024), Tokyo, Japan|Chungbuk National University Hospital ( Site 0079), Cheongju si, Chungbuk, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0075), Seongnam-si, Kyonggi-do, Korea, Republic of|Ulsan University Hospital ( Site 0077), Ulsan, Ulsan-Kwangyokshi, Korea, Republic of|Asan Medical Center ( Site 0076), Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center ( Site 0078), Seoul, Korea, Republic of|Hospital Tengku Ampuan Afzan ( Site 0062), Kuantan, Pahang, Malaysia|Hospital Pulau Pinang. ( Site 0065), Georgetown, Pulau Pinang, Malaysia|Sarawak General Hospital ( Site 0064), Kuching, Sarawak, Malaysia|Beacon Hospital Sdn Bhd ( Site 0067), Petaling Jaya, Selangor, Malaysia|Institut Kanser Negara - National Cancer Institute ( Site 0063), Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia|University Malaya Medical Centre ( Site 0061), Kuala Lumpur, Malaysia|Gleneagles Penang ( Site 0066), Pulau Pinang, Malaysia|Medica Sur S.A.B de C.V. ( Site 0384), Mexico City, Distrito Federal, Mexico|Consultorios de Medicina Especializada del Sector Privado ( Site 0388), Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 0381), Madero, Tamaulipas, Mexico|Instituto Nacional de Cancerologia. ( Site 0382), Mexico City, Mexico|Oaxaca Site Management Organization SC ( Site 0389), Oaxaca, Mexico|SPZOZ USK nr 1 im. Norberta Barlickiego UM w Lodzi ( Site 0256), Lodz, Lodzkie, Poland|Szpital Uniwersytecki im. Karola Marcinkowskiego ( Site 0247), Zielona Gora, Lubuskie, Poland|Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 0253), Krakow, Malopolskie, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0243), Krakow, Malopolskie, Poland|Centrum Medyczne Pratia Ostroleka ( Site 0242), Ostroleka, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0252), Warszawa, Mazowieckie, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 0250), Przemysl, Podkarpackie, Poland|Ars Medical Sp. z o.o. ( Site 0254), Pila, Wielkopolskie, Poland|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0262), Ufa, Baskortostan, Respublika, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0266), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0265), Samara, Samarskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 0263), Saint Petersburg, Sankt-Peterburg, Russian Federation|Railway Hospital of OJSC ( Site 0268), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 0260), Saint Petersburg, Sankt-Peterburg, Russian Federation|National Taiwan University Hospital Hsin-Chu Branch ( Site 0087), Hsinchu, Taiwan|Taipei Medical University Shuang Ho Hospital ( Site 0090), New Taipei, Taiwan|National Cheng Kung University Hospital ( Site 0086), Tainan, Taiwan|National Taiwan University Hospital ( Site 0088), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 0091), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0089), Taipei, Taiwan|Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 0321), Konya, Adana, Turkey|Gulhane Egitim ve Arastirma Hastanesi ( Site 0316), Ankara, Turkey|Abdurrahman Yurtaslan Onkoloji Hastanesi ( Site 0318), Ankara, Turkey|Baskent Universitesi Ankara Hastanesi ( Site 0319), Ankara, Turkey|Antalya Memorial Hospital Department of Medical Oncology ( Site 0324), Antalya, Turkey|Akdeniz Universitesi Tip Fakultesi ( Site 0322), Antalya, Turkey|Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0314), Izmir, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 0323), Sakarya, Turkey|Samsun Medical Park Hastanesi ( Site 0320), Samsun, Turkey|Cherkasy Regional Hospital ( Site 0336), Cherkasy, Cherkaska Oblast, Ukraine|City Clinical Hosp.4 of DCC ( Site 0338), Dnipro, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 0346), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 0337), Kharkiv, Kharkivska Oblast, Ukraine|Ukranian Center of TomoTherapy ( Site 0344), Kropyvnytskiy, Kirovohradska Oblast, Ukraine|Medical Center Verum ( Site 0334), Kyiv, Kyivska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 0339), Kyiv, Kyivska Oblast, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 0331), Kyiv, Kyivska Oblast, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0341), Lviv, Lvivska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 0333), Odesa, Odeska Oblast, Ukraine|Podillya Regional Center of Oncology ( Site 0343), Vinnytsia, Vinnytska Oblast, Ukraine",7253286,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_LENVATINIB,NCT04199104,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","California Cancer Associates for Research & Excellence ( Site 0025), Fresno, California, United States|California Cancer Associates for Research & Excellence ( Site 0059), San Marcos, California, United States|University of Colorado Cancer Center ( Site 0023), Aurora, Colorado, United States|Northwest Georgia Oncology Centers PC ( Site 0028), Marietta, Georgia, United States|University of Louisville, James Graham Brown Cancer Center ( Site 0045), Louisville, Kentucky, United States|University of Michigan ( Site 0064), Ann Arbor, Michigan, United States|Karmanos Cancer Institute ( Site 0054), Detroit, Michigan, United States|Henry Ford Health System ( Site 0001), Detroit, Michigan, United States|Washington University School of Medicine ( Site 0060), Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center ( Site 0008), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0053), Omaha, Nebraska, United States|University of North Carolina- Chapel Hill ( Site 0056), Chapel Hill, North Carolina, United States|Providence Portland Medical Center ( Site 0048), Portland, Oregon, United States|Blue Ridge Cancer Care ( Site 0015), Blacksburg, Virginia, United States|Inova Schar Cancer Institute ( Site 0009), Fairfax, Virginia, United States|Cancer Care Northwest ( Site 0017), Spokane Valley, Washington, United States|Chris OBrien Lifehouse ( Site 1002), Camperdown, New South Wales, Australia|Royal Adelaide Hospital ( Site 1004), Adelaide, South Australia, Australia|Princess Margaret Cancer Centre ( Site 0200), Toronto, Ontario, Canada|Centre Leon Berard ( Site 1901), Lyon, Auvergne, France|Hopital de la Timone ( Site 1903), Marseille, Bouches-du-Rhone, France|Hopital Foch ( Site 1905), Suresnes, Hauts-de-Seine, France|Centre Henri Becquerel ( Site 1904), Rouen, Seine-Maritime, France|Gustave Roussy ( Site 1906), Villejuif, Val-de-Marne, France|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 2200), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Orszagos Onkologiai Intezet ( Site 2202), Budapest, Hungary|Nagoya University Hospital ( Site 1106), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 1100), Kashiwa, Chiba, Japan|Kagawa University Hospital ( Site 1108), Kita-gun, Kagawa, Japan|Yokohama City University Hospital ( Site 1104), Yokohama, Kanagawa, Japan|Kindai University Hospital ( Site 1107), Osakasayama, Osaka, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 1105), Sunto-gun, Shizuoka, Japan|Hiroshima University Hospital ( Site 1109), Hiroshima, Japan|National Cancer Center Hospital ( Site 1102), Tokyo, Japan|Medical Hospital, Tokyo Medical And Dental University ( Site 1101), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 1103), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 1202), Hwasun-gun, Jeonranamdo, Korea, Republic of|Seoul National University Bundang Hospital ( Site 1205), Seongnam-si, Kyonggi-do, Korea, Republic of|Ajou University Hospital ( Site 1200), Suwon-si, Kyonggi-do, Korea, Republic of|Asan Medical Center ( Site 1201), Songpa-gu, Seoul, Korea, Republic of|The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 1204), Seoul, Korea, Republic of|Hospital Nacional Cayetano Heredia ( Site 0704), Lima, Peru|Dolnoslaskie Centrum Onkologii. ( Site 2507), Wroclaw, Dolnoslaskie, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2504), Gdynia, Pomorskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2506), Gliwice, Slaskie, Poland|Przychodnia Lekarska Komed ( Site 2500), Konin, Wielkopolskie, Poland|Altay Regional Oncology Dispensary ( Site 2611), Barnaul, Altayskiy Kray, Russian Federation|FSCC FMBA of Russia ( Site 2603), Moscow, Moskva, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2609), Kazan, Tatarstan, Respublika, Russian Federation|Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2605), Yaroslavl, Yaroslavskaya Oblast, Russian Federation|Hospital Duran i Reynals ( Site 2701), Hospitalet de Llobregat, Barcelona, Spain|H.U. Vall de Hebron ( Site 2700), Barcelona, Spain|Hospital Universitario 12 de Octubre ( Site 2702), Madrid, Spain|Hospital Universitario La Paz ( Site 2706), Madrid, Spain|Hospital de Valme ( Site 2705), Sevilla, Spain|Hospital Clinico Universitario Lozano Blesa ( Site 2703), Zaragoza, Spain|National Cheng Kung University Hospital ( Site 1603), Taiwan, Tainan, Taiwan|National Taiwan University Hospital ( Site 1600), Taipei, Taiwan|MacKay Memorial Hospital ( Site 1602), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1601), Taipei, Taiwan|Hacettepe Universitesi Tip Fakultesi ( Site 2805), Ankara, Turkey|Ankara Sehir Hastanesi ( Site 2802), Ankara, Turkey|Trakya Universitesi Tip Fakultesi ( Site 2801), Edirne, Turkey|Medipol Universite Hastanesi ( Site 2800), Istanbul, Turkey|Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 2803), Malatya, Turkey|Christie NHS Foundation Trust ( Site 2903), Manchester, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,ADVANCED NON-SMALL CELL LUNG CANCER,_LENVATINIB,NCT03516981,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, PC- HAL ( Site 8001), Tempe, Arizona, United States|University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States|University of California San Francisco ( Site 0111), San Francisco, California, United States|UCLA Hematology/Oncology -Santa Monica ( Site 0108), Santa Monica, California, United States|Yale University School of Medicine ( Site 0100), New Haven, Connecticut, United States|Mayo Clinic Florida ( Site 0115), Jacksonville, Florida, United States|University of Maryland ( Site 0136), Baltimore, Maryland, United States|Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117), Rochester, Minnesota, United States|John Theurer Cancer Center ( Site 0112), Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center ( Site 0113), New York, New York, United States|Oncology Hematology Care ( Site 8005), Cincinnati, Ohio, United States|University of Pennsylvania ( Site 0132), Philadelphia, Pennsylvania, United States|UPMC Cancer Center/Hillman Cancer Center ( Site 0104), Pittsburgh, Pennsylvania, United States|Texas Oncology-Memorial City ( Site 8006), Houston, Texas, United States|Texas Oncology-Tyler ( Site 8003), Tyler, Texas, United States|Emily Couric Clinical Cancer Center ( Site 0134), Charlottesville, Virginia, United States|Northwest Cancer Specialists, P.C. ( Site 8000), Vancouver, Washington, United States|University of Wisconsin- Madison Carbone Cancer Center ( Site 0130), Madison, Wisconsin, United States|Blacktown Hospital Western Sydney Local Health District ( Site 0200), Blacktown, New South Wales, Australia|Greenslopes Private Hospital ( Site 0202), Greenslopes, Queensland, Australia|Fiona Stanley Hospital ( Site 0201), Murdoch, Western Australia, Australia|The Ottawa Hospital ( Site 0306), Ottawa, Ontario, Canada|Sunnybrook Health Science Centre ( Site 0304), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0309), Toronto, Ontario, Canada|CIUSSS du Saguenay-Lac-St-Jean ( Site 0305), Chicoutimi, Quebec, Canada|Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada|Prince of Wales Hospital ( Site 1801), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 1800), Hong Kong, Hong Kong|St James Hospital ( Site 2200), Dublin, Ireland|Mid Western Cancer Centre ( Site 2201), Limerick, Ireland|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0700), Rozzano, Milano, Italy|AOU San Luigi Gonzaga di Orbassano ( Site 0707), Orbassano, Torino, Italy|AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701), Legnago, Verona, Italy|Azienda Ospedaliera Papardo ( Site 0706), Messina, Italy|Seconda Universita degli Studi di Napoli ( Site 0704), Napoli, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0703), Roma, Italy|Azienda Ospedaliera Universitaria Senese ( Site 0705), Siena, Italy|National Cancer Center Hospital ( Site 2001), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2000), Tokyo, Japan|Seoul National University Bundang Hospital ( Site 0803), Seongnam-si, Kyonggi-do, Korea, Republic of|Asan Medical Center ( Site 0801), Songpa-gu, Seoul, Korea, Republic of|Seoul National University Hospital ( Site 0800), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0802), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0805), Seoul, Korea, Republic of|Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0910), Warszawa, Mazowieckie, Poland|MED-POLONIA Sp. z o.o. ( Site 0907), Poznan, Wielkopolskie, Poland|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003), Ufa, Baskortostan, Respublika, Russian Federation|The Loginov Moscow Clinical Scientific Center ( Site 1008), Moscow, Moskva, Russian Federation|N.N. Blokhin NMRCO ( Site 1000), Moscow, Moskva, Russian Federation|Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site, Omsk, Omskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 1001), Saint Petersburg, Sankt-Peterburg, Russian Federation|St Petersburg City Clinical Oncology Dispensary ( Site 1002), St. Petersburg, Sankt-Peterburg, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005), Kazan, Tatarstan, Respublika, Russian Federation|National Cancer Centre Singapore ( Site 1900), Singapore, Central Singapore, Singapore|National University Hospital ( Site 1901), Singapore, Singapore|MPOC ( Site 2310), Groenkloof Pretoria, Gauteng, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 2316), Johannesburg, Gauteng, South Africa|Wits Clinical Research ( Site 2313), Parktown-Johannesburg, Gauteng, South Africa|Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315), Pretoria, Gauteng, South Africa|Vaal Triangle Oncology Centre ( Site 2314), Vereeniging, Gauteng, South Africa|Umhlanga Oncolgy Center ( Site 2311), Umhlanga, Kwazulu-Natal, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 2312), Kraaifontein, Western Cape, South Africa|Hospital General Universitari Vall d Hebron ( Site 1100), Barcelona, Spain|Hospital Universitario Ramon y Cajal ( Site 1101), Madrid, Spain|Hospital Universitario 12 de Octubre ( Site 1102), Madrid, Spain|Universitaetsspital Basel ( Site 2104), Basel, Basel-Stadt, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 2106), Geneva, Geneve, Switzerland|Kantonsspital Graubuenden ( Site 2103), Chur, Grisons, Switzerland|Kantonsspital St. Gallen ( Site 2102), St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Zuerich ( Site 2100), Zuerich, Zürich, Switzerland|Kaohsiung Chang Gung Memorial Hospital ( Site 1203), Kaohsiung, Taiwan|National Cheng Kung University Hospital ( Site 1202), Tainan, Taiwan|National Taiwan University Hospital ( Site 1200), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1204), Taipei, Taiwan|University College London Hospital NHS Foundation Trust ( Site 1308), London, London, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 1306), Cambridge, United Kingdom|Derriford Hospital ( Site 1301), Plymouth, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BRAIN TUMOR,_ABEMACICLIB,NCT03220646,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_ABEMACICLIB,NCT03655444,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,GLIOBLASTOMA,_ABEMACICLIB,NCT02977780,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lifespan / Rhode Island Hospital, Providence, Rhode Island, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BLADDER CANCER,_ABEMACICLIB,NCT03837821,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medicine, New York, New York, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,NON SMALL CELL LUNG CANCER,_LORLATINIB,NCT02927340,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts general Hospital, Boston, Massachusetts, United States",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"CARCINOMA, NON-SMALL-CELL LUNG",_LORLATINIB,NCT03052608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Ocala, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, The Villages, Florida, United States|Florida Cancer Specialists, Winter Park, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute., Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro Medico Austral, Caba, Argentina|Bendigo Day Surgery Collection Centre and Laboratory, Bendigo, Victoria, Australia|Bendigo Medical Imaging, Bendigo Hospital, Bendigo, Victoria, Australia|Melbourne Pathology, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Department of Respiratory,the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Guangdong General Hospital, Guangzhou, China|Fakultni nemocnice Olomouc, Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Hopital Haut-Léveque-Centre François Magendie, Pessac, Aquitaine, France|Hopital de Chevilly Larue, Chevilly Larue, France|Centre Hospitalier du Mans, Le Mans, France|Institut Paoli-Calmettes, Marseille cedex 09, France|Département d'Imagerie Médicale, Marseille cedex 20, France|Hôpital Nord, Marseille cedex 20, France|Service Ophtalmologie, Marseille cedex 20, France|Clinique Monticelli-Paradis-Dr Stephan Fauquier, Marseille, France|Groupe Hospitalier Bichat Claude Bernard, AP-HP, Paris, France|CHU de Rennes Hopital Pontchaillou, Rennes cedex 9, France|CHU de Rennes, Hopital Pontchaillou, Rennes cedex 9, France|Hopital Foch, Suresnes, France|Hopital Larrey, Toulouse Cedex 9, France|Hopital Pierre Paul Riquet, Toulouse cedex 9, France|Hôpital Larrey, Toulouse Cedex 9, France|Department d'imagerie medicale, Villejuif, France|Institut Gustave Roussy, Villejuif, France|Uberortliche Radiologische Gemeinschaftspraxis Dr. med. Marc Amler, Dresden, Germany|Technische Universitat Dresden , Medizinische Fakultat Carl Gustav Carus, Dresden, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Innere Medizin V, Homburg - Saar, Germany|Universitätsklinikum des Saarlandes, Homburg - Saar, Germany|Universitatsklinikum Regensburg, Institut fur Rontgendiagnostik, Regensburg, Germany|Universitatsklinikum Regensburg, Klinik und Poliklinik fur Innere Medizin II, Regensburg, Germany|The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong|The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Artemis Hospital, Gurugram, Haryana, India|Manipal Hospital, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispeciality Hospitals India Pvt Ltd, Bangalore, Karnataka, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|ASST Monza - A.O. San Gerardo, Monza, MB, Italy|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Azienda Ospedaliera di Perugia - Ospedale S. M. Misericordia, Perugia, PG, Italy|Centro di Riferimento Oncologico-IRCCS, Pordenone, PN, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, PR, Italy|AUSL della Romagna - Ospedale degli infermi, Faenza, RA, Italy|AUSL della Romagna - Ospedale ""Umberto I"", Lugo, RA, Italy|UO Farmacia Oncologica, Ravenna, RA, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy|Az.Osp.San Camillo-Forlanini, Roma, RM, Italy|Azienda Ospedaliera Dei Colli Ospedale Monaldi, Napoli, Italy|Istituto Nazionale Tumori di Napoli, Napoli, Italy|Ausl della Romagna- Ravenna, Ravenna, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Department of Pulmonary Medicine and Oncology, Wakayama, Japan|The Catholic University of Korea, St. Vincents Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Division of Medical Oncology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Promotora Medica Aguascalientes SA de CV, Aguascalientes, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Distrito Federal, Mexico|University Medical Center Groningen, Groningen, Netherlands|Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warszawa, Poland|RBHI Kursk Regional Clinical Oncology Dispensary, Kislino, Ryshkovsky Rural Council, Kursk Region, Russian Federation|Budgetary Healthcare Institution Omsk Region ""Clinical Oncological Dispensary"", Omsk, OMSK Region, Russian Federation|LEC at SBIH ""Saint-Petersburg Clinical Research Practical Center of specialized types of, Pesochniy Poselok, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|RBHI Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|FSBI ""N.N.Blokhin Medical Research Center of Oncology"", Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario De Navarra, Pamplona, Navarra, Spain|Hospital Teresa Herrera C.H.U.A.C., A Coruna, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia Girona, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Marmara Univ Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom|Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,PARKINSON'S DISEASE,_CLARITHROMYCIN,NCT03440112,Phase 1|Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States",6010718,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,GLIOBLASTOMA,_IBRUTINIB,NCT03535350,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,HEAD AND NECK SQUAMOUS CELL CARCINOMA,_DUVELISIB,NCT04193293,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",8193182,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,METASTATIC RENAL CELL CARCINOMA,_DECITABINE,NCT04049344,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,PARKINSON'S DISEASE,_EXENATIDE,NCT04305002,Phase 2,Recruiting,All,"25 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Academic Specialist Center, Center for Neurology, SLSO, Stockholm, Sweden",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,PARKINSON'S DISEASE,_MOXIFLOXACIN,NCT04342273,Phase 1,Completed,All,20 Years to 54 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan|Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan",4990517.0,C07D401/04,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,POST-DURAL PUNCTURE HEADACHE,_TETRAC,NCT02813655,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hospices Civils de Lyon / hôpital de la Croix rousse, Lyon, France",4490221,C07C51/377,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,PARKINSON'S DISEASE,_CAPSAICIN,NCT03321019,,Recruiting,All,"45 Years to 85 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Case-Control|Time Perspective: Prospective,"University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida, United States",6239180,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDONE,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",5792477,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDON,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,HUNTINGTON'S DISEASE,_COENZYME_Q1,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,HUNTINGTON'S DISEASE,_HALOPERIDOL,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",3947579,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,21.8813527998521,629.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.7,375.864,40.54,3.0,1.0,3.0,39.15,102.59,6.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,TOURETTE SYNDROME,_ARIPIPRAZOLE,NCT03487783,Phase 3,Enrolling by invitation,All,6 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Anding Hospital of Capital Medical University, Beijing, Beijing, China",5006528,C07D215/227,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,UTERINE FIBROIDS,_BUPIVACAINE,NCT04068766,Not Applicable,Recruiting,Female,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of",8182835.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,CHALAZION,_TRIAMCINOLONE,NCT02025023,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Eye Institute at Harborview, Seattle, Washington, United States",5976573,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHALAZION,_TRIAMCINOLONE_ACETONIDE,NCT02025023,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Eye Institute at Harborview, Seattle, Washington, United States",3962430,A61L2/0023,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,PARKINSON'S DISEASE,_OXYCODONE,NCT02601586,Phase 2|Phase 3,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital of Aix-en-Provence, Aix-en-Provence, France|CHU Amiens, Amiens, France|University Hospital of Bordeaux, Bordeaux, France|University Hospital of Clermont-Ferrand, Clermont-Ferrand, France|Henri Mondor Hospital, Créteil, France|University Hospital of Lille, Lille, France|University Hospital of Limoges, Limoges, France|Hospital Pierre Wertheimer, Lyon, France|University Hospital of Marseille, Marseille, France|University Hospital of Nancy, Nancy, France|University Hospital of Nantes, Nantes, France|University Hospital of Nîmes - Caremeau, Nîmes, France|Pitié-Salpêtrière Hospital, Paris, France|University Hospital of Poitiers, Poitiers, France|University Hospital of Rennes, Rennes, France|University Hospital of Rouen, Rouen, France|University Hospital of Strasbourg, Strasbourg, France|Chu Toulouse, Toulouse, France",5508042,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,BLADDER CANCER,_PIOGLITAZONE,NCT01935466,,Recruiting,Male,"50 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Retrospective,"Deptt of Endocrinology, Chandigarh, India",4687777,C07D213/30,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,HEMANGIOMA,_TIMOLOL,NCT01873131,Not Applicable,Recruiting,All,up to 3 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,HEMANGIOMA,_TIMOLOL_MALEATE,NCT01873131,Not Applicable,Recruiting,All,up to 3 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",4281654,A61K9/0051,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,COLORECTAL NEOPLASMS,_ENTECAVIR,NCT02777814,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",5206244.0,C07D239/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
NC[C@H]1CC[C@H](C(=O)O)CC1,BLADDER CANCER,_TRANEXAMIC_ACID,NCT01869413,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Northern Alberta Urology Centre, Edmonton, Alberta, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|London Health Sciences Complex (LHSC), London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Québec (CHUQ), Québec, Canada",8273795.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,LUNG CANCER,_GEFITINIB,NCT03292133,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,NSCLC,_GEFITINIB,NCT02856893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Bergonie, Bordeaux, France|CHU de Brest, Brest, France|Centre Francois Baclesse, Caen, France|Centre Hopitalier Intercommunal De Creteil, Créteil, France|Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|CHU Toulouse - Hopital Larrey, Toulouse, France|Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France|King Hussein Cancer Center, Amman, Jordan|Medical University of Gdansk, Gdansk, Poland|University Clinic Golnik, Golnik, Slovenia|The Institute Of Oncology, Ljubljana, Slovenia|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|University Hospital A Coruna-Hospital Teresa Herrera, Coruna, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Mataró, Spain|Virgen del Rocio University Hospital, Sevilla, Spain",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,NSCLC,_OSIMERTINIB,NCT02856893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Bergonie, Bordeaux, France|CHU de Brest, Brest, France|Centre Francois Baclesse, Caen, France|Centre Hopitalier Intercommunal De Creteil, Créteil, France|Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|CHU Toulouse - Hopital Larrey, Toulouse, France|Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France|King Hussein Cancer Center, Amman, Jordan|Medical University of Gdansk, Gdansk, Poland|University Clinic Golnik, Golnik, Slovenia|The Institute Of Oncology, Ljubljana, Slovenia|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|University Hospital A Coruna-Hospital Teresa Herrera, Coruna, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Mataró, Spain|Virgen del Rocio University Hospital, Sevilla, Spain",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"CARCINOMA, NON-SMALL-CELL LUNG",_OSIMERTINIB,NCT03784599,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maastricht UMC+, Maastricht, Limburg, Netherlands|VU medical center, Amsterdam, Noord Holland, Netherlands|Antoni van Leeuwenhoek ziekenhuis - Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands|Erasmus MC, Rotterdam, Zuid Holland, Netherlands|Univercity Medical Center Groningen, Groningen, Netherlands",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,LUNG CANCER,_OSIMERTINIB,NCT03567642,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,METASTATIC NON SMALL CELL LUNG CANCER,_OSIMERTINIB,NCT03497767,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St. Vincents Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|ICON Cancer Centre Greenslopes, Brisbane, Queensland, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Monash Health, Melbourne, Victoria, Australia|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,NON SMALL CELL LUNG CANCER,_CRIZOTINIB,NCT03375242,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Case-Only|Time Perspective: Prospective,"Pfizer local country office, Tokyo, Japan",7230098,C07D413/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,NON SMALL CELL LUNG CANCER,_APATINIB,NCT03267654,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital;, Shanghai, Shanghai, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,GLIOBLASTOMA,_APATINIB,NCT03567135,,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Observational Model: Case-Control|Time Perspective: Retrospective,"Fuzhou General Hospital, Fuzhou, Fujian, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,HEAD AND NECK NEOPLASMS,_APATINIB,NCT02989259,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, Beijing, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,GLIOMA,_APATINIB,NCT03741244,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the Second Hospital of Hebei Medical University, Shijiazhuang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,NSCLC,_APATINIB,NCT03801200,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hubei Cancer hospital, Wuhan, Hubei, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,NON SMALL CELL LUNG CANCER,_SAVOLITINIB,NCT03944772,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Herlev, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Drammen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",US-20140255428-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,15.8360541284215,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,345.37,91.61,6.0,0.0,5.0,35.72,119.06,3.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,NON SMALL CELL LUNG CANCER,_ALECTINIB,NCT03944772,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Herlev, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Drammen, Norway|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",9126931,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,LUNG CANCER,_ICOTINIB,NCT01996098,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",US-20040048883-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,METASTATIC BREAST CANCER,_ICOTINIB,NCT02362230,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China",US-20040048883-A1,A61P35/00,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,NON-SQUAMOUS NSCLC,_ICOTINIB,NCT03992885,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China",US-20040048883-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,SMALL CELL LUNG CANCER,_TOPOTECAN,NCT03088813,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sutter Cancer Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Cancer Treatment Centers of America-Georgia, Newnan, Georgia, United States|Illinois Cancer Care, PC, Peoria, Illinois, United States|Southern Maine Health Care, Biddeford, Maine, United States|Maine Research Associates, Lewiston, Maine, United States|University of Maryland Medical Group, Baltimore, Maryland, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Tri County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|OHSU Community Hematology Oncology, Portland, Oregon, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Greenville Hospital System University Medical Center, Greenville, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|MultiCare Health System Institute for Research and Innovation, Spokane, Washington, United States|Summit Cancer Treatment Center, Spokane, Washington, United States|Northwest Cancer Specialists, P.C.-Portland-West, Vancouver, Washington, United States|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|South West Healthcare, Warrnambool, Victoria, Australia|Southern Medical Day Care Centre, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|AZ Klina, Brasschaat, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier de l'Ardenne, Libramont, Belgium|AZ Sint-Maarten, Mechelen, Belgium|Rua Antenor Duarte Villela, 1331, Barretos, Brazil|Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil|Hospital de Caridade de Ijuí, Ijuí, Brazil|Oncobio Servicos de Saude, Nova Lima, Brazil|HGB - Hospital Giovanni Battista - Mãe de Deus Center, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil|INCA - Instituto Nacional de Câncer, Rio De Janeiro, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, Brazil|Beijing Cancer Hospital, Beijing, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, China|Jilin Cancer Hospital, Changchun, China|The First Hospital of Jilin University, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Xinmin, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Linyi Cancer Hospital, Linyi, China|Henan Cancer Hospital, Zhengzhou, China|Centre Francois Baclesse, Caen, Calvados, France|CHU Brest - Hôpital Morvan, Brest, France|Hopital Albert Calmette - CHU Lille, lille Cedex, France|Hôpital de la Timone, Marseille, France|Hôpital Nord - CHU Marseille, Marseille, France|Hôpital Saint-Louis, Paris, France|Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France|Centre Hospitalier de Saint-Quentin, Saint-Quentin, France|Hôpital d'Instruction des armées Sainte Anne, Toulon, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Evangelisches Krankenhaus Hamm GmbH, Hamm, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Semmelweis Egyetem, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Tudogyogyintezet Torokbalint, Törökbálint, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Universitaria- Università degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Italy|Azienda Socio Sanitaria Territoriale Bergamo Ovest (Ospedale Treviglio Caravaggio di Treviglio), Treviglio, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of|KO-MED Centra Kliniczne Biala Podlaska, Biała Podlaska, Poland|Szpitale Pomorskie spółka z ograniczoną odpowiedzialnością, Gdynia, Poland|SP Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznań, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|S.C Gral Medical S.R.L, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|S.C Medisprof S.R.L, Cluj-Napoca, Romania|S.C Centrul de Oncologie Sf. Nectarie S.R.L, Craiova, Romania|S.C Radiotherapy Center Cluj S.R.L, Floreşti, Romania|S.C Oncocenter Oncologie Clinica S.R.L, Timisoara, Romania|Oncomed SRL, Timişoara, Romania|SBIH of Arkhangelsk region ""Arkhangelsk Clinical Oncological Dispensary"", Arkhangel'sk, Russian Federation|""VitaMed"" LLC, Moscow, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncological Dispensary"", Pyatigorsk, Russian Federation|SBHI of Kaluga Region ""Kaluga regional clinical oncology dispensary"", Saint Petersburg, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", Saint Petersburg, Russian Federation|SBIH ""Samara Regional Clinical Oncological Dispensary"", Samara, Russian Federation|SBIH of Yaroslavl region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation|Clinical Center ""Bezanijska kosa"", Belgrade, Serbia|Oncomed System, Belgrade, Serbia|Military Medical Academy, Belgrad, Serbia|Clinical Center Kragujevac, Belgrad, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|General Hospital Uzice, Užice, Serbia|Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|Baskent University Adana Application and Research Center, Adana, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Istanbul, Turkey|Inonu Uni. Med. Fac., Malatya, Turkey|Namik Kemal University, Tekirdağ, Turkey|CI Chernivtsi RC Oncological Dispensary, Chernivtsi, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipro, Ukraine|Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, Ukraine|CI Kryvyi Rih Oncological Dispensary of DRC, Kryvyi Rih, Ukraine|Treatment and Diagnostic Center of LLC Specialized clinic Dobryi Prognoz, Kyiv, Ukraine|Treatment-Prevention Institution Volyn Regional Oncological Dispensary, Luts'k, Ukraine|Odesa Regional Oncologic Dispensary, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|CCCH City Oncological Center SHEI Uzhgorod NU, Uzhgorod, Ukraine|Medical Clinic Innovacia, LLC, Vyshhorod, Ukraine",5004758,C07D491/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,GLIOBLASTOMA MULTIFORME,_DISULFIRAM,NCT02715609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",3932346,C08F2/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],GLIOBLASTOMA MULTIFORME,_COPPER_GLUCONATE,NCT02715609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4112066,A61Q11/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,PARKINSON'S DISEASE,_QUETIAPINE,NCT04164758,Phase 2,Recruiting,All,"50 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Tucson Neuroscience Research, Tucson, Arizona, United States|SC3 Research, Pasadena, California, United States|SC3 Research, Reseda, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Galiz Research, Hialeah, Florida, United States|Charter Research, LLC, Lady Lake, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Charter Research, LLC, Winter Park, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Hawaii Pacific Neuroscience, LLC., Honolulu, Hawaii, United States|University of lowa Hospital and Clinics, Iowa City, Iowa, United States|SRI International, Plymouth, Michigan, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Prisma Health-Upstate, Greenville, South Carolina, United States|Inland Northwest Research, Spokane, Washington, United States",4879288,C07D281/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,PARKINSON'S DISEASE,_PIMAVANSERIN,NCT04164758,Phase 2,Recruiting,All,"50 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Tucson Neuroscience Research, Tucson, Arizona, United States|SC3 Research, Pasadena, California, United States|SC3 Research, Reseda, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Galiz Research, Hialeah, Florida, United States|Charter Research, LLC, Lady Lake, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Charter Research, LLC, Winter Park, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Hawaii Pacific Neuroscience, LLC., Honolulu, Hawaii, United States|University of lowa Hospital and Clinics, Iowa City, Iowa, United States|SRI International, Plymouth, Michigan, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Prisma Health-Upstate, Greenville, South Carolina, United States|Inland Northwest Research, Spokane, Washington, United States",7115634,C07D417/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,69.6523542577876,22.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.19,427.564,44.81,3.0,1.0,3.0,47.76,122.93,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,NON SMALL CELL LUNG CANCER,_APREPITANT,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5145684,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,NON SMALL CELL LUNG CANCER,_DESLORATADINE,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.48,310.821,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,MULTIPLE MYELOMA,_FOSAPREPITANT,NCT02780609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",5691336,C07D413/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,COLORECTAL CANCER,_PYROTINIB,NCT03843749,Not Applicable,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China",US-20130338190-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.1,583.09,112.4,8.0,2.0,5.0,60.8,164.5,10.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,METASTATIC BREAST CANCER,_PYROTINIB,NCT04034589,Phase 2,Recruiting,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-Sen University Cancer Center, Guangyuan, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China",US-20130338190-A1,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.1,583.09,112.4,8.0,2.0,5.0,60.8,164.5,10.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,"CARCINOMA, NON-SMALL-CELL LUNG",_MOCETINOSTAT,NCT02954991,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yuma Regional Medical Center, Yuma, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego, La Jolla, California, United States|University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States|University of California Los Angeles - Torrance - Community Cancer Care, Santa Clarita, California, United States|Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, United States|Baptist Health, Louisville, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Oncology Hematology Care-Blue Ash, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Hematology Oncology Associates - Barnett Office, Medford, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|USOR - Texas Oncology - Sherman, Sherman, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Virginia Cancer Specialist, Fairfax, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,LUNG CANCER,_MOCETINOSTAT,NCT03220477,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Hopkins Medical Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],NON SMALL CELL LUNG CANCER,_PEMETREXED_DISODIUM,NCT04379635,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China|Beijing Cancer Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital - Oncology, Beijing, Beijing, China|Capital Medical University Xuanwu Hospital, Beijing, Beijing, China|Peking University Pepole's Hospital, Beijing, Beijing, China|Fujian Medical university union hospital, Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|Quanzhou First Hospital of Fujian Province, Quanzhou, Fujian, China|First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China|Guangxi Medical University Affiliated Tumor Hospital& Oncology Medical College, Nanning, Guangxi, China|Hainan Cancer Hospital, Haikou, Hainan, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Luoyang Central Hospital, Luoyang, Henan, China|The second affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|General Hospital of Eastern Theater Command, Nanjing, Jiangshu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The First affiliated hospital of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Affilliated Hospital of Jilin University, Changchun, Jilin, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fudan University Affiliated Zhongshan Hospital, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital ,Sichuan University, Chengdu, Sichuan, China|Sichuan Cancer Hospital, Chengdu, Sichuan, China|General Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China|Sun Yat-sen University - Cancer Center (SYSUCC), Guangzhou, China",WO-2001062760-A2,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F,METASTATIC COLORECTAL CANCER,_TRIFLURIDINE,NCT04166604,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Amiens, Amiens, France|Institut de cancérologie de l'Ouest, Angers, France|CHRU Jean Minjoz, Besançon, France|centre Pierre Curie, Beuvry, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre hospitalier de Chauny, Chauny, France|Polyclinique Sainte Côme, Compiègne, France|Clinique de Flandre, Coudekerque-Branche, France|Hôpital Henri Mondor, Créteil, France|Centre Georges François Leclerc, Dijon, France|CHD Vendée, La Roche-sur-Yon, France|Hôpital Franco-Britannique, Levallois-Perret, France|Hôpital Privé Jean Mermoz, Lyon, France|Hôpital Européen, Marseille, France|Hôpital Layne, Mont-de-Marsan, France|Hôpital Nord Franche Comté, Montbéliard, France|Groupe Hospitalier Pitié Sapêtrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Haut Lévêque, Pessac, France|CHU Poitiers, Poitiers, France|CHU Robert Debré, Reims, France",5744475,C07D239/553,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.183104375859802,772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.45,296.1999,99.1,5.0,3.0,2.0,23.07,56.34,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O,ADENOMA COLON,_ACETIC_ACID,NCT04464135,Not Applicable,Recruiting,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Department of Gastroenterology, Second Affiliated Hospital, Lanzhou University, Lanzhou, Gansu, China|Department of Holistic Integrative Medicine, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China|Department of Gastroenterology, Huaihe Hospital of Henan University, Kaifeng, Henan, China|Department of Gastroenterology, Shaanxi Second People's Hospital, Xi'an, Shaanxi, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.12,60.052,37.3,2.0,1.0,0.0,5.34,12.64,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,LUNG CANCER,_ITRACONAZOLE,NCT03664115,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"oncology department Ain shams university, Cairo, Egypt",6407079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,PARKINSON'S DISEASE,_NABILONE,NCT03773796,Phase 3,Recruiting,All,"30 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Neurology - Medical University Innsbruck, Innsbruck, Tyrol, Austria",3944673.0,C07C49/747,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,PARKINSON'S DISEASE,_RIFAXIMIN,NCT03575195,Phase 1|Phase 2,Recruiting,All,"30 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California San Francisco, San Francisco, California, United States",6861053,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,NON SMALL CELL LUNG CANCER,_PEVONEDISTAT,NCT03228186,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",8207177,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,64.8226862974599,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.18,443.519,132.36,7.0,3.0,5.0,46.22,117.23,6.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,DEMENTIA WITH LEWY BODIES,_BOSUTINIB,NCT03888222,Phase 2,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedStar Georgetown University Hospital, Washington, District of Columbia, United States",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,COLORECTAL CANCER,_IDASANUTLIN,NCT03555149,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Centre Georges François Leclerc; Pharmacie des Essais Cliniques, Dijon Cedex, France|Centre Leon Berard, Lyon, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Universidad de Navarra - Clinica Universitaria de Navarra (CUN), Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|CHUV; Departement d'Oncologie, Lausanne, Switzerland|Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",US-20100152190-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,LYMPHOMA,_PARSACLISIB,NCT03235544,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama At Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Rocky Mountain Cancer Center-Aurora, Aurora, Colorado, United States|Asclepes Research Centers, Brooksville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Bond & Steele Clinic, P.A., Winter Haven, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States|Clinical Research Alliance, Inc., New Hyde Park, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Willamette Valley Cancer Institute, Eugene, Oregon, United States|Kaiser Permanente - Northwest, Portland, Oregon, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Yakima Valley Memorial Hospital/North Star, Yakima, Washington, United States|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium|Institut Jules Bordet, Brussels, Belgium|Hopital de Jolimont, La Louviere, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Prague 10, Czechia|Charles University General Hospital, Prague 2, Czechia|Fakultni Nemocnice Kralovske Vinohadry, Interni Hematologicka Klinika, Prague, Czechia|Aalborg University Hospital, Aalborg, Denmark|Aarhus Universitets Hospital, Aarhus, Denmark|Odense Universitetshospital (Ouh) (Odense University Hospital), Odense C, Denmark|Zealand University Hospital, Roskilde, Denmark|Avicenne Hospital, Bobigny, France|Chu de Clermont - Ferrand- Hospital Estaing, Clermont-ferrand, France|Centre Hospitalier Universitaire Henri Mondor, Creteil, France|University Hospital Grenoble, Grenoble, France|Centre Hospitalier Departemental - La-Roche-Sur-Yon - Les Oudairies, La Roche Sur Yon, France|Centre Hospitalier Universitaire de Grenoble, La Tronche, France|Centre Hospitalier de Versailles, Le Chesnay, France|Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Lyon, France|Centre Antoine Lacassagne, Nice, France|Hopital Saint-Louis, Paris, France|H�Pital Universitaire Piti�-Salp�Tri�Re, Paris, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite Cedex, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Centre Henri Becquerel, Rouen, France|Chru Hopitaux de Tours, Hospital Bretonneau, Tours, France|Institute Gustave Roussy (Igr), Villejuif Cedex, France|Praxis Brudler, Heinrich, Bangerter, Augsburg, Germany|Universitaetsklinikum Essen, Essen, Germany|Universit�Tsklinikum Essen, Essen, Germany|Justus-Liebig University, Giessen, Germany|Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, Germany|Kliniken Maria Hilf, Moenchengladbach, Germany|Rotkreuzklinikum Munich, Munchen, Germany|Universit�Tsklinikum Ulm, ULM, Germany|Rambam Medical Center, Haifa, Israel|Hadassah Hebrew University Medical Center, Jerusalem, Israel|Hadassah Hebrew University Medical Center Ein Karem Hadassah, Jerusalem, Israel|Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, MI, Italy|Centro Ricerche Cliniche, Bologna, Italy|Azienda Policlinico Vittorio Emanuele, Catania, Italy|Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|A.O.U. Di Modena - Policlinico, Modena, Italy|A.O.U. Federico Ii, Napoli, Italy|Aou Maggiore Della Carita, Novara, Italy|Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Sapienza University, Rome, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena, Italy|Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza, Torino, Italy|Beskidzkie Centrum Onkologii Im.Jana Pawla Ii, Bielsko-biala, Poland|Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozow, Poland|University Clinical Center, Gdansk, Poland|Pratia McM Krakow, Krakow, Poland|Nu-Med Centrum Diagnostykii I Terapii Onkologicznej, Tomaszow Mazowiecki, Poland|Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital Del Mar, Barcelona, Spain|Hospital General Universitari Vall D Hebron, Barcelona, Spain|Hospital Universitari Mutua Terrassa, Barcelona, Spain|Institut Catala D Oncologia, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Md Anderson Cancer Centre Madrid, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Fundacion Jimenez Diaz University Hospital, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de La Paz, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario Y Politecnic La Fe, Valencia, Spain|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|University College London Hospitals (Uclh), London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.67,432.88,107.95,6.0,2.0,4.0,42.87,123.54,5.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,NON SMALL CELL LUNG CANCER,_PLINABULIN,NCT02504489,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Memorial Health Care System, Colorado Springs, Colorado, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Peachtree Hematoloy-Oncology Consultants, PC, Atlanta, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Kansas University Medical Center, Westwood, Kansas, United States|University of Louisville-Brown Cancer Center, Louisville, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States|Central Care Cancer Center, Bolivar, Missouri, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Toledo Cancer Center, Toledo, Ohio, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Cookeville Regional Medical Center Cancer Center, Cookeville, Tennessee, United States|Blacktown Cancer Centre, Blacktown, New South Wales, Australia|Border Medical Oncology Research Unit, East Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Adult Mater Hospital, South Brisbane, Queensland, Australia|Peninsula and South East Oncology, Melbourne, Victoria, Australia|Epworth Hospital, Richmond, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Oncology/Mount Hospital, Perth, Western Australia, Australia|St John of God Hospital, Subiaco, Subiaco, Western Australia, Australia|Anhui Provincial Hospital, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|The PLA General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guizhou Provincial Hospital, Guiyang, Guizhou, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Cancer Hospital of Harbin Medical Unive, Ha'erbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|The Second Xiangya Hospital of Central South Unive, Changsha, Hunan, China|Jiangyin People's Hospital, Jiangyin, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi, China|Jilin Province Cancer Hospital, Changchun, Jilin, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong U, Xi'an, Shaanxi, China|Shandong Cancer Hospital, Jinan, Shangdong, China|527-Linyi Cancer Hospital, Linyi, Shangdong, China|Yantai Yuhuangding Hospital, Yantai, Shangdong, China|Shanghai Chest Hospital, Shanghai Jiaotong Univers, Shanghai, Shanghai, China|The Fifth People's Hospital of Shanghai, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chendu, Sichuan, China|Tianjin People's Hospital, Tianjin, Tianjin, China|Affiliated Tumor Hospital of Xinjiang Medical Univ, Ürümqi, Xinjiang, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hanzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,336.395,86.88,3.0,3.0,3.0,37.16,98.02,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,NON-SMALL CELL LUNG CANCER METASTATIC,_PLINABULIN,NCT02812667,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.12,336.395,86.88,3.0,3.0,3.0,37.16,98.02,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,DEMENTIA WITH LEWY BODIES,_NILOTINIB,NCT04002674,Phase 2,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedStar Georgetown University Hospital, Washington, District of Columbia, United States",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,HUNTINGTON'S DISEASE,_NILOTINIB,NCT03764215,Phase 1,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Medical Center, Washington, District of Columbia, United States",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
FC(F)(F)C(F)(F)C(F)(F)F,KIDNEY CANCER,_PERFLUTREN,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",6723303,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
FS(F)(F)(F)(F)F,KIDNEY CANCER,_SULFUR_HEXAFLUORIDE,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5686060,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,31.0150105751658,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,146.05,0.0,0.0,0.0,0.0,7.11,18.44,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=[As]O[As]=O,AML,_ARSENIC_TRIOXIDE,NCT03031249,Phase 1|Phase 2,Recruiting,All,"14 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",6723351,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,OVERACTIVE BLADDER|PARKINSON DISEASE,_SOLIFENACIN,NCT03149809,Phase 3,Recruiting,All,"Child, Adult, Older Adult",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States",6017927,C07D453/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,28.9122979937986,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.9,362.473,32.78,2.0,0.0,5.0,40.13,106.06,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],GLIOBLASTOMA,_GADOTERIDOL,NCT02359097,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",5474756,C07F9/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,3.0,11.7291936179387,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.36,558.68,153.58,11.0,1.0,1.0,39.42,133.55,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],GLIOBLASTOMA,_FERUMOXYTOL,NCT02359097,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],BRAIN NEOPLASM,_FERUMOXYTOL,NCT03234309,Phase 2,Recruiting,All,"5 Years to 18 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"OHSU Knight Cancer Institute, Portland, Oregon, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
N[C@]1(C(=O)O)C[C@@H](F)C1,PROSTATE CANCER,_FLUCICLOVINE,NCT04009083,Not Applicable,Recruiting,Male,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"NYU Langone Health, New York, New York, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
N[C@]1(C(=O)O)C[C@@H](F)C1,PROSTATE ADENOCARCINOMA,_FLUCICLOVINE,NCT03762759,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Health System, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,PROSTATE ADENOCARCINOMA,_FLUCICLOVINE_F18,NCT03762759,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Health System, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N[C@]1(C(=O)O)C[C@@H](F)C1,GLIOBLASTOMA,_FLUCICLOVINE,NCT03926507,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"M D Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,GLIOBLASTOMA,_FLUCICLOVINE_F18,NCT03926507,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"M D Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1[nH]c(=O)ncc1F,COLORECTAL NEOPLASMS,_FLUCYTOSINE,NCT04194034,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NHS St James's University Hospital, Leeds, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.69,129.0925,67.48,3.0,2.0,1.0,10.04,28.15,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,NON SMALL CELL LUNG CANCER,_INDOCYANINE_GREEN,NCT02570815,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,LUNG CANCER,_INDOCYANINE_GREEN,NCT04182152,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Shanghai Chest Hospital, Shanghai, Shanghai, China",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,URINARY RETENTION,_TAMSULOSIN,NCT03609580,Phase 1|Phase 2,Recruiting,Male,65 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HackensackUMC, Hackensack, New Jersey, United States",4703063,C07D203/10,0.0,0.0,1.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,27.3024086736894,325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.05,408.51199999999994,99.88,6.0,2.0,2.0,43.95,108.86,11.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,NON SMALL CELL LUNG CANCER,_MIFEPRISTONE,NCT02642939,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cooper Institute for Reproductive Hormonal Disorders, Melrose Park, Pennsylvania, United States",10500216,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,85.0,242.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.33,429.5937,40.54,3.0,1.0,5.0,50.69,132.58,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,BREAST CANCER,_MIFEPRISTONE,NCT02788981,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama - Birmingham, Birmingham, Alabama, United States|University of Chicago, Chicago, Illinois, United States",10500216,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,85.0,242.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.33,429.5937,40.54,3.0,1.0,5.0,50.69,132.58,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)C(=O)O,PROSTATE ADENOCARCINOMA,_PYRUVATE,NCT03933670,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC(=O)C(=O)O,GLIOMA,_PYRUVATE,NCT03739411,Phase 1,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC(=O)C(=O)O,PANCREATIC DUCTAL ADENOCARCINOMA,_PYRUVATE,NCT04565327,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,PARKINSON'S DISEASE,_TERAZOSIN,NCT03905811,Phase 1|Phase 2,Enrolling by invitation,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",5212176,C07D405/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,34.629047824390604,855.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.12,387.4329,103.04,8.0,1.0,4.0,41.26,105.18,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,PARKINSON'S DISEASE,_FLUMAZENIL,NCT03462641,Phase 1|Phase 2,Recruiting,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States",4316839,C07D333/42,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,16.690281114601902,263.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.54,303.2884,64.43,3.0,0.0,3.0,29.97,87.93,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_AFURESERTIB,NCT04060394,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urological Associates of Southern Arizona, Tucson, Arizona, United States|California Cancer Associates for Researh & Excellence, Inc, Encinitas, California, United States|Eastern Connnecticut Hematology/Oncology Associates, Norwich, Connecticut, United States|Associated Medical Professionals of NY, Syracuse, New York, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",US-20090209607-A1,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,NON SMALL CELL LUNG CANCER,_CAPMATINIB,NCT04139317,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sarah Cannon Research Institute, Nashville, Tennessee, United States|Novartis Investigative Site, Wollongong, New South Wales, Australia|Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Ostrava Vitkovice, Czechia|Novartis Investigative Site, LILLE Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,"CARCINOMA, NON-SMALL-CELL LUNG",_CAPMATINIB,NCT04427072,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Torokbalint, Pest, Hungary",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,BLADDER CANCER,_GENISTEIN,NCT01489813,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Department of Urology, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",5213971,C12N15/76,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,NON SMALL CELL LUNG CANCER,_TIPIFARNIB,NCT03496766,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|ICO-Badalona, Badalona, Barcelona, Spain|ICO-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Provincial de Castellón, Castelló de la Plana, Castelló, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de la Arrixaca, El Palmar, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|H. Clinic i Provincial, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario de Ciudad Real, Ciudad Real, Spain|ICO Girona -H. Dr. Josep Trueta, Girona, Spain|Hospital de Jaén, Jaén, Spain|Hospital Lucus Agustí, Lugo, Spain|Hospital La Princesa, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|H. 12 de Octubre, Madrid, Spain|H. Carlos Haya, Málaga, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Virgen de La Macrena, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|H. General U. de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain",6545020,A61K41/0038,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C,MULTIPLE MYELOMA,_TASQUINIMOD,NCT04405167,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",6133285,C07D215/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,41.0,15.146101562660403,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.26,406.361,70.08,4.0,1.0,3.0,36.89,100.19,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CUSHING DISEASE,_SELICICLIB,NCT03774446,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cedars-Sinai Medical Center, Los Angeles, California, United States",US-20020049218-A1,A61P17/00 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,CHRONIC LYMPHOCYTIC LEUKEMIA,_BNC105,NCT03454165,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.13,452.352,133.89,8.0,2.0,3.0,43.41,109.33,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_ENZASTAURIN,NCT03263026,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States|Cedars Sinai Hospital, Beverly Hills, California, United States|Desert Hematology, Rancho Mirage, California, United States|Centura Health Corporation, Denver, Colorado, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Christiana Care Health Services, Newark, Delaware, United States|Watson Clinic, Lakeland, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Aurora-Advocate Health, Park Ridge, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville, Kentucky, United States|Regional Cancer Care Associates, MD, Bethesda, Maryland, United States|Minnesota Oncology Hematology Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System/ Morristown Meeical Center, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Comprehensive Cancer Cente, Buffalo, New York, United States|New York Medical College, Hawthorne, New York, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Baylor Scott and White University Medical Center, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Oncology Consultants: Memorial City, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Clinic, Houston, Texas, United States|Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee, Wisconsin, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital (Hematology Dept), Beijing, China|JiLin Cancer Hospital（Lymphoma hematology Dept), Changchun, China|West China Hospital of Sichuan University (Hematology Dept), Chengdu, China|Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Medical University Union Hospital, Fuzhou, China|GuangDong General Hospital, Guangzhou, China|ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou, China|Harbin Medical University Cancer Hospital (Oncology Internal), Harbin, China|Fudan University Shanghai Cancer Hospital, Shanghai, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The First Affiliated Hospital of Medical School of Zhejiang University (Hematology Dept), Zhejiang, China|HeNan Cancer Hospital (Hematology Dept), Zhengzhou, China|The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou, China",EP-0817627-B1,C07D335/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,27.0,122.811556705476,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.86,515.617,72.16,4.0,1.0,7.0,56.74,151.61,5.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_ENZASTAURIN_HYDROCHLORIDE,NCT03263026,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States|Cedars Sinai Hospital, Beverly Hills, California, United States|Desert Hematology, Rancho Mirage, California, United States|Centura Health Corporation, Denver, Colorado, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Christiana Care Health Services, Newark, Delaware, United States|Watson Clinic, Lakeland, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Aurora-Advocate Health, Park Ridge, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville, Kentucky, United States|Regional Cancer Care Associates, MD, Bethesda, Maryland, United States|Minnesota Oncology Hematology Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System/ Morristown Meeical Center, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Comprehensive Cancer Cente, Buffalo, New York, United States|New York Medical College, Hawthorne, New York, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Baylor Scott and White University Medical Center, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Oncology Consultants: Memorial City, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Clinic, Houston, Texas, United States|Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee, Wisconsin, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital (Hematology Dept), Beijing, China|JiLin Cancer Hospital（Lymphoma hematology Dept), Changchun, China|West China Hospital of Sichuan University (Hematology Dept), Chengdu, China|Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Medical University Union Hospital, Fuzhou, China|GuangDong General Hospital, Guangzhou, China|ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou, China|Harbin Medical University Cancer Hospital (Oncology Internal), Harbin, China|Fudan University Shanghai Cancer Hospital, Shanghai, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The First Affiliated Hospital of Medical School of Zhejiang University (Hematology Dept), Zhejiang, China|HeNan Cancer Hospital (Hematology Dept), Zhengzhou, China|The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,NSCLC,_POZIOTINIB,NCT04402008,Phase 1|Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center East, Kashiwa, Chiba, Japan|Osaka City General Hospital, Miyakojima-ku, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan",WO-2008150118-A2,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.93,491.34,76.58,6.0,1.0,4.0,48.59,124.72,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,PARKINSON DISEASE PSYCHOSIS,_SARACATINIB,NCT03661125,Early Phase 1,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Mitul Mehta, London, Camberwell, United Kingdom",WO-2003045395-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,32.7488,21.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.53,542.026,90.44,10.0,1.0,6.0,57.31,143.64,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,NEUROENDOCRINE TUMORS,_DOTATATE,NCT04318561,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Peking Union Medical College Hospital, Beijing, Beijing, China",9375498,C07B59/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,46.5882256309164,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.85,1435.63,497.46,24.0,17.0,6.0,144.3,364.83,26.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
C[S@@](=O)CCCCN=C=S,LUNG CANCER,_SULFORAPHANE,NCT03232138,Phase 2,Recruiting,All,"55 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",5411986,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,25.659664469496196,283.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.24,177.28,29.43,2.0,0.0,0.0,19.12,49.57,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,HEAD AND NECK CANCER,_PIMONIDAZOLE,NCT02414048,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Department of Cranio-, Maxillofacial and Oral Surgery, Zürich, Switzerland",5674693,G01N33/57492,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.678494424936794,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.58,254.29,84.43,5.0,1.0,2.0,25.32,65.83,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1,MYELODYSPLASTIC SYNDROME,_LB-100,NCT03886662,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.97,268.313,70.08,5.0,1.0,3.0,27.89,67.27,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0
COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,NON SMALL CELL LUNG CANCER,_ENCORAFENIB,NCT03915951,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA - Westwood, Los Angeles, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States|The William W. Backus Hospital, Norwich, Connecticut, United States|Day Kimball Healthcare, Putnam, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, Lady Lake, Florida, United States|Florida Cancer Specialists NORTH - SCRI - PPDS, Saint Petersburg, Florida, United States|Florida Cancer Specialists PAN - SCRI - PPDS, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists South, Venice, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Menorah Medical Center Laboratory, Overland Park, Kansas, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts University School of Medicne New England Eye Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center/East, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General/Chelsea HealthCare Center, Chelsea, Massachusetts, United States|North Shore Cancer Center, Danvers, Massachusetts, United States|Quest Diagnostics Massachusetts LLC, Marlborough, Massachusetts, United States|Tufts Medical Center at Stoneham, Stoneham, Massachusetts, United States|Tufts University School of Medicne New England Eye Center, Stoneham, Massachusetts, United States|Mass General Hospital West, Waltham, Massachusetts, United States|Centerpoint Medical Center, Independence, Missouri, United States|Sarah Cannon Cancer Center Laboratory at Centerpoint Medical Center, Independence, Missouri, United States|HCA Midwest Health - SCRI - PPDS, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center - Moses Pharmacy, Bronx, New York, United States|Motefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Weill Cornell Eye Associates, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Ohio State University Wexner Medical Center Clinical Laboratories, Columbus, Ohio, United States|Providence Oncology and Hematology Care Clinic - Southeast, Clackamas, Oregon, United States|Providence Cancer Center Oncology and Hematology Care - Newberg, Newberg, Oregon, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UPMC Eye Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Weaver Eye Associates, York, Pennsylvania, United States|WellSpan Oncology Research, York, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|SCRI Tennessee Oncology- Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology Hendersonville, Hendersonville, Tennessee, United States|Tennessee Oncology NASH - SCRI - PPDS, Nashville, Tennessee, United States|Houston Eye Associates - Gramercy Location, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Millenium Oncology, Shenandoah, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Ospedale di Faenza, Faenza, Emilia-romagna, Italy|Ospedale Civile Umberto I, Lugo, Emilia-romagna, Italy|Laboratorio a risposta rapida AUSL della Romagna - Ravenna, Ravenna, Emilia-romagna, Italy|Ospedale S.Maria delle Croci, Ravenna, Emilia-romagna, Italy|Ausl della Romagna Ospedale degli Infermi, Rimini, Emilia-romagna, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Naples, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Ospedale Cervesi di Cattolica, Cattolica, Rimini, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Azienda Ospedale Policlinico Federico II di Napoli, Naples, Italy|National Cancer Center Clinical Pharmacy, Goyang-si, Gyeonggido, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands|Netherlands Cancer Institute, Amsterdam, Noord-holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Hospital Universitario Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|C.H. Regional Reina Sofia - PPDS, Córdoba, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,15.310375983079734,13.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.16,540.01,140.13,7.0,3.0,3.0,54.11,145.6,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,NON SMALL CELL LUNG CANCER,_BINIMETINIB,NCT03915951,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA - Westwood, Los Angeles, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States|The William W. Backus Hospital, Norwich, Connecticut, United States|Day Kimball Healthcare, Putnam, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, Lady Lake, Florida, United States|Florida Cancer Specialists NORTH - SCRI - PPDS, Saint Petersburg, Florida, United States|Florida Cancer Specialists PAN - SCRI - PPDS, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists South, Venice, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Menorah Medical Center Laboratory, Overland Park, Kansas, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts University School of Medicne New England Eye Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center/East, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General/Chelsea HealthCare Center, Chelsea, Massachusetts, United States|North Shore Cancer Center, Danvers, Massachusetts, United States|Quest Diagnostics Massachusetts LLC, Marlborough, Massachusetts, United States|Tufts Medical Center at Stoneham, Stoneham, Massachusetts, United States|Tufts University School of Medicne New England Eye Center, Stoneham, Massachusetts, United States|Mass General Hospital West, Waltham, Massachusetts, United States|Centerpoint Medical Center, Independence, Missouri, United States|Sarah Cannon Cancer Center Laboratory at Centerpoint Medical Center, Independence, Missouri, United States|HCA Midwest Health - SCRI - PPDS, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center - Moses Pharmacy, Bronx, New York, United States|Motefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Weill Cornell Eye Associates, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Ohio State University Wexner Medical Center Clinical Laboratories, Columbus, Ohio, United States|Providence Oncology and Hematology Care Clinic - Southeast, Clackamas, Oregon, United States|Providence Cancer Center Oncology and Hematology Care - Newberg, Newberg, Oregon, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UPMC Eye Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Weaver Eye Associates, York, Pennsylvania, United States|WellSpan Oncology Research, York, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|SCRI Tennessee Oncology- Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology Hendersonville, Hendersonville, Tennessee, United States|Tennessee Oncology NASH - SCRI - PPDS, Nashville, Tennessee, United States|Houston Eye Associates - Gramercy Location, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Millenium Oncology, Shenandoah, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Ospedale di Faenza, Faenza, Emilia-romagna, Italy|Ospedale Civile Umberto I, Lugo, Emilia-romagna, Italy|Laboratorio a risposta rapida AUSL della Romagna - Ravenna, Ravenna, Emilia-romagna, Italy|Ospedale S.Maria delle Croci, Ravenna, Emilia-romagna, Italy|Ausl della Romagna Ospedale degli Infermi, Rimini, Emilia-romagna, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Naples, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Ospedale Cervesi di Cattolica, Cattolica, Rimini, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Azienda Ospedale Policlinico Federico II di Napoli, Naples, Italy|National Cancer Center Clinical Pharmacy, Goyang-si, Gyeonggido, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands|Netherlands Cancer Institute, Amsterdam, Noord-holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Hospital Universitario Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|C.H. Regional Reina Sofia - PPDS, Córdoba, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_DAROLUTAMIDE,NCT04237584,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Myrtle Beach, South Carolina, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,52.403540113760045,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,398.85,119.62,5.0,3.0,3.0,41.86,117.16,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,PROSTATE CANCER,_VALACYCLOVIR,NCT01436968,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arizona Oncology Services Foundation, Multiple Locations, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|VA Northern California Health Care System, Mather, California, United States|Precision Radiation Oncology, Tustin, California, United States|Valley View Hospital, Glenwood Springs, Colorado, United States|Colorado Clinical Research, Golden, Colorado, United States|Advanced Urology, Parker, Colorado, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|21st Century Oncology, Fort Lauderdale, Florida, United States|21st Century Oncology, Lakewood Ranch, Florida, United States|21st Century Oncology, Naples, Florida, United States|21st Century Oncology, Plantation, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|James A. Haley Veteran's Hospital, Tampa, Florida, United States|Florida Urology Partners, Tampa, Florida, United States|Atlanta VA Health Care System, Decatur, Georgia, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|Silver Cross Hospital, New Lenox, Illinois, United States|Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, United States|VA Maryland Health Care System, Baltimore, Maryland, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Adult & Pediatric Urology, P.C., Omaha, Nebraska, United States|Sheldon Freedman MD, Ltd., Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|New Jersey Urology - Cherry Hill, Cherry Hill, New Jersey, United States|New Jersey Urology - Englewood, Englewood, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|New Jersey Urology - Milburn, Millburn, New Jersey, United States|New Jersey Urology - Saddle Brook, Saddle Brook, New Jersey, United States|New Jersey Urology - Voorhees, Voorhees, New Jersey, United States|New Jersey Urology - West Orange, West Orange, New Jersey, United States|New Mexico Oncology Hematology Consultants (NMOHC), Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|James J. Peters VA Medical Center, Bronx, New York, United States|Advanced Radiation Centers of New York (Integrated Medical Professionals), North Hills, New York, United States|Associated Medical Professionals of NY, PLLC, Syracuse, New York, United States|Durham VA Health Care System, Durham, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|Southwest Urology, Clinical Research Solutions, Middleburg Heights, Ohio, United States|VA Portland Health Care System, Portland, Oregon, United States|Oregon Urology Institute, Springfield, Oregon, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Triangle Urological Group, Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Cancer Institute, Wexford, Pennsylvania, United States|Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States|Austin Urology Institute, Austin, Texas, United States|VA North Texas Health Care System, Dallas, Texas, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Dr. Irving Fishman's Office, Houston, Texas, United States|Houston Willowbrook Radiation Oncology, Houston, Texas, United States|Dr. Ned Stein's Office, Houston, Texas, United States|South Texas San Antonio VA Healthcare System, San Antonio, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Texas Urology Specialists-The Woodlands, The Woodlands, Texas, United States|The Methodist Hospital - The Woodlands, The Woodlands, Texas, United States|Texas Urology Specialists, Tomball, Texas, United States|Potomac Urology Center, Alexandria, Virginia, United States|Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington, United States|MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States|VA Caribbean Healthcare System, San Juan, Puerto Rico",4957924,C07D473/00,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,EARLY BREAST CANCER,_RIBOCICLIB,NCT03701334,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham/ Kirklin Clinic, Birmingham, Alabama, United States|Cancer Treatment Centers of America, Goodyear, Arizona, United States|St Bernards Medical Center, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center SC-2, Bakersfield, California, United States|UCLA Beverly Hills, Beverly Hills, California, United States|UCLA Burbank, Burbank, California, United States|Encino Research Center, Encino, California, United States|UCLA Hematology Oncology, Laguna Hills, California, United States|Southern California Oncology Research Alliance SCORA, Los Angeles, California, United States|UCLA Central Regulatory, Los Angeles, California, United States|Valley Breast Care and Women s Health Center, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCLA Pasadena Health Care Hematology Oncology, Pasadena, California, United States|UCLA Porter Ranch Hematology and Oncology, Porter Ranch, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Sharp Memorial Hospital Regulatory, San Diego, California, United States|University of California San Francisco Gynecologic Oncology, San Francisco, California, United States|Central Coast Medical Oncology Corporation Onc Dept, Santa Maria, California, United States|UCLA Santa Monica Hematology / Oncology Regulatory-2, Santa Monica, California, United States|Lundquist Inst BioMed at Harbor, Torrance, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Cntr, Truckee, California, United States|UCLA Valencia, Valencia, California, United States|Wellness Oncology Hematology TRM, West Hills, California, United States|UCLA Cancer Center, Westlake Village, Westlake Village, California, United States|St. Jude Heritage Medical Group Dept.of Virginia K Crosson Ctr, Yorba Linda, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Greenwood Village, Colorado, United States|Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Norwalk Hospital Pulmonary Medicine, Norwalk, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates Regulatory, Norwich, Connecticut, United States|Holy Cross Hospital - Ft. Lauderdale CLCZ696BUS01, Fort Lauderdale, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Orlando Health, Clinical Trials Orlando Health Inc, Orlando, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Florida Cancer Specialists Panhandle, Tallahassee, Florida, United States|Florida Cancer Specialists- East Region, West Palm Beach, Florida, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc., Fort Wayne, Indiana, United States|Cancer Care Center, New Albany, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Mercy Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Fairview Health Services, Maple Grove, Minnesota, United States|Metro Minnesota CCOP Metro Minneapolis CCOP, Saint Louis Park, Minnesota, United States|Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|David C Pratt Cancer Center, Saint Louis, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Saint Francis Medical Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Perlmutter Cancer Centre, New York, New York, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|Alamance Regional Medical Cancer Center, Burlington, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Kaiser Permanente NW Region, Clackamas, Oregon, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Cancer Treatment Centers of America Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|The West Clinic, Germantown, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Center for Cancer and Blood Disorders Research Department, Fort Worth, Texas, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance Medical Oncology, Seattle, Washington, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center, Madison, Wisconsin, United States|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Caba, Argentina|Novartis Investigative Site, Jujuy, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Campbelltown, New South Wales, Australia|Novartis Investigative Site, Coffs Harbour, New South Wales, Australia|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Ryde, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Auchenflower, Queensland, Australia|Novartis Investigative Site, Birtinya, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Bendigo, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Epping, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Graz, Styria, Austria|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Barretos, Sao Paulo, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Caxias do Sul, Brazil|Novartis Investigative Site, Ijui, Brazil|Novartis Investigative Site, Passo Fundo, Brazil|Novartis Investigative Site, Piracicaba, Brazil|Novartis Investigative Site, Recife, Brazil|Novartis Investigative Site, Rio De Janeiro, Brazil|Novartis Investigative Site, Salvador, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, North Vancouver, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Sault Ste Marie, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Windsor, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, St-Jerome, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Dijon Cedex, Cote D Or, France|Novartis Investigative Site, Limoges cedex, Haute Vienne, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Rennes Cedex, Ille Et Vilaine, France|Novartis Investigative Site, Amiens, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Argenteuil, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Grenoble cedex, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nantes cedex 2, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre-les-Nancy cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bavaria, Germany|Novartis Investigative Site, Georgsmarienhuette, Lower Saxony, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, North Rhine-westphalia, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Liebenwerda, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Cottbus, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Halle S, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Moenchengladbach, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Schweinfurt, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Waterford, Ireland|Novartis Investigative Site, Torrette AN, Ancona, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Seoul, Daegu, Korea, Republic of|Novartis Investigative Site, Wonju-si, Gangwon-do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Suwon, Kyonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seongnam Si Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ulsan, Korea, Republic of|Novartis Investigative Site, Warsaw, Ul Roentgena 5, Poland|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Grudziadz, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Ostroleka, Poland|Novartis Investigative Site, Otwock, Poland|Novartis Investigative Site, Wieliszew, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, St Petersburg, Saint Petersburg, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kostroma, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Obninsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Rostov-na-Donu, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St- Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Huelva, Andalucia, Spain|Novartis Investigative Site, Jaen, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Avila, Castilla Y Leon, Spain|Novartis Investigative Site, Burgos, Castilla Y Leon, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Badalona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Manresa, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Lugo, Galicia, Spain|Novartis Investigative Site, Fuenlabrada, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Madrid, N Ap, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Vitoria-Gasteiz, País Vasco, Spain|Novartis Investigative Site, Vigo, Pontevedra, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bilbao, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Navarra, Spain|Novartis Investigative Site, Sabadell, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Maidstone, Kent, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, United Kingdom",8324225,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,NON SMALL CELL LUNG CANCER,_BRIGATINIB,NCT04074993,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",9012462,C07F9/65717,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,72.0,70.99940450522591,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.11,584.1,85.86,9.0,2.0,5.0,64.1,164.77,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,SMALL CELL LUNG CANCER,_VENETOCLAX,NCT04422210,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke Cancer Institute, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO, L'Hospitalet de Llobregat, Barcelona, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,NON SMALL CELL LUNG CANCER,_SELINEXOR,NCT03095612,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Cancer Center, Aurora, Colorado, United States|University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Vanderbilt Medical Center-Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,GLIOBLASTOMA MULTIFORME,_SELINEXOR,NCT04421378,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami, Florida, United States|Hackensack Meridian Health, 92 Second Street, Hackensack, New Jersey, United States|Columbia University Irving Medical Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=NN(CCCl)C(=O)NC1CCCCC1,GLIOBLASTOMA MULTIFORME,_LOMUSTINE,NCT04421378,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami, Florida, United States|Hackensack Meridian Health, 92 Second Street, Hackensack, New Jersey, United States|Columbia University Irving Medical Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",4631289,C07D233/91,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,42.9084786135238,262.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.62,233.695,61.77,2.0,1.0,1.0,23.61,58.65,4.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BIRTH ASPHYXIA,_SILDENAFIL,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,BIRTH ASPHYXIA,_SILDENAFIL_CITRATE,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",WO-1999030688-A1,A61K9/19,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
NS(=O)(=O)Cc1noc2ccccc12,PARKINSON'S DISEASE,_ZONISAMIDE,NCT04182399,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Neurology, Ain Shams University Hospital, Cairo, Abbasia, Egypt|Ain Shams Univeristy, Cairo, Egypt",4172896,C07D261/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.67,212.226,86.19,3.0,1.0,2.0,19.48,50.3,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,PARKINSON'S DISEASE,_CANNABIDIOL,NCT03582137,Phase 2,Recruiting,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Colorado hospital, Aurora, Colorado, United States",10195159,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,LYMPHOMA,_FAMOTIDINE,NCT03647072,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Cairo, Egypt",5075114,A61K9/5047,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,ACUTE MYELOID LEUKEMIA,_TALAZOPARIB,NCT02878785,Phase 1|Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States",8012976,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.359,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O,BREAST CANCER,_CALCIPOTRIENE,NCT03596073,Phase 1,Recruiting,All,"45 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",5763426,C07C5/321,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,34.8590320129776,581.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.63,412.6047,60.69,3.0,3.0,4.0,49.59,125.45,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,SMALL CELL LUNG CANCER,_RUCAPARIB,NCT03958045,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States",6495541,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,PROSTATE CANCER METASTATIC,_RUCAPARIB,NCT03413995,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States",6495541,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,ACUTE MYELOID LEUKEMIA,_ATOVAQUONE,NCT03568994,Early Phase 1,Recruiting,All,"1 Month to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Medicine, Baltimore, Maryland, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",5998449,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,25.199696092322196,296.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.74,366.837,54.37,3.0,1.0,4.0,39.64,103.11,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,PARKINSON'S DISEASE,_BUMETANIDE,NCT03899324,Phase 2,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chu Nantes, Nantes, France",4110445,C07D233/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,16.296022505595502,672.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,364.416,118.72,5.0,3.0,2.0,37.21,95.78,8.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,OVARIAN CANCER,_FOSTAMATINIB,NCT03246074,Phase 1,Recruiting,Female,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",7449458,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE,_OLAPARIB,NCT03047135,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccnc1,PARKINSON'S DISEASE,_NICOTINAMIDE,NCT03568968,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Arendal Hospital, Arendal, Norway|Haukeland University Hospital, Bergen, Norway|Vestre Viken Hospital, Drammen, Norway|Førde sykehus, Førde, Norway|Haugesund Hospital, Haugesund, Norway|Akershus university hospital, Oslo, Norway|Oslo University Hospital, Oslo, Norway|St. Olavs Hospital, Trondheim, Norway",3931207,C07D207/44,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_RUCAPARIB,NCT04253262,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lifespan Cancer Institute, Providence, Rhode Island, United States",6495541,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,MUSCULOSKELETAL PAIN,_ETORICOXIB,NCT04565600,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Guangdong General Hospital, Guangzhou, Guangdong, China",5861419,C07D213/65,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0
[C-]#[O+],SMOKING CESSATION,_CARBON_MONOXIDE,NCT03059940,Early Phase 1,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,RETINAL VEIN OCCLUSION|MACULAR EDEMA,_FLUORESCEIN,NCT04140448,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Renmin Hospital of Wuhan University, Wuhan, Hubei, China",10293047,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,18.135896014291802,9013.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.64,332.3063,75.99,3.0,2.0,5.0,33.14,91.22,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C[C@H](O)[C@H](O)[C@H](O)CO,PROSTATE CANCER,_RIBOSE,NCT03334500,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.3,150.1299,97.99,5.0,4.0,0.0,13.39,31.38,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,CANCER,_CYCLOPHOSPHAMIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CANCER,_SIROLIMUS,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5212155,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,CANCER,_ETOPOSIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CANCER,_CELECOXIB,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,QUALITY OF LIFE,_CAPECITABINE,NCT03577392,Phase 2|Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Sichuan Provincial People Hospital, Chengdu, Sichuan, China",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,CANCER,_GEMCITABINE,NCT03507491,Phase 1,Recruiting,All,"6 Months to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CANCER,_ERLOTINIB,NCT02714530,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital, Oslo, International/Other, Norway|St Olavs Hospital, Trondheim, Norway",5747498,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CANCER,_GEFITINIB,NCT02929693,Phase 3,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CN(C)CCCN1c2ccccc2CCc2ccccc21,BREAST CANCER,_IMIPRAMINE,NCT03122444,Early Phase 1,Recruiting,All,"18 Years to 71 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States",3961060.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,78.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.53,280.4073,6.48,2.0,0.0,3.0,33.39,90.61,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
